var title_f14_51_15152="Diagnosis cardiac amyloidosis";
var content_f14_51_15152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Suspected cardiac amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 560px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow diagram for the evaluation of a patient with suspected cardiac amyloidosis. Clinical evaluation may reveal clues, but a tissue diagnosis is mandatory. Although special staining of the biopsy may confirm the type of amyloid, further workup of AL amyloid is required to exclude myeloma and to quantify free light chains. If the biopsy stains positive for transthyretin, further testing is needed to determine whether this is a wild-type or mutant transthyretin.",
"    <div class=\"footnotes\">",
"     APoA1: apolipoprotein A1; IFE: immunofixation electrophoresis; FLC: free-light-chain assay; SSA: senile systemic amyloidosis; and TTR: transthyretin.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15152=[""].join("\n");
var outline_f14_51_15152=null;
var title_f14_51_15153="Calculator: Calcium correction in hypoalbuminemia (SI units)";
var content_f14_51_15153=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"CalciumAlbumin_SI_form\" name=\"CalciumAlbumin_SI_form\" onkeydown=\"clrResults();\" onkeyup=\"CalciumAlbumin_SI_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Calcium correction in hypoalbuminemia (SI units)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          Ca = SerumCa + 0.02 * (NormalAlbumin - PatientAlbumin)",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Ca",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Ca_param\" onblur=\"CalciumAlbumin_SI_fx(); minMaxCheck();\" onchange=\"CalciumAlbumin_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Ca_unit\" onchange=\"CalciumAlbumin_SI_fx();\" style=\"width:105px;\">",
"              <option value=\"0.001|0|mcmol/L\">",
"               mcmol/L",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Normal Albumin",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Normal_Albumin_radio\" onclick=\"CalciumAlbumin_SI_fx();\" type=\"radio\" value=\"40 g/L|40\"/>",
"              40 g/L",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Normal_Albumin_radio\" onclick=\"CalciumAlbumin_SI_fx();\" type=\"radio\" value=\"44 g/L|44\"/>",
"              44 g/L",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Patient Albumin",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Patient_Albumin_param\" onblur=\"CalciumAlbumin_SI_fx(); minMaxCheck();\" onchange=\"CalciumAlbumin_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Patient_Albumin_unit\" onchange=\"CalciumAlbumin_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|g/L\">",
"               g/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Ca",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Ca_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Ca_unit\" onchange=\"CalciumAlbumin_SI_fx();\" style=\"width:105px;\">",
"               <option value=\"0.001|0|mcmol/L\">",
"                mcmol/L",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|mmol/L\">",
"                mmol/L",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"CalciumAlbumin_SI_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The",
"       <b>",
"        Normal Albumin",
"       </b>",
"       parameter is set to 40 gm/L.",
"      </li>",
"      <li>",
"       Some practitioners prefer 44 gm/L as normal (see article 1 below.)  Simply change the",
"       <b>",
"        Normal Albumin",
"       </b>",
"       value above and the page will recalculate instantly.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Figge J, Jabor A, Kazda A, Fencl V. Anion gap and hypoalbuminemia.",
"        <i>",
"         Crit Care Med",
"        </i>",
"        . 1998 Nov;26(11):1807-10.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum  proteins.",
"        <i>",
"         Br Med J",
"        </i>",
"        . 1973 Dec 15;4(5893):643-6.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15153=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function CalciumAlbumin_SI_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.CalciumAlbumin_SI_form){",
"",
"",
"doCalc = true;",
"if (Serum_Ca_param.value.indexOf(',') >= 0){ Serum_Ca_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Ca_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Ca_unit.options[Serum_Ca_unit.selectedIndex].value.split('|');",
"Serum_Ca = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Normal_Albumin_radio[0].checked){ Normal_Albumin = 40; }",
"if (Normal_Albumin_radio[1].checked){ Normal_Albumin = 44; }",
"if (Patient_Albumin_param.value.indexOf(',') >= 0){ Patient_Albumin_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Patient_Albumin_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Patient_Albumin_unit.options[Patient_Albumin_unit.selectedIndex].value.split('|');",
"Patient_Albumin = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Ca =  Serum_Ca + 0.02 * (Normal_Albumin - Patient_Albumin);",
"",
"unit_parts = Ca_unit.options[Ca_unit.selectedIndex].value.split('|');",
"if (doCalc) Ca_param.value = fixDP((Ca - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CalciumAlbumin_SI_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CalciumAlbumin_SI_form){",
"",
"Ca_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f14_51_15153=null;
var title_f14_51_15154="Angioedema lip 1";
var content_f14_51_15154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angioedema lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angioedema is a diffuse, nonpitting, tense swelling of the dermis and subcutaneous tissue. It develops over minutes to hours, and resolves over subsequent hours or days. Angioedema typically does not itch, unless it is associated with urticaria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Neville B et al: Color Atlas of Clinical Oral Pathology. Philadelphia: Lea &amp; Febiger, 1991. Copyright &copy;1991 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15154=[""].join("\n");
var outline_f14_51_15154=null;
var title_f14_51_15155="Patient information: Insect bites and stings (The Basics)";
var content_f14_51_15155=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15338\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/37/24144\">",
"         Insect sting",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/30/33250\">",
"         Patient information: Anaphylaxis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/57/15250\">",
"         Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/22/18786\">",
"         Patient information: Bee and insect stings (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/44/19138\">",
"         Patient information: Fire ants (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/0/27649\">",
"         Patient information: Lyme disease prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/17/32022\">",
"         Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/19/16690\">",
"         Patient information: West Nile virus infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/10/13474\">",
"         Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Insect bites and stings (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/insect-bites-and-stings-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H40567109\">",
"      <span class=\"h1\">",
"       How are insect bites and stings different?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When an insect bites you, it uses its mouth parts. When an insect stings you, it uses a special &ldquo;stinger&rdquo; on the back of its body.",
"     </p>",
"     <p>",
"      Biting insects usually bite other people and animals, too. When they bite you, they can transfer blood from their other victims to you. That means that they can infect you with the diseases their other victims have. Mosquitoes, for example, can carry a few infections. And certain types of ticks can infect you with the germ that causes Lyme disease.",
"     </p>",
"     <p>",
"      Stinging insects, such as bees, wasps, and fire ants, do not usually carry disease. But stinging insects can inject you with venom that can irritate your skin. Plus, insect stings can be deadly to people who are severely allergic to the insect venom.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40567116\">",
"      <span class=\"h1\">",
"       What should I do if I am stung by a bee, wasp, or fire ant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are stung by a bee or wasp, quickly remove the stinger from your skin if it is still there. If you are stung by a fire ant, kill the ant with a slap as soon as you feel the sting.",
"     </p>",
"     <p>",
"      Some people have a severe allergic reaction to insect stings called anaphylaxis. Call 9-1-1 for an ambulance if you suddenly:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have trouble breathing, become hoarse, or start wheezing (hearing a whistling sound when you breathe)",
"       </li>",
"       <li>",
"        Start to swell, especially around the face, eyelids, ears, mouth, hands, or feet",
"       </li>",
"       <li>",
"        Develop belly cramps, nausea, vomiting, or diarrhea",
"       </li>",
"       <li>",
"        Feel dizzy or pass out",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40567123\">",
"      <span class=\"h1\">",
"       What is a normal reaction to an insect sting?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Insect stings can cause the area around the sting to swell, turn red, hurt, and feel hot (",
"      <a class=\"graphic graphic_figure graphicRef63900 \" href=\"UTD.htm?23/37/24144\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      To treat the pain and swelling around the area of the sting, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wash the area with soap and cool water",
"       </li>",
"       <li>",
"        Keep the area clean and try not to scratch it",
"       </li>",
"       <li>",
"        Put a cold, damp washcloth on the area",
"       </li>",
"       <li>",
"        Take or apply anti-itch medicine",
"       </li>",
"       <li>",
"        Take a non-prescription pain medicine for the pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40567130\">",
"      <span class=\"h1\">",
"       What should I know about tick bites?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ticks are found in the grass and on shrubs, and can attach to people walking by. One type of tick can spread Lyme disease. But a tick has to stay attached for a while before it can give you the infection. If you are bitten by a tick, gently remove the tick from your skin, using tweezers. If you can&rsquo;t remove a tick, see your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40567137\">",
"      <span class=\"h1\">",
"       What can I do to reduce the chances of getting bitten or stung?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wear shoes, long-sleeved shirts, and long pants when you go outside. If you are worried about ticks, tuck your pants into your socks and wear light colors so you can spot any ticks that get on you.",
"       </li>",
"       <li>",
"        Wear bug spray",
"       </li>",
"       <li>",
"        Stay inside at dawn and dusk, when mosquitoes are most active",
"       </li>",
"       <li>",
"        Drain areas of standing water near your home, such as wading pools and buckets. Mosquitoes breed in standing water.",
"       </li>",
"       <li>",
"        Keep foods and drinks covered when you are outside",
"       </li>",
"       <li>",
"        If you see a stinging insect, stay calm and slowly back away",
"       </li>",
"       <li>",
"        If you live in an area that has fire ants, avoid stepping on ant mounds",
"       </li>",
"       <li>",
"        If you find an insect nest in or near your house, call a pest-control service to get rid of the nest safely",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40567144\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=see_link\">",
"       Patient information: Anaphylaxis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"       Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/22/18786?source=see_link\">",
"       Patient information: Bee and insect stings (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/44/19138?source=see_link\">",
"       Patient information: Fire ants (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/19/16690?source=see_link\">",
"       Patient information: West Nile virus infection (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=see_link\">",
"       Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"       Patient information: Lyme disease prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"       Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/51/15155?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15338 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15155=[""].join("\n");
var outline_f14_51_15155=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40567109\">",
"      How are insect bites and stings different?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40567116\">",
"      What should I do if I am stung by a bee, wasp, or fire ant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40567123\">",
"      What is a normal reaction to an insect sting?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40567130\">",
"      What should I know about tick bites?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40567137\">",
"      What can I do to reduce the chances of getting bitten or stung?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40567144\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15338\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/37/24144\">",
"      Insect sting",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/22/18786?source=related_link\">",
"      Patient information: Bee and insect stings (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/44/19138?source=related_link\">",
"      Patient information: Fire ants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=related_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=related_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/19/16690?source=related_link\">",
"      Patient information: West Nile virus infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=related_link\">",
"      Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_51_15156="Dist phalanx fx types";
var content_f14_51_15156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal phalanx fracture types",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 532px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fracture patterns seen in the distal phalanx are (A) longitudinal, (B) transverse, (C) tuft, (D) dorsal base, (E) volar base, and (F) complete articular.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bucholz RW, MD and Heckman JD, MD. Rockwood &amp; Green's Fractures in Adults, 5th ed. Lippincott, Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15156=[""].join("\n");
var outline_f14_51_15156=null;
var title_f14_51_15157="M mode mitral valve HCM";
var content_f14_51_15157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral valve in hypertrophic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M-mode echocardiogram recorded from an area of the left ventricular outflow tract in a patient with hypertrophic cardiomyopathy. There is significant anterior movement (SAM) of the anterior leaflet of the mitral valve, and prolonged appositon of the mitral valve leaflet with the septum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15157=[""].join("\n");
var outline_f14_51_15157=null;
var title_f14_51_15158="Migratory periictal MRI changes";
var content_f14_51_15158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F63800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F63800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Migratory periictal MRI changes in a patient with multifocal seizures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 499px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHzAZwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooryX4pfHLRPh14lXRdU0zUrq4a3S4324TbtYsAPmYHPymgD1qivnX/AIau8K/9ALW/yi/+Lo/4au8K/wDQC1v8ov8A4ugD6Kor51/4au8K/wDQC1v8ov8A4uj/AIau8K/9ALW/yi/+LoA+iqK+df8Ahq7wr/0Atb/KL/4uj/hq7wr/ANALW/yi/wDi6APoqivnX/hq7wr/ANALW/yi/wDi6P8Ahq7wr/0Atb/KL/4ugD6Kor51/wCGrvCv/QC1v8ov/i6P+GrvCv8A0Atb/KL/AOLoA+iqK+df+GrvCv8A0Atb/KL/AOLo/wCGrvCv/QC1v8ov/i6APoqivPvhH8UtL+Jtvqc2k2N7aLYPGji525beGIxtJ/umuI8SftMeG9B8Rapo9zo2sST6fdS2kjxiLazRuVJGWzjIoA94or51/wCGrvCv/QC1v8ov/i6P+GrvCv8A0Atb/KL/AOLoA+iqK+df+GrvCv8A0Atb/KL/AOLo/wCGrvCv/QC1v8ov/i6APoqivnX/AIau8K/9ALW/yi/+Lo/4au8K/wDQC1v8ov8A4ugD6Kor51/4au8K/wDQC1v8ov8A4uj/AIau8K/9ALW/yi/+LoA+iqK+df8Ahq7wr/0Atb/KL/4uj/hq7wr/ANALW/yi/wDi6APoqivIPhn8eNC+IHimPQtM0vU7a4eJ5RJcCPZhRkjhial+KPxy0T4deJV0XVNM1K6uGt0uN9uE24YsAPmYHPymgD1qivnX/hq7wr/0Atb/ACi/+Lo/4au8K/8AQC1v8ov/AIugD6Kor51/4au8K/8AQC1v8ov/AIuj/hq7wr/0Atb/ACi/+LoA+iqK+dv+GrvCv/QC1v8AKL/4uk/4au8K/wDQC1v8ov8A4ugD6Kor51/4au8K/wDQC1v8ov8A4uj/AIau8K/9ALW/yi/+LoA+iqK+df8Ahq7wr/0Atb/KL/4uj/hq7wr/ANALW/yi/wDi6APoqiqWiahHq+jWGpQI6RXlvHcIr/eUOoYA4781doAKKKKACiiigAooooAKKKKACiiigAooooAK+IP2yf8AkrkP/YMh/wDQ5K+36+IP2yf+SuQ/9gyH/wBDkoA8LpKKWgBKWpIIZJ5FjhQvIxwFA610934UOjQRPrkqwzSqHWHPzBfU+lAHJ0oBJAAyTXa6Dp3hzVNRtrG7uja+c4QTp8wXPTIJ6V1upeB7P4f6nFfahe21xDv/ANHkaMyb+AdyrwDjI4J70AeY3Ph7WLW0FzcabdxW+0NvaIgYPQ1l163pvxE1hPEEl1cXN1eaXMSs1tdYkUxcA/L265x+FY9z4Av/ABJrE0vhGzjlsnDSjZMPLQZ9T07cHmgDzulre1Lwve6dNJDcvb+chwypKHwfTI4rGmt5YWxIjLzgEjg0AQ0UtFAH1p+w5/yCvF3/AF2tv/QZK+dfix/yVPxl/wBhq9/9HvX0V+w5/wAgrxd/12tv/QZK+dfix/yVPxl/2Gr3/wBHvQBylFL2ooASlrR0DRdQ1/U4dP0i1luruU4VI1yfqfQV6zbfDLwn4cwPG3iN7nUYxuk0vR4/Odf9ln6KfrQB4rSV7+194C09WTTfAXmLwEk1O+IZj7hc1ea88IzukGp+AdJMTHlrC/YS4PoGxn8xQB85UV75ffDfwH4nKp4T1ufQ9VcZTT9YGA59Ffof1ryTxj4Q1nwhqZstdspLd+qORlJB6q3QigDnqKWigD2n9kP/AJLLbf8AXlP/ACFW/wBsn/krkP8A2DIf/Q5Kqfsh/wDJZbb/AK8p/wCQq3+2R/yVyH/sGQ/+hyUAeF0px2o96Q80AHX60d6tafp91qN0ltYQSTzuflSNSSa9a8P/ALPXi7ULUXWqfZNHt8Z3XkgUgeuOtAHjhGOtA617w3wG0yKQxXHj/QUmUHIDk4qhqf7PXiHyGufDWo6brsCjObWYbj+BoA8VorU1zQdU0G7a11ixntLgdUlQg1l0ABFFFL1GD2oA/TP4e/8AIg+Gv+wZbf8Aopa36wPh7/yIPhr/ALBlt/6KWt+gAooooAKKKKACiiigAooooAKKKKACiiigAr4h/bJ/5K5D/wBgyH/0OSvt6viH9sj/AJK3D/2DIf8A0OSgDwqgAnoKK9U/Z88DReLvFpudTjd9H00CecBSRI2flQ+xPX2zQBo+B/Dh8M+D9S8T3FvHNqVvAskccw+WLecICO5P3semB/FXI+LrLWtVkgvZGn1CWaPzXcAscnk/gM4r139onWrbTIrfw3ZJGoRzdXQTgyXDjgH2RSBjtkY6VmfBHxlJ4RuYpL9LefSHTZMAQ0sZz98Z7c9O9AHkfgzwnq/iLxDZWGn2dw0skyruCkBOepPavcP2oLuysLTQtFRBIbNmSQgc5Cpg/wA6961rxPoWmJa6nYC1aF4vNieFQA4PB5HfBr5V+Nmqp4p8UXq6ZItzHLcJL5g6jEYU49ATk/hQByP2g2WkLKURkdR5in0Zs49egr274UYk/Z98Q3FihGpM9w4ZSQxCImP5mvENVspjYXEMKEBCqpz129TXuP7MuoWtvZXUN3lbJbUmRJjkeY7hTgdwRgY96APmEXl0rs6zSqxYk4Y8n6V1nhjULO8s57fX7dprViA0yD54SeA49cdx6V9T6h+z/wCCNajGsObu081fNdLdwqZ78EHFfO3j3/hHtE1SfQ/Cs/22y3qJLlh3B5UHv9aAOE8V6FPoGqvaTEOmA0cg6Oh5BH1HP41j19C/FvwnJr/hOw8QaNbrJaf2fHd5QcoVwkyfgcEf7tfPZGMe9AH1n+w5/wAgrxd/12tv/QZK+dfiz/yVPxl/2Gb3/wBHvX0V+w7/AMgrxd/12tv/AEGSvnX4sf8AJU/GX/Yavf8A0e9AHK1seE/D194o1y30rS499xMeSeFRe7MewArHAycDkmvYJR/wrzwDb2VsdniPX4hLdyD71van7sY9C3egCfVNesPCdlL4X8Av+9K7NT1pRiWc944z/CufTrXLxw3BgdIWEDE/JEq8sfVietb3g3w5bR2S3l3vM7klAeAB68jmtC109oZpp51ZrmLJRiByuO/uKAKEnhZZ7m3BvJhF5REgL9G/wrG8LaCb+N7mS5dLdG2jJySfb0FdzZWkV9p4jkZ183IkIOC+fU+lUNGhhtfD7RWh3PGxEoPBHPXFAHN679q06/Fiyfb4njEibRkge/pW1pPi2C704+H/ABY0t94clYRo8p3z6a/Z0Y8lQeo9KuRxJcSQsjBLhiMuBkuAOPpXG+JbaHT766AleSRn5WQffU9x9DxQBieO/Ctz4S16SyuGEtuwEltcpyk0Z5VgfcVzdew6AP8AhM/B174Vum8y+0+E3ukTNwxRfvw5PXjkfSvH5FZHZXGGU4IoA9p/ZD/5LJbf9eU/8hVv9sj/AJK5D/2DIf8A0OSqn7If/JZbb/ryn/kKt/tkf8lch5x/xLIf/Q5KAPC/WtTw3ol74h1m10vS4WmvLlwiKvOPc1mKMnAGfSvpr4SaRbfC/wCG9z441iFH1q+Qx6dA/UAnAI9M/wAqANq1TQ/gpp1tp2mwQX3i6ZAbm5YAiDPOB6V5P4k8U654r1GSO/1KWZ2JITcdi5PTA4xWJqeo3WqalcS3Ejz3k8he4k6sSew9ucV1+neCZY5bKeG6ZoJNpkhQYbnv/jQBz0+iSaNCLn7RHvUqWWYAhlOMHGORzU2ieJtQ0O+WexvDbSyNuWS1JCH8PTjpXf6/4YtpTpMO138ydhK7Pu3RhSWHp6VjeKPDNo9hdPp4WJokLqucrkdceh4oA7jTPG+h/ELSU0X4hWULTS/JDqMagMDnAOe3avn34peBr3wJ4lmsLnMlq37y2uB92VD0NTafNc2M4jnSRYnwrKxwRXtVrGnxT+Gt9oOoNG3iHS4/tFlJ/E6c/L+lAHy6cdRRjnrUk8bQyvFIpSRCUYEdxUeOcUAfpn8Pf+RB8Nf9gy2/9FLW/WB8Pf8AkQfDX/YMtv8A0Utb9ABRRXnvj34g33hzxdpHhzRvDcuualqVvJcRol5Hb4CfeGXGOgJ60AehUV57oHxY0C90XU7zWhPoVzpdytnf2d4haSCVs7QNmdwbBwR1wa2NP+IXhPUNNt7+01y0ktJ7xdPSTJX/AEhvuxkEZVj74oA6qis/Tta07Ur/AFCysbuKe6091juo05MTMMgH3xWHqXxF8I6Z4g/sS/1+yg1PesbQsx+Rm+6rNjapPoSKAOsorzPSfilFrXxdvfBuk29nJb6flbq6kuisjSBWLLFHt+YIwCsSwwSfTn0ygAooooAKKKKACviD9sn/AJK5D/2DIf8A0OSvt+viH9sn/krcP/YMh/8AQ5KAPCxivq74PXdr8PvgsmsXqKZr6R73y+8u0hIk/F+fpmvlOGMyyoi8szBQPXNe2/GK4aysNC8MWjHz7W3hR0Q4xtQH8y8j/wDfNAHG6g+q+O/F13cShEuJnMshLcRL6e/WtG68LXNhf24kli+ygf6yRBgn0wP51t+G9Fh0ezjM+5b7GWIJ79azvFFxrGrawmk28apCg3sP7y+pPYUASanpOoQwRrp9zI1mFyYg+UUdTtHam+HvChkuPtERcktyGOOnNdNDqFvarHaXcRtpIkC7cZUqB2IrKj8UQQ6htRXwcgBRwDQAapoczWjCIHaSRgdDg4/pXMaO2qeH7udslkZ8NGmfm9iK7i68QxGxSH/VTfKdj9cE5Yj25qaCOCSaO4YDLHeW/u4oAi8U+PPGV54chsJY5LbSEQRyRKwDSD/aIOQPpXmWsWs0TW089p9lhYhMk/KR6g967f8Atu3v9altJpQtsPljQfxt3Jq34tsDfaCNPs4jJuKgbuoxzkGgD0b9nvXLa/0C80G7cXMllcGN88q0cp2Nj2zg/nXzB410kaH4t1fTFyVtLmSIZ9A3H6V3vwi1KXRvGVrFFJKPNjktriPb8wfnAGOvQEe9Y3x1MbfFfxBJD/qppEmT6NGrD+dAHu37Dv8AyCvF3/Xa2/8AQZK+dfix/wAlT8Zf9hq9/wDR719FfsOf8grxd/12tv8A0GSvnX4sf8lT8Zf9hq8/9HvQBb+FmiQ6hrT6jqO0aXpi/aJy3RiPur+JrXilu/Gni68168ZRAJQUQ5+6OFUD0Ap9zGPD/wAKLC3bMd1rMrTOehMY4WpvDOmyxaZGrxLgMSmG+9nvQB09xK7TKkWeRgEjGR3xT9QlCW+wIxeRQo56Y4qpM2Fj3L5RjGQARgfTFNln3XdrJIcxRsP8/wAqAL9raFYXRn2sqkuVPC8dM/rUs175dlE9tbpsZSnzphhTbsvHYXSRkbyu4Y9Ccn9Kkv0kW0leRgSEAAxwen60AYNt5gKsGIDMBj19qke0t5764N+ocsuxexAx1qurKJFLglR6GgTRmTJZ2I9R0oA5Gz1G58I+KtPv4C6pBNvjyMlkPBU/hTPizo8OneKGu7DnT9RQXcBHo3JH4HNbXxAtGudEW5GwLC4ULjnkVm+IprvWPh5o9wbf9xprtbmbHXJyBQB1v7If/JZbb/ryn/kKtftk/wDJXIf+wZD/AOhyVV/ZD/5LLbf9eU/8hVr9sn/krkP/AGDIf/Q5KAPPPhH4ZbxZ480vTcfuTIHmOOiLyf0FemfGTxPP4s8YLpmmhV0vTD5NtEOnyjGaz/ghC+heC/FPimLyxcrELOBnONhfqR74qX4faOZJZbm7SVLlC2WdOGJ5JB7/AIUAXfA+irpm6/lhAdCyEk5y2O30B/lXQT3Tp/rVYc4LZ6A0thFJEGs5G3B5t4kRchQQAdwz7frUEoc3sX2t/MTcRtUZ4+lADr6C/wBR1axH21YLaFXmSOJME8gEfqKbcNFNNeBvks2Ty5snad2eMdefapIftMfi7NxKjJ9n3wqq7dik4wc9T70+3j86/wBRjVyxlfbtHYHqQPwoA5DWfDd1dR38nmH7Lt3QmUYc8d/1rnfAniiTw74gstQDFXgby5VDfejzg/1r1dpP9MkEyq6qxVwc/KvXle/1rzP4i+H47G8+32aGOKU8qEwpzzwf6UAUPj94fg0bxsbrTgP7O1OFLyFh0IYZP65rzUEjkHpXsnxOzq3wl8Haq4LSW4e0LHnIByOa8b+nWgD9M/h7/wAiD4a/7Blt/wCilrfrA+Hv/Ig+Gv8AsGW3/opa36ACvLviJ4Q8V3/xF8P+KvCEmhmXTLSa3aLVJJVVjJkZAjU9j6ivUa4vxb46OheJrHw/Y6Hf6vqt9ayXUMVtJFGu1DghmkdQKAOEn+GPjG20bWdRstetj4t1vU7e81I20klpC9vEGAt4pFBkThvv9ccepOTqXwyvNC+F/wARhrTW4kvpF1KxWzuJ7uSKWNQUXfIA7MXAXPOQe3Suxi+NGmXFl4aks9D1q7u9ba7ijsreNGmhltgPMRgWAzzwQenJxVXxJ8dNI0PULq3k0m9lXT0iOon7RBG9s0gB2LGzhpWXPzbAQD3oA3fgXoN5o3gG3udZ3HXNZlfVdQd12sZpjuwR2IXaMdiDXGeIfhf4qurXxj4d0+TRX0DxPqp1OW/uHk+02u5kZ0EYUhsFBt+YfhnjpbP4wadqXjVtA0fTLi9SO5jtZblbmCMqzY+dYXcSOgzksF6A+lUpfjpoSeIxYrZXD6aNQGltqAuIeJt23Ih3+YY88b9uOvWgDpfB/hG90T4ieN9duJ4JLHW1sFtVV2aVfIgMb+ZlQBknIwTnviu3ryi5+NNjb6jcxt4e1k6baa2+hXOogRmKOcMFBxu3EEkHpwPU8U3wn8Sdc1HxR41sb3w5dzWejXEqQywGJdqpGWCOWk5Z8fKQMfMM45oA9Zorxd/jal7pXiy3sdIeHxBpGky6nHEt3b3kRVcLuZ4pCBtLAsmQ23pVjRviJqWp6f8AD241S21LR7jWZ442VIoHivd0AcuMszJGSSRjDetAHsFFeXab8YrG9udOuf7D1SLw3qV//ZtnrTmLyZZtxUfIG3qhZSAxGPpziFPjTYtqUMbeHtZTTW1g6G+okR+Ulxu2jgNuIPXOOB6nigD1eviD9sn/AJK5D/2DIf8A0OSvt+viH9sn/krkP/YMh/8AQ5KAOB+Dmix6146s0uU321qr3cqf3ljBbH44ra06WXxJ41vNV1AgASFm54VmJOB7Ak/pWb8IZWgvfENwhw8ei3hBz0/dGui8D2Yj0FnkXcbmRmOeeASP6UAbsgfz5GmHDHCkD7wpcxRfaJiQ00gRM46KOgq/pNpJeTC1bqMFSx5PpWLeWs8V7Lb3HymJznn8qANlls73y1uHTeoKgA881589rBZeILlQrmMscSkYB9BXRz3dtYvHGilnC8yHrzjiklt45kVZlMguF2+gUev1oA5DVRJqF9Cm4iTIIfsvHTNeiWfh+O3gQSzzSR7cGPfwaxre1t4ovLRP3EYCOrc54xn862tDurecFHnZplBQIW4yDx+mKAKNxZWZ1GKeKFI54XGCB29Kkt7jDBo8lhwQT157VFqaiB2C539SKfAsYgHOJAM0Aee+IAdN8WSyMj+RM6yHH3h3yD61a+NEaT+IrDVbZzJb6jYQurEcgovlsD7/ACD860fiKqtYWblclJQN46YPaqHxYnAtfCNqAEeLShIyg9C8rsP0xQB7l+w5/wAgrxd/12tv/QZK+fPiVAbr4v8AiuBesuu3aj8bh6+g/wBh3/kFeLv+u1t/6DJXg/jMkfHTxDgZP/CQ3OB/28NQBsfGKAW3iXR9LUuxtbaKJkJJ2nAyAK1dG3paxW84lhliUbUIxkD0qv8AFx1PxnmkdQURoy2312jmtO5uXaXs+OcHn/8AVQBXvPmOGjOfXNSSN+5iGAce1Olk+0BcJtIGTTJc4GeQvTFAGlp8jyCQzAMS6fKOuNwpl9cs8E6ZwGbgUzSTKYnlP3nYdf7o5/pVOIszbmJAJJoAjEDSyKqkbsZ/D1rrfBfh+3vpnF1IEQDOW4rm1xFIXTlenPcUs80buGBkLkYxuIH5UAZPxBuUhW6ttO33SQvn7Qi5RSOOvSsu0uHX4H6h50oMcmopHFFt5DBdzHP4jitbxTfImhXlsoBkKhdsY+5k9T6Vi3gWP4G2KkYZ9Vkb64UCgDo/2Q/+SyW3/XlP/IVc/bI/5K3Fx/zDIef+ByVT/ZD/AOSyW3/XlP8AyFaX7Xcfm/GezjPRtPtx/wCPyUAR38P9kfs/6PbIDHJqd9vftuCj/wCvWzoiQQ6JafZpZZJJYwWKyDdn2/z2rO+Nyy2WkeCtESMK0FqJhyMHd0JrY0y3ktdHt45FhWZVH+oGOfXnFAFqAQW2m7o5pNi9WADO2T3J70kRFtq0ypI0igBCcdPrT4FJbaWH7pAF2gFckg5x/erPsGWQsxIkmMpLEkjj1HqaALVjC/8AbOpXDO0jgL5ckvRExkp+fNVbGDzNQkJPmkMBhTjOT1o0q9e9t9Qnurf7PIblohGTuwFUDP45qbSY7dIprqRGdkOThtpxQAt67fa2HzqJCu9iAMKOg/MmsPxtO6afb2l1GIrOZhtuQ28ZXkDHY8Vsyu8zk+WuQQESQlRg5JJwD3PSsTxlp1zcaXLLf3Mcdvbx5WGEE/MeM5PXj6dTQBgy2d1qPwWupmk2adZXpMC7ss5PqO1eRDgg5x9K910shP2b9SyhU/bR83UH2rwnI6UAfpn8Pf8AkQfDX/YMtv8A0Utb9YHw9/5EHw1/2DLb/wBFLW/QAV5f488GeINc+KOhavouoy6Ta2unT28l/CsUjo7MCF2SA5BGeQOPWvUKKAPPfD/wp0fQ7vwjcWd1etL4da8kjaRlY3Ulyu2R5Tjk9xjFVfEHwmtr/wAS6jrOk6zdaTLqZU3sSWtvcJIwGNyeajGNiOpH1r0yigDyu7+Ddlf+KLDVdS1u9u4bG6jvIYZLa3EodOVU3AjEpQEfczjp6CnJ8H7W01q5udI1y9sNOurs3s1ktrbyYctuYRyvGXRSewPrXqVFAHnVx8KNKm0fVtOa+vhFqOvt4hkYbMrMWVtg4+58o9/eotR+FMF5qniiRNf1O30vxGrfb7CNY9rSFNm9XKllx1x0PfI4r0qigDy7Rfg7YWM15Lf6zf38l1oUnh9wYoYVW3ds5URoPmHqcnkk5q1o/wALls7fwxDqPiHUdRXw5cibT/Miij2RrGI1iO1fmAA6nn3r0eigDy7Tfg7Y2Vzp1t/bmqS+G9Nv/wC0rPRXEXkxTbiw+cLvZAzEhScfXnNz/hVGlf2P/Z326+8r+3/+Eh3ZTd527ds6fc/X3r0WigAr4h/bJ/5K3D/2DIf/AEOSvt6viH9sn/krcP8A2DIf/Q5KAOG+FToF8UxnG99FutufZMn9M12XhNZI/DVkpkBcx5UY45JNeefDC/trHxhaJf4+xXavZzknGElUoT+td/4c+06el9pGoLi502ZoH568nBHsR0PpQBvW07LgozJMoyCRiqiyvc6jK0/+sPLH1PrWfdXty2Vt3IGcYHaore4aObziSzFSCc0AP1awEkoiDAkncpHbNU9C1qC2Elrq8qpJC5Cs3AYfWtOCQRkPNl3A+XPaqN9p9nfWtxFOAFMm8MAMoeOfxoAbdalHd6pHp+msJHky8j54VBWtodmkDSFDwxLM+P0rM0LSLSz1aaeD5Ujh8vcSPmZjk1v2SKNw8wAc4x3oAra2oMnmNjcQo49s/rzVSCN2TeRhAeeaNRmywRPmOcA9cn1qxbDL7WZlK84xwaAMDx/E0mj2Ua7NrXKjGeScH/P4VzHxcOzxvcW27P2S3trbjsUhRSPzBrrEik1Dx3YWmoSxy6ZYq2oXBjXASNASc+/BH415fruoS6vrV9qM+PNup3mbHQFiT/WgD6m/Yd/5BXi7/rtbf+gyV4V4ubb8eNfOM48RXPH/AG8NXuv7Dn/IK8Xf9drb/wBBkr5++I032f4yeKJicCPXrps/S4egDr/HcSH40avkboop/u5yANv9M1ZEeJScEnbkYJp/jZvL+K8l8E32uqQRXCE91dByPxqWVng818NKVBZFA5HHTPegBseRs3HO4ZOSOKfHgTYAyO+RUPmv5UZdfmK5fb2NPtSXLtGeSQuO2Dz/AEoA1UWPZAuCuxjtBPXg1RngSLb97LetPkkRZraOR9r5ZgFOBkDv+BovJxJCMjo+M/4UARygKQoB+gGapzKPmCuUA9BgmrUcgKcjjqCen1pLiLfxFIA69QV3Ej16j1FAHPeK5fsOjCCCJSJ2IY9xjkmq3iwLZfB7wnbEYluZp7k5/u7iB/KrfjKMGxhtbf8AfXksmzbnLZJwAAPfFUPjTJHa6rpWhwMCmk2Udu2P74HzfrmgDpP2RP8Akstt/wBeU/8AIV0P7TiLJ+0BpKScqbK3BGcfxyVz37If/JZLb/ryn/kK2P2rrn7H8cdPuADmOwt24P8AtyUAa37Qlkh8VeHVZcxyWyop3c42jI/+vVOxugLRLadybmECNgx5IXgEexGOa3/jvK+p+FvCHie3RZIVVUcqfucYIP61yV+GubW1ubFle4yrRybsAA8MCe4wefpQBuwTpteITLGCPlG05B71DalIjtCnbzh16j3qjGs+0gTQu4UZXysEe+Mk/pVi0BdWivNjbwUcLnDDtx2NAEOhqIRc7bjzbMXDYbqWOBu/XvWrpZ2QzxOo2vyCevXH/wBesPw5DHYaSREQIZncru5CjcV49DxV+QlpMKn7vbyS2D+Axz9elAF0TmPe7yRhk5LBsKfc1wni3xJMY72wgVrq0lxtuNuAD6E4wfqK6hI5JLebzWWEMCoxg7UOB1zjP8qx/EMP9sajp2i2K+YZZFj2qRxzgfl60AaWrqulfsxW8UiEPd3hZd3ceor56PvXvf7SWoQaXY6J4Qs5S32CENPg8FyOa8EPWgD9NPh7/wAiD4a/7Blt/wCilrfrA+Hv/Ig+Gv8AsGW3/opa36ACiiigAooooAKKKKACiiigAooooAKKKKACviH9sj/krkP/AGDIf/Q5K+3q+IP2yf8AkrkP/YMh/wDQ5KAPDY3KOrqcEHIr6A1QxanoPhvxXCBi/iXS7/HaeMfI59yuB+FfPte3fA9v+Eq8K+IfBEs6JNdxi4sWkP3J05XH156UAS3UGwNsXauMM3eqjxBCY+CEIPPpUOi3N3fWctpqBKajZSmG4jYYKkcc1YMIiw24sWOGoAGJHPAz1zVa+hlFzbSWsjhywQlB2z39sZrQljOUCjAYAVDlI7mGAZ3tkqB3x1zQBMo2IAzMSvO71NCu0cRJHBHPNOcKsJO4hB1zzz7USDftWNQCBk7vWgCkd7PuU4ZTnpznNaaXMhh33WxYl5LZI6Cq+no8cjBkyQeTTtEiHiPxebWeQL4f0qP7XqUgyAQvOzd7nA/GgDF8Xvb+FPBkttHHs1rxGRNKCTugswcop93IyfYD1ryY1ueNten8S+J9Q1S5wGnlJVR0VRwqj2AAFYYoA+tP2HP+QV4u/wCu1t/6DJXzr8WDj4p+Mv8AsNXv/o96+iv2Hf8AkF+Lv+u1t/6DJXzt8WP+Sp+Mv+w1e/8Ao96AO+vFOvfCTRddgy17oU32a4A6mFjlT+ByKmiuluLWK8hy8IjJ+U5HHX8ayfgP4ps9Mv7zRtZUSaTqUZgnjP8AdPce461f8UaJqPgDVZLGV/O0W5y1ldDlGU9DnscdaAF09tqGR3crINyxHnYD1BNSwxlVIQ4Vjjr/AD/Os4XATSPtESlpVUAxk/8ALQnH5VqBWCHj5iMEDpu74/OgCaSVo722jVkVDFIxQjlunSopUA3RQ/dbBCgdO+asllJZM5kSMA/7IOf8KgfcqqVGBngAfr/OgCO3wZ1j5xsLhl656EfrVgutskl1cvlI1xgAAdfbqc0sEcab5Jf3cQzknqBWBoVjqXjzWY9E0cS+UDumncnZGg6s3sBQBf8AhjZLdaxqfi/VgBpekb5139JLk52KPp1/CvJde1GXVtYu764YtJPIzkn3Ner/ABn8S2Wm6bbeCfDTKumWX+udes0n8TMfc14z1oA9p/ZD/wCSy23/AF5T/wAhVz9sjj4uQn00yH/0OSqn7If/ACWW2x/z5T/yFW/2yM/8LchA/wCgZD/6HJQB3Xweni8dfCe/8L3TL58KeZbnvkelebeH49RsdSl0eedIUgciUSx5cD1Tt1Fc18HvGs3hDxDDMrnyywyP519AfELwlZ/ETSv+Eq8GSFdWjUGa2U4Zsf560AcXFHAEhe1KTJBcAs4O5mYYzk/3sH9KWaDUBcKljHayJszlmKkHnrxzyM/jXNeG7mDT797S+a402fpcLtyGP+6eh96311r+zWvJ5ZVntFiLQO2FYHoFPbv+lACWd7bWukQNeyxwzJvBROcvvOQv4nGa0bg/Zisb7vNdyiIq7mJUAnJ6Y5rM0zVNPvdEtFjsDeSsX8wqoyMY559eao+JfE4sLrTnt7QuIWIaORh82RjHHsKANLxBdtpFkZowrpcsVNu545HVfT3HIre+FOjHQdG1Dx7rgAigRhZxyJ1Y8AiqvgT4f6l4y1ddZ8Qg6f4fgbzcyEguOuFz2rD/AGjfiHb6gYPDnh+ULpNqNoWPoexoA8Y8Ya1ca/4hvtSunZ5J5C2Se2axe2KXPrQaAP0z+Hv/ACIPhr/sGW3/AKKWt+sD4e/8iD4a/wCwZbf+ilrfoAKKKKACiiigAooooAKKKKACiiigAooooAK+IP2yf+SuQ/8AYMh/9Dkr7fr4h/bJ/wCSuQ/9gyH/ANDkoA8JrY8J67deG9etNUsXKzW7hx+FZFFAH0d4qjs/G9j/AMJ74O/5C0Kj+2dNjIy6D/loq9/euatpobqBZraRZUbnOcEfh615d4Y8Sap4Z1OK+0e6kt50OflPB9iOhrvbfxHofiO7+1I8fhvW5f8AXEKWs7hv7xUcoT7ZH0oA3WleRlUZJxleOn1qukitqMULMDNHEXYdxkjH9akTS9daXFtDpN2T0eHUosN+BORVWPwH43XVP7T/ALNSeZlCkR3UbDb6cNQBqJcGCOTAC7uKzr3UYNOhSe4cqjcAjkAnjmrM2i+KhEWl0NbVgMtJdXKRxj8SaybgeHbDbceLtbXVJU+ZNK0sERk9vMlxjH0zQBsaVpGo+NVki0OQ2WkRPuvNXmJSKMdwD/EfYVn+PfFmg+H/AAi3g3wM7zRSvv1DUWGHunH8lHYVyXjT4i6t4jiSxhKado0BxBY2o2RoO3Tqfc81xROTzQAHrxRSUUAfWv7Dv/IK8Xf9drb/ANBkr51+LH/JU/GX/Yavf/R719FfsO/8grxd/wBdrb/0GSvnX4sf8lT8Zf8AYavf/R70AcxDK8MqyRMVdTkEdq9X8C/FU22nvoviq1i1TSZePLnGdnup/hP0rySigD6A/wCENOo2k9x8PdUivbSTDtplw4SVMEMApPXBFYmo3ur6ZMv9paHeW9wAw2tESPqD9a8p07V77TZQ9ncyRMOflOK7PT/i54qswgF/JIE+6JDux+dAF/Tb3VYnvr+bT7+fzSCqrCwQKPXitS2v9T1B449E0a+ubp+CnkNtz6ZxVCX45eLHkyLkKm3BRVAX64xVS7+M/i2eMol80IPXy8Ln8hQB6BF8OtWu4Um8eavZ6LZKd5thIDI4PbAz+tVPGHxM0Xw1ocugeALVbVGGyW6H+sm+p9K8U1bxBqeqyFr68mlzyQXNZZ9TQBLczyXM7zTMXkc5Zj3NQ0UUAe1/sh/8lktv+vKf+Qq3+2T/AMlbh/7BkP8A6HJVT9kP/kstt/15T/yFW/2yP+SuQ/8AYMh/9DkoA8L53YBNdX4R8e674XlV9MvJYwOwbt6VyfaigD6Dg+I/hLxlaL/wmemCO/B5u7f5ZPqexqwnhn4b38MjJ4m1CFWGGDkHAyOPftXzqCMe9OEjrwrsB7GgD6RHgD4bAMIPGV+sS8soTJI61dtdT+FPghBc20M2uX8Yyj3RwAfpXzCJpBnDtj60jOzD5yT9TQB7B8RvjhrPidHtbMCzsAcJFGMKBXkEsjyys8jF2Y5JPemUEUAKoyaD1o6daDjtQB+mfw9/5EHw1/2DLb/0Utb9YHw9/wCRB8Nf9gy2/wDRS1v0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeE/Gv4EXPxH8YprcGvQ2Crapb+U9sZD8pY5yGH96vdq+Sv2o/iF4s8L/EqKw8P67eWFmdPilMULALuLOCensKAF/4ZKvv+hutv/AFv/i6P+GSr7/obrb/wBb/4uvH/APhcvxD/AOhs1L/vof4Uf8Ll+If/AENmpf8AfQ/woA9g/wCGSr7/AKG62/8AAFv/AIuj/hkq+/6G62/8AW/+Lrx//hcnxD/6GzUv++h/hR/wuT4h/wDQ2al/30P8KAPYk/ZO1FPueMYF+lkw/wDZ6nT9lnWUXavjhQPT7I//AMcrxb/hcnxD/wChs1L/AL6H+FKvxi+IrkBfFepknoAw/wAKAPZZP2VdWkGJPGsbDpg2jn/2pUP/AAyVff8AQ3W3/gC3/wAXXI2mr/HO7sFvINQ114HTzFIxkr64xmuRn+L3xHgmeKfxRqscqHDIxAIP0xQB65/wyVff9Ddbf+ALf/F0f8MlX3/Q3W3/AIAt/wDF14//AMLl+If/AENmpf8AfQ/wo/4XL8Q/+hs1L/vof4UAewf8MlX3/Q3W3/gC3/xdH/DJV9/0N1t/4At/8XXj/wDwuT4h/wDQ2al/32P8KP8AhcvxD/6GzUv++h/hQB9gfAf4VTfC601iGfVo9R+3vE4KQGLZsDDuxznd+lea+L/2YLzX/Fmt6ynii3gXUb6e7ERsyxQSSM+3O/nGcZrd/ZH8X6/4t07xK/iTVbnUXt5YFiMxB2Bg+cfXA/KvD/iR8WPHenfETxRY2PifUILS21W6hhiVhhEWZgqjjoAAKAO9/wCGSr7/AKG62/8AAFv/AIuj/hkq+/6G62/8AW/+Lrx//hcvxD/6GzUv++h/hR/wuX4h/wDQ2al/30P8KAPYP+GSr7/obrb/AMAW/wDi6P8Ahkq+/wChutv/AABb/wCLrx//AIXL8Q/+hs1L/vof4Uf8Ll+If/Q2al/30P8ACgD2D/hkq+/6G62/8AW/+Lo/4ZKvv+hutv8AwBb/AOLrx/8A4XL8Q/8AobNS/wC+h/hR/wALl+If/Q2al/30P8KAPYP+GSr7/obrb/wBb/4uj/hkq+/6G62/8AW/+Lrx/wD4XL8Q/wDobNS/76H+FH/C5fiH/wBDZqX/AH0P8KAPYP8Ahkq+/wChutv/AABb/wCLo/4ZKvv+hutv/AFv/i68f/4XL8Q/+hs1L/vof4Uf8Ll+If8A0Nmpf99D/CgD6Y+DfwCufh541i16bX4b5Egkh8lLUxk7hjOSxqb41/Ai5+I/jFNbg16GwRbVLfyntjIcqWOchh/e/SvN/wBmb4i+LvEvxSg07Xtevb6ya1mcwysCpYAYPSrP7UfxC8WeF/iXFYeH9dvLCzOnxSmKFgF3FnBPT2FAC/8ADJV9/wBDdbf+ALf/ABdH/DJV9/0N1t/4At/8XXj/APwuX4h/9DZqX/fQ/wAKB8ZPiH/0Nmpf99D/AAoA9g/4ZKvv+hutv/AFv/i6P+GSr7/obrb/AMAW/wDi68f/AOFy/EP/AKGzUv8Avof4Uf8AC5fiH/0Nmpf99D/CgD2D/hkq+/6G62/8AW/+Lo/4ZKvv+hutv/AFv/i68f8A+FyfEP8A6GzUv++h/hR/wuX4h/8AQ2al/wB9D/CgD2D/AIZKvv8Aobbb/wAAW/8Ai6P+GSr7/obbb/wBb/4uvH/+Fy/EP/obNS/76H+FB+MnxD/6GzUv++x/hQB7Cf2S789fF1t/4At/8XSf8MlX3/Q3W3/gC3/xdeP/APC5fiH/ANDZqX/fQ/wo/wCFyfEP/obNS/76H+FAH6B+HNOOj+HtL0xpBK1laxW5kAwGKIFzjtnFaNYvgm5mvfBmg3V1I0txPp9vLJI3VmaNSSfqTW1QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8Qftk/8lch/wCwZD/6HJX2/XxB+2T/AMlch/7BkP8A6HJQB4X3pKX60AZoAltbeW6uI4LeNpJpGCoijJYmvV9M+GlnpOjf2l4pu4oW2krCTknHYKOW+vA+tXvgf4Qk+xSeILmAq0jGK1mk4SJFBMsx+ijAPqfasu30m98YLd/ZZZbnUrq5KZAOSucKAvZcYwBQBX0nWfBI1CO1vLK5+xlgplVUyB69D/Oum8b6DoXhZP7S8PT/AGm3+VkLQ/Mu7p/+sVix/BvWNM177PrIEUEbj5s4398D3Nd/+0/APD9v4a0uxtlRBagNGuC2VI6kfzoA8jbxJrc92+oWN/fW5gICEXLMUznqfWt42q/FC4iNtCh1hjHG7khJGyMFiAMMMg88da4+0muY7aa0TCCU73Q/w4GRz3Nenfsr3Fo/jS90+9hV5bxAilhgqQwY4x06UAcv4s+F8Hha4+zanrdobvGTDE25l+tcjdeE71bVrqzVp7cdwBn9M1tfGTRL7S/H+rC8DyQvOxil5IK5I6+1Hw71XVdIa5aziWaDHzQXC7o5B12kf1oA4NlKsVYYI60hr0X4l6PZ3FlZ+JdGt2trS9QPJAxyYycj8RkEZ9Nvc151QB9afsOf8grxd/12tv8A0GSvnX4sf8lU8Zf9hm9/9HvX0V+w5/yCvF3/AF2tv/QZK+dfix/yVPxl/wBhq9/9HvQBylFFKBmgBKntLS4vJlhtIJJpW6JGpYn8q7TwN4DOsWMut6/drpHhq3bEl5IPmlb+5GvVm+leg23jyz8M2xs/AWkW+jQhflv7qMT3s3+0eyCgDjNE+CnjvVrdZ49Flt4GAIe5YRAj15q9d/ATxxBHujtLS4b+5DdIzfkDVu/8Ua3fujahf65qM0g3bJZHWNvU7VwMdagXxXYfao4bXTDBcpwZYXdHLe2MY5oA4LxD4Q8QeHZCmtaTd2h9ZIyB+dYRFfQ2kfE3XLaA28l5Drlg3D6fqyh2+iv1z9RWT4h8G+G/HUU954HRtJ8QRoZJ9DuD9/HUwn+L6UAeHUuKkuYJLad4Z42jljJVlYYIIqKgD2r9kP8A5LLbf9eU/wDIVc/bJ/5K3D/2DIf/AEOSqf7If/JZbb/ryn/kKuftkf8AJXIf+wZD/wChyUAeFUUvA96THp0oADjHFFejfCz4U6z49laaIpZaTCf315Nwqj29TXsC6J8JfA4MDWk3iTUEADNI2I8kD6Dv70AfLe1uyn64pCCDgjBr6Yb4leHJr2OK08F6DDFHwolXJB+uK14dU8AeJ1eLxD4RtLdiSpuNOblPcgYx+RoA+T8UZr6L8Yfs/wBte6bLq/w31ZNTt1UubR2HmD2H+Br591CznsLuW2u4nhnjO143GCDQBWo/GilNAH6Z/D3/AJEHw1/2DLb/ANFLW/WB8Pf+RB8Nf9gy2/8ARS1v0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfEH7ZP/JXIf8AsGQ/+hyV9v18Qftk/wDJXIf+wZD/AOhyUAeFj6V1Hw38Kz+MvGmm6HCSonk/eyAZ2Rjlm/AA1y4r274HuPC3g/xB4scFLmcrplk2OdzfM7L7hR+tAHbfGHxXbaX4fbw3oEiWunWqraKi8NMg6jpgAnk+vHqa8c0XXtR8PX2n6roVx5F5bctuwVZSehzx3qlqOo3Wt6rdxQuSszeZITyAB0Gf8PWuh0DTdPazH2twrqeI2bG7HfFAHZ+I/i63iWbS794PLvbVv3kI6OexB9Mj9azfEHiPUfiH4nbVtShMEMMfkxx+gA7/AI1H9isJDBILaHj5lZOQR0/Q1paeI47ebYERWJyq9Rg+tAHPXvh6FUneNMOI0GOmc5z/ACq74EubbwP8S9Mv7qMJbed88vsRyD+dbkYL3l0GA8sCPGOcAhqqeKNJi1TKK20n5h6CgD1jwnr2geJNZ1t9dhs5tPSQywtKgJUE5AH6mvGPi54m8O3XiC6t/BEGyDBWaQD5Gbodlc7L4f1OK0V7ebe24M8CsRuHb9O1c9fJ9jnlVQsMyHOwjHzdfzoA9v8ACPhqL4h/DWCwimSC/sYnspUYcSKcvE31Dgj8K+Z7y2ls7ua2uUMc0LmN1PUMDgivdvgj4os9G1uFhqDma5+SaJ48DeW3Ag+gIU/hXIftG6VFpXxa1c2ygQXZW6QjvvGSfzzQB7P+w5/yCvF3/Xa2/wDQZK+dfix/yVTxl/2Grz/0e9fRX7Doxpfi7/rtbf8AoMlfOvxY/wCSp+Mv+w1e/wDo96AOVruPhf4St/EOoT32tSG38PaavnXs/qOyL/tHpXFQxNNLHFGMu7BQB6mvXvHzr4Z8LaJ4JsyFlCre6jt6yzMPlU/QdqAM7xP4kuvFeswQ28IttJtB5dhZoP3dug6MR3b1JpLaBdPk8mA/arm4wrTMOfp7Ctnw3bSaTpwRxGZZfmdl/hGO579KtCJFnuZo/vSKWII56dvQ0AMtZfJiQHLNECkfq7AdB7Vz3hOzllmvdSuOL1ZSAp6YPJ/Gum0258iBPMzgttVff0o0uzlaGdpQogu2MyAHBTd6igDG1zSYddu7ORyLZo8h5k4Leg/CsS4lntNWlihuZVubF8wXaghkYdBnv0rpoGXzvKfBUPuyexHcVnav519fXdpa2qSCVAWkDbTHjpzjrQBe8XWNv8Q/DE3iKxhSHxLpqAarboMeevQTKO/vXjhGK9N8B63/AMI/4ssbqc4hZ/sd5H2eJ8qc/TOa5r4maD/wjnjPUbFMfZ/MLwsOjRnlSPwoA9C/ZD/5LJbf9eU/8hVv9sj/AJK5Dz/zDIf/AEOSqn7If/JZLb/ryn/kKt/tk/8AJW4f+wZD/wChyUAeFj0ruvhF4DuvHviuDT4gUsoz5lzN2RB1NcPEhkdUQEsxCgDua+rdKtl+EvwZREUL4h10ZY9GRCOPyB/WgCp8TvGdlp8Efhnw3i30HTcRHyjtFw4HJJHWvI1ddT1BhezwxFuiOSDj2UfhjNFnbXmvamkVmFZYz+7LnC7ueWP0yfwr0+w0PSbSawmurW2S8gUNJKg3Bz34756igDjfEmhTafo9pcW+ya0DD5Sm35jxycYIrHjsNR066YCI2sqgHahOXHcj1r6L+Ih0Z/BOgx3DxxtLfRbhIdrcHIGPTArz7Wzb3q39tqMIkhCNKM8Hj+JSOhoA5jwh4u1DRtVM+l3TW9yGyVb7snsy11Pxo8K2vjvwgnjTQrcR6pbjZqNugHJxy/FeWv4euLCVp4rqO52HJcOd4HoRXqPwe8Swad4kgtLsn+ztWhaG4WRvl3HgGgD5nIx1pCDmu6+Mnhf/AIRTxzqFnGpW1Ll4T2Kn0rhaAP00+Hv/ACIPhr/sGW3/AKKWt+sD4e/8iD4a/wCwZbf+ilrfoAKKKp32qafYMq319a2zMMqJplQke2TQBcopsbpIivGyujDIZTkEexp1ABRRUUtzBDNFFLNGksxIjRnALkcnA7/hQBLRUF3eW1lGsl5cQ28bMEDSuEBJ6DJ71PQAUUUUAFFFFABXxD+2T/yVyH/sGQ/+hyV9vV8Q/tk/8lch/wCwZD/6HJQB4WoJIA5JOAK9a8fX6+HfD3h7w5bki40+2S4nUD5fOmG9s+p2lB7YNcr8I9Di1/x3p9vdY+yQk3NwWOB5cY3Hn8Ksa3LceK/HFxLPxJc3DTS4OQqDsD6DoPpQBr+DrW1stPNxe4W4k+c57DHFa/hXT9N1J2vplWad3aRCRkKoOAB+VTbEnnXKAW0Awd3TB4pngy38q+1iWJsWm/ZGgH3eOce1AGrK3nzN9mRYYUJwQByTVuxtcKMITgEYJGM5zk/lWNdXf2ZhHFtJP6VY0S/leeRWd5Bszt9TQBV8H3V7cPqFvcwYWKdnaQNks2en4DFa0mUZIxubC7STx0P9azdCvIU0RbmCPyXnlkYknO/Ln+mKui6M6OrnaSOqdaAIdYubmwgE9tbRzoFy259p3f8A6u1YWjWsOvQanfTQ8XC7VRh0YDr/ACrT1xJLjwrqdvECPLiLqR1Jqt4fkH/CL2Btccw4bH97JzmgDzvSD9ivZD9oEc0DKyKRgu27BA+hrtf2hGkutS8NX86bZZtLWNvcxuyZ/ICuX8dWgt9Yilx8jjnHr9a2/iFEbr4c+E72NxIlrLcWbHOSoO10B/8AH/yNAHtP7Dv/ACCvF3/Xa2/9Bkr51+LH/JVPGX/YavP/AEe9fRX7Dn/IK8Xf9drb/wBBkr51+LH/ACVPxl/2Grz/ANHvQBo/BzSor7xYLy8UNZ6bG11LnodoyBUtrfxa14pvtV1WJ5zPMWVQCdvPHHpitfwjs8P/AAn1vUiyfa9RYW0SHqV7n9aZ4W0i3TSlui7iSYnGT90DpQBt71kWLI2oTtCYwVFTXshWGNEbG47egBNUZB5LY3M7D1AFSyOXMEwUjaRgGgC5bxos7ySjba2m7JP8bAfMfwqG3eQ6dD58qFnXMYX06jNTagqtp19GG6wPkDqCRmlFtFFZhk+8kIBz1zigDKXamCQdxOAB6VJCUtbt2ixlyMt7elQbWAGOnbNSwJJM+FVc988UAcv47spliXUCVG47W2/oa0viiw1nwd4V18Jtla3+yzH1ZOP5Vb8U2ML6Bdb1JmG0KQ3AOR/9esnytQvvhVLGFzZafdnLjkEsOgoA6T9kP/kstt/15T/yFW/2yf8AkrkP/YMh/wDQ5Kqfsh/8lltv+vKf+Qq7+2P/AMlch6/8gyHp/vyUAcB8GNAHiT4jaPYsuYfODycfwjk16d8adcPiHx/LawtugtWNvFt4CAdcVnfsz2a26eJ9eldofsViwSVQMozccfhmsvwkbW61y6l1V4JoHDSK7ElwT3oA6TwTpa2dg87T72ikMa478Akk/Q4H4+tad35qyI2Qqlwwixgn0qr4dg8uV/sLSLo8kpkPmgkHHB2NnPbHerkaCa/3w7QYm3/Oeij1oArX1lYXXibTotRDTSSRSSbWJIDcEcdv/rVPdvIt7MSgc2qEiKMjLAjnk8YrMMVlH4+U2DGRzEXm+cuFOCAB6dTxWi/lG8uElbb5gCltvpjKn64IoApvodq+oS3l2FW6niCiKADZ9QMcn3+lebJdTade3MEqvC8UmY1YYKkHIr11LlxfvFsKKqLMsitlNh4AOeR06CuT+IOkGe3OqIiEJwzjIcf4j+VAF79odI9b8F+DvE0SAyTwGGdu+8f5NeAY/OvfPEkZvf2dNPfkm2vSCSeeQa8DNAH6afD3/kQfDX/YMtv/AEUtb9YHw9/5EHw1/wBgy2/9FLW/QAV8/fGyTw3F8cPBb+NhZnQxp11532xd0eeduR65xivoGoZ7W3uCDPBFKRwC6BsfnQB8t6HryeG/DHiu60O61jTvBN/r1ta6DLBIsGC4czMJJlYRQkgHcVOMeua0dC8aeM5fh54u1G01r7fP4X1WK4V0mjuhc2YAMsRmVFDrty28KDwccV9KXFvDcwNBcwxzQsMNHIoZSPcHis7xBoNprWgahpErS21tfwtBM9qQj7CMEA4PUcdOhoA5L4Ma5qnizStW8TX9xKdN1K/k/sq2dQvk2sZKKeBnLEMTnPQYrzz4s6h4c0b9oTwFqVxq0UNzE1z/AGkJ7slLZfJQREqTiPduboBu96940HSrTQtFsdK02Py7OyhSCJe4VRgZPc8cnuanlsrWZy81tDI56s0YJoA+Yv2mZNdvZrq51bRNRTSrC9t4dLlSSP7OckGSRhv3GRj8q5XCgHuxr6c0+eS6sLa4mtpbWWWJZHt5SC8RIBKNgkZHQ4JHFSyxRzLtljR1znDDIp9ABRRRQAUUUUAFfEH7ZP8AyVyH/sGQ/wDoclfb9fEH7ZP/ACVyH/sGQ/8AoclAHK/AWcx+KdThjx59xpd1HET/AHvLJH8qqeAkNxe6lecKABGoHbJzgflVP4OXDW/xK0EocGS4ER9w3BH61seA4DDDqUG4BopdkiMMYI4/oaAOotvurASZG55A+8PQ+/NS6LZPp9new84MhdSR1B7H3HSptPvhp8iSCNGxztbBB9wRUd/qZnnlmiypkGWU8cn0oAzDDG1w8kpztHAp9jG3mF1bagBPHpUIBIDSHhj8ue9P1W4khsF+xhWuH64/ujk/4fjQA2NC+l2Ihx5BiBX8Tn+ZNPk3R+W0TEtwGGaXRZluLHyZE2SwfIqn+7xUcu9WwmOD2oA27BwLS5MhOwxnIrF02AaXYwwIxPTINWLO5ZIHwMnGDntUcYLyFipck8nHFAGf45jN54ZlfOBbkOOPeotWm3/AG0VgM/2wNpxg58tifqPmFSeK5VtvDF6kzZaUBVHqc9qzviM403wN4O0QArI0EmoTDPUyNtX/AMdQfnQB7Z+w7/yCvFv/AF2tv/QZK+dvisC3xV8YqOp1q8H/AJHevon9hz/kF+Lv+u1t/wCgyV89fE7n4u+LM/8AQcu//Sh6AO/+I1qdF+EHhi0iyPtjmY47H/OKqaPDeWel28UyrLEV3KYzhlB5wQevXtW78fAI9H8CaeuQ/wBiEmzHY4wf5isRNQWS2jaUNb7QFKyjaAfagB8quZNyljH05FSSuViT1BwKEO4ZblTyCDSAMZFKjOOeaANGK3Z1kiV8s4Xcx7AnkVFfPsacYGNu0fn/APWp1qSqDzGMZZxtHc4Ofy4qO8KvjAOC2TzQBWRE86ISfcIyT/Sta3vtOgd47nCk/cUKSx9his3O7aAACBxxSNKeFAXKn72eRQBi+MIL68trmW2SO2sVyxDklmHr7VP4QjcfBXxNK8rCIToipgYJ9fXPaq3iK/nuNMlit/8AVD5Xd+D16AfhT9RkfSvgTYwhgG1HUJXIAxlV4FAGp+yH/wAlltv+vKf+Qq3+2Rn/AIW3Dj/oGQ/+hyVU/ZD/AOSy23/XlP8AyFXP2xRu+L0A9dMh/wDQ5KANP4XWjaf8APF98w2PdbYlY9wKz/h9cJJo6QpZMiKfmnZBsP19fwrstJswP2ap3hJG1m84HoePlP51yngOyWDQY5UuZMSkOUYBlz7Dr+tAHTXGo/Z7OGCxsrd55sNHA652gnlhjoB/9ao3eM6uXt0RCq7GdBhWPsO1VbxW8qPyiouSQEYj5gM9P931zxUCIk0sojaSOLzDIpjbBA5HPbHsaAKmkRTjxLrU4t4oIiFRwcgluoI+oFWVy9xNHbuUm4CMwzgbhux74ziqnhQfZm1if7ZJexSXRRXccnCj+WcVraVG3LKMEFuh6kD070ARKsDzTSR42tJ5chydxK9jn69uOawviOtxaaXbTi5VrFpgHtMYJ98+2K6WzjWed4XYoRx8g2EHdkkZ659a5n4h6VpltYme2upbmePPyyS7wM+34UAOuLS6uvgLdXM1yEshd74oEUbs8DG70rwavojxJHNpn7PFjDOqoJ5yy46leSM/nXzwSD0GKAP0z+HvPgHw1/2DLb/0Utb9YHw9/wCRB8Nf9gy2/wDRS1v0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfEH7ZP/JXIf+wZD/6HJX2/XxB+2T/yVyH/ALBkP/oclAHjvhu+fTdf0+9iYq8E6SAjtgivWJ7X+z/iJ4qtU4humF9CPVZcOPy34/CvFlO1gR1BzXuniV47nS/AXixXbyp7Y6VeP0VZEJKA/gT+VAFXyCZSsTKp7rupZoTHtRzhyMjntV2XzFIAkRc8jqcCqxDLLmeRHLdCvtQBhNfPdxy28N1Kt1bXWCnl/II+md3rx+tWdZkeHTpbq0Qnau0oOoz0Na0sMclw7KqBDlvQE+9M1S3E+nTIVA3gZVOM4PagDP0WGWCxSW++eaRAyg/wjA6j1NWdEvXvrGWZ7BQTIyIQxyMdSRV24jUqzKCNgG3d1IHbFZv9hww6supQllLKf3eeNx74oAm8uQjyxyzHtV63Plq0UK5wPm9Afr60iRywS7yoYbeT1wMUsMqRNJ5jKgHz7uxFAHK67BeeIfFGj6FB5btJKFIT1OOv4VgfFbU49T8cah9lYtZWm2ztj/0ziUIp/Hbn8a7fSNnhnwzq3jWWQfbLtpLDSQTyS2fNmH0BwP8A61eNyMXcuxJZjkknmgD6z/Yd/wCQV4u/67W3/oMlfO/xUO34r+LyOo1u8P8A5Hevoj9hz/kFeLv+u1t/6DJXzr8WP+Sp+Mv+w1ef+j3oA9R+NTtPoPw81cZYDT/KLY/utnH8656aaz1MxJBdo2cOoRsnjsRXVqG8U/AO2aNN95ocnmAbcnyz/k15sb21trJZ7YxxzMwLqB3oA6FLvy7tYpwF3DAbOAT9KvBgXBUjbjHrVctCzwI7KTL90Abs8ZJ9qW5ZLeB3DAIiFgP0oALmRo7mydSeZtuGJIAwe1XHbfIVLbgTnJ/p6Vy41pbi8sEVSUWQuxxxnFdAJElhSWIkxEnn8aAJnJwQjbTggE88/wCFVovPKBpxEz/7JNTTTRIoecoqMMBvT6ntUV66QS26SpthlO3eTjaaAOd8SeZFD5TPEd7+Yypk7QAcZ/E1a+LIOneGPCGjOcSw2fnyJn7rOc8/hWnoWjDxN40h0yCJVtY38yeQcAIvLMfyxXF/FTXF17xtqFzCc2yP5UI9EXgfyoA739kP/kstt/15T/yFXP2xjj4vwH002D/0OSqf7If/ACWS2/68p/5Crf7ZH/JXIf8AsGQ/+hyUAeo/DOA638Btas12yMYzjBB7d68r8I6vFb6fFp8siRyxNhNxA3f7J9CDmu1/ZJ8SQvBeaDeNlLhdqqehNcH8SvBZsfiE9ldq1tb/AGgyK5YZMZOePegDoLSGC2nMkIkdjHsLSSlzjr0J/lVyNlD7otyjnKgfe9K4q0uvD82rNYaek63UZCo1vvPmewYHnHvXQ6ZbG1eWIPLLC7bl3sWZW74J6g8fTFAD9Enk1BL9ngNtJ9pJMDEfKAoAPoc4rQRvIt38qYK5IILDgev6ZqlLKyQAwQtLLI7YQtt5yRknsMDNMkjv5Zg8txFbRqMmNE3Bvqxx+QoA1fNt5NzsARjOX5AOOorzKHTJvEPjiMafAIILuRVSNDjcM4yceuCa669gFtpt1dXjPdvgbYx8q4z0ABx6nPJr0L4DeGorm/uPEt/F5NlZx4iGcAkDnmgDm/2m7mPQ/CGg+HYWG5U3OB1HHevmY/rXoXxv8UnxT45vLhD/AKPGxVBnjFeeGgD9NPh7/wAiD4a/7Blt/wCilrfrA+Hv/Ig+Gv8AsGW3/opa36ACiiigAooooAKKKKACiiigAooooAKKKKACviD9sn/krkP/AGDIf/Q5K+36+IP2yf8AkrkP/YMh/wDQ5KAPC69t+DEll4w8I6t8P9QdYp7v/SLCZv8AlnOv3fz6V4jV7R9TudI1G3vrGRop4WDqynuKAPVvDaXcFvd6fqyFNQ02UwSRHlgR6/lU7SAzSMRlh0X+6D0H171p3WrQfEqGHXvD/k2vje0jC3tgSFXUkA+8nq49OprntP1Jb8y+ZGILpGKy2z/KyHgcg0AaCviM5OT70ea6vBGUZg7rkjnaM9aaufLwFCgHHSqd1fW0NzZ2xfY8smdvsBn8qANHeGbfIB/s+ufenz+aEJUjI6r7etNiJVuF3NngjoBQhy6tI6pk9zigCxbt5lsGkkwAM5HBArFgsb3xn4us/C+lkOsrBpp9uBFH1YnHYDrVm3+1+ILx9D8KWb3+ouCGlXAigB6sW6AD8q3dd8S6J8KPDVxoXhW4TUPFV9Ht1PUxyF9UQ+g/p+QBw/x0120vPEUGh6IQNE0WIWlso6HH3m+pOSa8zp80jzSvJISzuSWJ7mo6APrX9hz/AJBXi7/rtbf+gyV86/Fj/kqfjL/sM3v/AKPevor9hz/kFeLv+u1t/wCgyV86/Fj/AJKn4y/7DV7/AOj3oA7b9nnxPFpuvPpV+3+gagpt5QfRuM1D4/8ACknhTX77SbqLNtLmWzkK5DLyR/KvLLG6ks7qOeAkSI2RX0n4R8YaB8S/DNv4b8XTG31CEYtb4kZiOOAfUUAedWr2dlG1tpolleTD+Xj5jxznjgVbE0MhEMsTYYhdjrxnPHP1qx4l0DxB4Cu/I1S0E1lIf3d/GN0bp2wR7VX068t7yxImuQCy5LHAI5yMfTigCeaxtJbyJmUq4jfKr90YwAf1qGxglsrNxdThkBLFAPlUZyB7k8VUstbil1ieGeX5EjwzH5RgenvUt1daTLMjS6kRHFyI2fhsd8dTQBux+W6ENEQGUhkAyGBrjjKb6VIFMt3iTZBCTkg5wBir1pqOqatfCy8PRXN3cythIlhzsHQYIP8AOvWPDnhLSfhdpreIvGE8E/iHYXgscg+Wx6FvU0Ac74hVPhd8O57eUqPEusIPNAPzQRn+H8e9fOrsWYsxyxOTXTfELxXd+LfEVzqF7JvLMdoHQCuYoA9p/ZD/AOSy23/XlP8AyFXP2yR/xduH/sGQ/wDoclU/2Q/+Sy23/XlP/IVc/bHOPi3D/wBgyHj/AIHJQB5v8N/EUvhzxFbXMTso3g5U9K+sfiVotr8UfAkGs6QEOoWyb2QffPHIFfEQJBBBwRzxXsHwa+KVz4X1OGO7lZ7bhXUnhhQBQin+xa9puy0FtfWtwYZYQMFlxhvxrrNY+zJeXAsNRuIbpU3yKq+ZGAOMnPQ9Ohr1LXfDPg34rh9Q0K+Ww1pDnBAAfjoRx+dcSPg742txeQIsFwjrnK3GRJ1x170AZWk6jYW/hmC6u7oi5VTFIJDgySbievvml8RatbaGtjPd2TXQuThSgUkPjI69sVCnwm8e3mh/2ZcaEyReb5m8yqPmyTnr712vhb4HT2ttbTeOtbSG1t1/dw+aGK+2egoA5Lwdo138RPEkEFnZyWdqG3XDBiUVe4PbNeg/HzxfaeB/B8fhnw5sjYptkKdvXPuat+Jfid4T+HugPpfhKKPzFUoWHXPqT3PvXyT4t8R3XiLVpbu8kd97FsE5/GgDGuJGllZ3bLMck1EaDyeaCe3agD9NPh7/AMiD4a/7Blt/6KWt+sD4e/8AIg+Gv+wZbf8Aopa36ACiiigAooooAKKKKACiiigAooooAKKKKACviD9sn/krkP8A2DIf/Q5K+36+Q/2qvA/ijxF8TYr3QtA1LULQafFGZreBnXcGfIyO/I/OgD5nortf+FU+Pf8AoUNb/wDAR/8ACj/hVPj3/oUNb/8AAR/8KAORsrueyuYri0leGeNgyOhwQa9Mt/HWh+KhHH4+0511BRhdY0/Ec/t5i9H+vB96wf8AhVPj3/oUNb/8BH/wo/4VT49/6FDW/wDwEf8AwoA7aXTtOmbzNF8f6Jcx7eE1PNtID78bf1rAuPDk8l6l1Lr/AIZkmT7rpq8C4/Amsj/hVPj3/oUNb/8AAR/8KP8AhVPj3/oUNb/8BH/woA6S3h1ZZUDaz4V2qDktq8GDxjs1TyW/he2Bk8X+LV1EId40/Rl3An0Mp4/LNcp/wqnx7/0KGt/+Aj/4Uf8ACqfHv/Qoa3/4CP8A4UAafiD4oXB0uTRfB9jF4e0VuHjtzmWbjGZJOp/lXnLuXcsxJJOSTXZ/8Kp8e/8AQoa3/wCAj/4Uf8Kp8e/9Chrf/gI/+FAHFUV2v/CqfHv/AEKGt/8AgI/+FH/CqfHv/Qoa3/4CP/hQB9AfsOf8grxd/wBdrb/0GSvnX4s/8lT8Zf8AYZvf/R719R/sgeF9d8M6d4nTxBpN7prTy25iFzEYy4AfOM9cZH514V8S/hp42v8A4jeKryy8LaxPa3Gq3csUsdqxWRGmYqwOOQQQaAPJqlt55LeUSQuyOOhBxXYf8Kp8e/8AQoa3/wCAj/4Uf8Kp8e/9Chrf/gI/+FAG54V+Mmu6RaJY3/l6jp44NvcqHTH0PSt9fEXwv1omTUNJutMmkzu+yTHZn/dPQVwn/CqfHv8A0KGt/wDgI/8AhR/wqnx7/wBChrf/AICP/hQB36N8G2QRTf2w7NnMvnqNv4YNR2svwgspPOkGrX4XkQyzAA/XFcJ/wqnx7/0KGt/+Aj/4Uf8ACqfHv/Qoa3/4CP8A4UAeh33xyg0e0az8CaJa6TBjb5ip+8Ye7HmvJPEfinVfEFw82pXUkhc5ILGtj/hVPj3/AKFDW/8AwEf/AAo/4VT49/6FDW//AAEf/CgDizSV2v8Awqnx7/0KGt/+Aj/4Uf8ACqfHv/Qoa3/4CP8A4UAdr+yH/wAlltv+vKf+Qq3+2T/yVyH/ALBkP/oclbX7MHgTxV4f+Ktvfa34f1OwsxaTIZri3ZEBIGBkirP7VXgfxR4i+JsV7oWgalqFoNPijM1vAzruDPkZHfkfnQB80UuTnIPNdn/wqnx7/wBChrf/AICP/hR/wqnx7/0KGt/+Aj/4UAc9pmuahpjhrO6kTBz97v612Vl8YfFtqwK6gx/AD+WKzv8AhVPj3/oUNb/8BH/wo/4VT49/6FDW/wDwEf8AwoA6uX4/+MpraOKW8BMbZDBQCR6HFcrr3xJ8Qa0WN3eSsG7FuB9BSf8ACqfHv/Qoa3/4CP8A4Uf8Kp8e/wDQoa3/AOAj/wCFAHI3N1NdSb55GdvUmoT1rtf+FU+Pf+hQ1v8A8BH/AMKP+FU+Pf8AoUNb/wDAR/8ACgDiqK7T/hVPj3/oUNb/APAR/wDCj/hVPj3/AKFDW/8AwEf/AAoA/QD4e/8AIg+Gv+wZbf8Aopa36xPA9vNaeCvD9tdRvFPDp9vHJG4wyMI1BBHqCK26ACiiigAooooAKKKKACiiigAooooAKKKKACvEPjL8ef8AhW3i5ND/AOEc/tLdapc+d9u8n7xYbdvlt/d65717fXxB+2T/AMlch/7BkP8A6HJQB2v/AA1z/wBST/5Vv/tNH/DXP/Uk/wDlW/8AtNfKtFAH1V/w1z/1JP8A5Vv/ALTR/wANc/8AUk/+Vb/7TXyrVvTdOvNTuVt9PtpbiZuixrk0AfT/APw1z/1JP/lW/wDtNH/DXP8A1JP/AJVv/tNeNaN8NSZEOv6pb2Skj9zB++l+nHyg+xIqzq0fgfw5eqltp9zrCxsBI11ceVn1+RRn9aAPXP8Ahrn/AKkn/wAq3/2mj/hrn/qSf/Kt/wDaa8m1XxL8PtQtoxb+CJbKQ4BeLUCMH8QacPBHhrV9O87R9SvLS56tHdR70Uf7y9fyoA9X/wCGuf8AqSf/ACrf/aaP+Guf+pJ/8q3/ANpr5/v/AANrFvlrZI71OubdtzY9dvUflXMSxvFIySoyOpwVYYIoA+p/+Guf+pJ/8q3/ANpo/wCGuf8AqSf/ACrf/aa+VaKAP0F+B3xX/wCFpWurzf2N/ZX9nvGmPtXn+ZvDHP3Fxjb79a868WftRf8ACP8AirWdG/4RD7R/Z17NZ+d/aezzPLcpu2+ScZxnGTj1qp+w5/yCvF3/AF2tv/QZK+dfix/yVPxl/wBhq9/9HvQB7/8A8Nc/9ST/AOVb/wC00f8ADXP/AFJP/lW/+018q0UAfVX/AA1z/wBST/5Vv/tNH/DXP/Uk/wDlW/8AtNfKtbPhzwzrXiW7Ftoem3V7Me0UZIH1PagD6R/4a5/6kn/yrf8A2mj/AIa5/wCpJ/8AKt/9przJfgVr1rbRz6/qmi6OjnG25u13D8Bmnr8ELm8Yx6J4r8N6jOBnyo7va360Aelf8Nc/9ST/AOVb/wC00f8ADXP/AFJP/lW/+014L4v+G/irwll9Z0mdLfOBcR/vIj9GXIrkKAPqn/hrn/qSf/Kt/wDaaP8Ahrn/AKkn/wAq3/2mvlWigD7f+EPx/wD+FieMo9B/4Rr+zt8Mk3n/AG/zsbRnG3y16/WpvjJ8ef8AhW3i5ND/AOEc/tLdapc+f9u8nG4sNu3y2/u9c968E/ZD/wCSy23/AF5T/wAhVv8AbJ/5K5D/ANgyH/0OSgDtf+Guf+pJ/wDKt/8AaaP+Guf+pJ/8q3/2mvlWloA+qf8Ahrn/AKkn/wAq3/2ml/4a4/6kn/yrf/aa+VKkiiklbbFGzseyjNAH1N/w1z/1JP8A5Vv/ALTR/wANc/8AUk/+Vb/7TXzbB4Y1ydd0OkX7r6rAx/pVG90+8sX2XlrNA3pIhX+dAH1B/wANc/8AUk/+Vb/7TR/w1z/1JP8A5Vv/ALTXyrRQB9Vf8Nc/9ST/AOVb/wC00f8ADXP/AFJP/lW/+018q0UAfqJ4e1H+2NA0zU/K8n7baxXPl7t2zegbbnAzjOM4FaFYHw9/5EHw1/2DLb/0Utb9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXxB+2T/wAlch/7BkP/AKHJX2/XxB+2T/yVyH/sGQ/+hyUAeFUUUtAGj4d0e617WrPS9PQyXN1II0A9+9e6aUlnoV2vhrwvb289wjCO7v5RvQN3JA+8fQHgDB5zVH4OaPZeEPCN3418Q7o5r1WttMjHDsOjuvpn7oPua5/R/FV5Z6vdX9ta4uDMZX8teA2Tx9MED8BQB9BeJPAqWtnbmO+vby7e2ZgrARgNxj5FAAHWvkePw9e6nq95DbDcImO52JwOa9U1f4ieJruZ5H3eYqFN2cbVb6dKPDFmunadMJFBu7jl2PXmgDgLbwNfSQXivJGksL7TET3xxz+Ir0L9n2xltL3VzcyyK1umJYwT0/OtAvHDcNMUJWWYluPRVH8waxLi9v8AQNcuNS0xcxXChHX++CoJ/wA+1AHtvirRXfwINc0HVJlkiAf7HcxJNC/zYwcjcPqDmvFPEOkw+PtG1GW2037J4k0xDJJFH8wlUDJAPUjAJGckYxzSwePPEn2C4sYI2a1YksFHA3c1V+HHjJtH8V3eoXELSWUoVbjA5QZAV/rn8+R3oA8ZNJXoXxp8JR+GfFKXOnEPouqxi9snXoFbkp/wEn+VefUAfWn7Dn/IK8Xf9drb/wBBkr51+LH/ACVPxl/2Gr3/ANHvX0V+w5/yCvF3/Xa2/wDQZK+dfix/yVPxl/2Gr3/0e9AHKUuKK7L4YeFofEmtyy6pIYNC06M3V/MOMRj+Ef7THgUAX/BHgq1fSh4k8XyS2ugB9kEMY/fX0mfuRj09W7V2ep+PtQ+wNp2jxf2JpceNtjpZ8vaO3my/eZuncVgavqV9428SJLbW7Q6ZaqIbS2QfJaw9sf7XvU8enhJ3t4ldLSLJm3dcgd6AI5pdUtrt57bT443iTz2lkfJfjrk9enrT9LvtZ1kSzT2lvcRhiGUouDz/AA/pW5NFd32jXPklC80TKMkfKD/D7nH86g00m08O2IyGIxyv16E/pQBFo3j/AFTR7qW0s7+aAJ8kthejzrdufulW6D6Yqn4g8MaX43trm/8ACdmum6/aoZbzSVbMcyDrJAe/utW30xLiO8WNYjJdIZGmkALbvcfhXL281xo15Y3NjebbuAB4bhOqN3Uj/PFAHnzoyOyspVgcEHqKbXqHxQ0y21nRbPxppUCQfaXNvqVug4iuR3A7Kw5ry+gD2r9kP/kstt/15T/yFW/2yf8AkrkP/YMh/wDQ5Kqfsh/8lltv+vKf+Qq3+2T/AMlch/7BkP8A6HJQB4VS/Skr0H4KeBZfHXjKC0cEabb/AL68l7LGPf3oA6H4T/CJfEGn/wDCQ+K7v+y/DkZ4c8POfRf8a7y/8feHfBwNh8P/AAtZrKp2i6u4/Mkc+vt+lZ/xU8bJqepJY6Mgi0PTv9GsYU43svBauX8I6Lql94htLY2sxachllY7Y+vXnqaAOkj+LvjdLhk1HULi3JG9EtYY22+2K3tI+KsWsWxh8X6TYa3ERiRZYFWZR3wf8MU74hfDK50m+0eSadVN0ziQQMRtwu4/yNeceKPD7aRC93a5uYw2DIn3vTLD+ooA6zxx8JvDvijSZ9a+GUrJdRKZJ9LkPzADrtB5/CvnSaJ4ZWjlVkdThlYYIPpXsfgbxXf6VqMFzZuUuojxg/6wd1atX47+FbDWdEtfHvhqFUiuGMeoW6f8s5B347UAeB0UrDB4ooA/TT4e/wDIg+Gv+wZbf+ilrfrA+Hv/ACIPhr/sGW3/AKKWt+gAooooAKKKKACiiigAooooAKKKKACiiigAr4g/bJ/5K5D/ANgyH/0OSvt+viD9sn/krkP/AGDIf/Q5KAPCq1fC+kTa94i07S7cZlu50iH4msqvR/g2v9n3OueI2yG0qxYwEruAmkIjQ8+m7d+FAHUfGLW4J9TbSbEFNJ0iAWVqhGAdnG7HqxyT6gD1qv4Mi8nRI3eIeYMhsjrnn+tchZQXOtaqsSwvIIVBcDk89M/oB9BXd6bBczzvapMtmIgpYMm5jnsAeMcUAWtPSKJpACsjOACXAOMdvpzT7fN7PwApc4VV9v8A9Zp95atvjgWXzJwctJtC7R6cVPollIk8ar1iY7iOc8UAX7u2jfT5pt4Hl54/2uh/Ws2zdPsKrJhmjOGBPI/yKZo8eozaZdC9QBVunMYHpvO7P41CkUiS4uR/o7sCcdcUALp/7ueVAgSN2BR15z7EV594005bXX/Ps/kWVd7IgwFAHJxXe3kF9Zx3F89rbNZwoXCo5DFR+GOlcYl1earqa6wItkEK7YgV3rxnhvY9DQB0uqsniX4MXlrK/m3+hSi9t2xyYHbZIB/sglW+pPpXidevfC+axuvEEumo0sNtqdpNZywuw+VpCVVR6hdyn1yK8idWR2VxhlJBHvQB9Z/sOf8AIK8Xf9drb/0GSvnX4sf8lT8Zf9hq9/8AR719FfsOf8grxd/12tv/AEGSvnX4sf8AJU/GX/Yavf8A0e9AHK16tqS/8I18K9K0WEEajrsv267UdfKXiND7dTXAeEdKfWvE2m6egz58yq3sM8/pXoWu30d/8TL6c7Tb2QNtaxnphBgcUAaOgW/9maYn7zmbDSHHT2H+NaThPsjzsqjchGSep5496ppKLmNmldTICCMHof8AA0XD7rdQFCtkZ46UAWbNJxbxwwsFaRXYEjoADz+dSubWPTn+xxbonTHDcZ6Zx65p9xKY7e+liBaTyXKY9AvAH6miaLy7bbGiJEsOSFHUn+VAGXZtIVdOm5eOOuKoyaRZyaZLHIm28b94XXruPYn0qclhhsnjpjqKfaMzTblLM3c4oAo/D648/U9Y8I6vnydWgKIG/huEGUYfX+teVX1s9neT20wIkicowPqDivRvFTTab4l0zVrVg88ZWQ7RjG1uM1hfFKyuIPFc95cQCEagBdIo6AMM0Ad1+yH/AMlltv8Aryn/AJCrf7ZP/JXIf+wZD/6HJVT9kP8A5LLbf9eU/wDIVb/bJ/5K5D/2DIf/AEOSgDwsA19M6AI/hr8D0eIBde8RjeD0ZIh0z/nvXzz4bsW1PX9Pso13GaZEwPc1718WZf7b+IK6Tpu2S20i1jtFx0O3G7H5UAcRoGkrqN9C9xKVtlIT5T83PUj3xmvUrDUV0y+tIoGDLAVVVkO7GDwf51j21nb2N6zeSsatbld7rgZBHc96S5X/AEyOExmJ2Zdzt6HHIoA7r4geNZvEuraTFpensEthIZpJmAyp+Ula4uVVaS7hEjCBWWRZGAYJgHg5qVLuaLxHBbvCI4WhZI2LA+b3PT0wPzptpbb7y7QBdqyqygjO3uT+XH40Acfr2i3cenT6m0MMT28h2mMbfMUHhvbNbnwo122vL9/DGosDpusgxtG/IWUjg+3JrYcx3PmR3Q8yFzh138ZHbArzfX9Kbw7rdve2ZlSMOHQOMFcEHg9xQBwHinSJdC8Q6jpdwMSWszRn8DWVXq/7Rlov/CY2mroFA1aziujt9SOa8ooA/TT4e/8AIg+Gv+wZbf8Aopa36wPh7/yIPhr/ALBlt/6KWt+gArgPHfxEl8M+KtK8P2Hh691rUtRgkuIo7aVEwqfe++QOgJrv68r+I3hbxXc/Erw74q8JwaVcHTLSe3eK/neIMZMjPyqexoA19B+K3hvUdC1HUdSml0NtMuBa39tqaiOS2lOcAgEg5wcEdcGtrT/HPhfUNOtr+y17T5rS5ulsopVmGGnblYv98joOteXT/DjxvaaTrWr2up2L+LNb1S2vNQjs5Wt4/s0QcCCCVlLI3zffIzj174+pfDe90T4XfEeTxA8UEt1Muq2LR3kl5JFLGoKAyuoZmLDbuxk7jQB79Y6tp9/e31nZXkE91YsqXMUbhmhZhkBh2JFcD46+J954Mvp5tU8I6kfDVvPHby6uk8eMvjlYs72XJxn1FWPgRot5pngKHUNaBOua5M+rX7MMHfKcqMdsJtGOxzXM/ELwt8QfEnjeC6a00G/8MadKJrHTbi8kiWSUdJZgqHeQc4XO0eh5yAaHjL4z2/h7xBr2nWuhXGoRaBHFLqU32qKFkWQAjy43O6TG4ZxjH4jPqWm3aahp1reQrIkdxEkyrIu1gGAIBHY89K+ffiD8KPFPiTxJr19c6bpOqT6nHB9g1CTUJLd9HZByFVVO9dxJ468E88V75oNrdWOh6daahdte3lvbRxT3LDBmkVQGc/Ugn8aAL1FFFABRRRQAV8Qftk/8lch/7BkP/oclfb9fEH7ZP/JXIf8AsGQ/+hyUAeFV6hBFN4e+DVvJ8yXGu35lXI4MEKFc592f9K8wGMV7H8Tpbeb4V/Do2xDhbOeLgfdfzVLZ9+RQBlfDyP7FAL6eVkaUkIn94dK7SOeS31WOU5niuyI9oHMeATuz3B5rFsLLbb2Cyxp5MEQIH91sdatx3D2+r6aWX9yNybh0BI4/OgC5qd4trdS5Odp/X0pnh/VZxqTyyEMroRgcYIHFVdStfOv5ElYrGXzUNqgabagwucDBoAvRa3NceH2kRXjZrmQHzDknDHOPzAqKDVhcAxTcSdMjoRTL9FNsjQ5EZZlx2zuOf1zVOS3jKwzRsQ+cMP8ACgDU8Wy3EfgeZITlh98552Z5qlo0tpc6VHb2qgW5j8tkU8gkck+9T61m70QadG2ZZU+Y9lX1NVrFLXT4Y47RFRVGMAdSO5oA4jRg+hfEGFUlwbe5VlY9DyOv51U+KOnR6V8QtetIdvlLdM6bem1/nGPb5q0/E9g0XiDSprUsZbmTls4JbI9PrVf4ySRP8SNYSJw4gaO2Zl6Fo41Rj+amgD6A/Yc/5Bfi7/rtbf8AoMlfOvxY/wCSqeMv+w1ef+j3r6K/Yc/5BXi7/rtbf+gyV86/FfH/AAtTxln/AKDN7/6PegDe+CNuY9b1DVTD5i2FnJIuSAA204OTWf4Xn868keZd/mO7At2YntXVfBTyj4H8fKceeLDepHUAMM1meB4bQaK4nSOSVnO7cORxxigDeVFWJiYVD9OgNOgQNBLuJJ9c1IJIwgjZWwowpzk+3P8AjTUBCsvHNAEtvIzrMuDhYHUAHknBqzqE26SaNflGAMVT00M9xKP4AjDcegyMVJd86pPgdD0BoAhEXnS4AwcdfapXVLWEiSTYwXIVfvMfpSn5X3qu0j8qjln2sZGWOEd3b/GgDjfG0d4+npO1o0NujYDswDH04rR+Lq/afCvgrUWkaSSWx2MzYzwxwM+3SjxbJcX+gzEoUt0bKlvvP6cdhU/xCC/8Kd8DtJt84iXBH93caANH9kP/AJLLbf8AXlP/ACFWv2yf+SuQ/wDYMh/9Dkqr+yH/AMlltv8Aryn/AJCrf7ZH/JXYf+wZD/6HJQByf7PliL74qaNuXKwyeacjgYGa7LR3/tbxTrWpPEhaK9fY+Su0Fugx1HFVf2WrVB4i1XUZFyLSzkcYGTnbjp+NUPAQe5vL8vFOYmdn8xZCiElj6HNAHoMCSXAmZ/JMJwAsbHk853ZHHbtVZv8Aj+gnmETxvkBVzjC8Y/DH6UkqshDDKDARZCMlT689frUN0QmpFCBsSM+UgyBkseCefU80AWBDJLrpmkAYRQD7OMYCknnJqrbqZdRlG/8AeZ5CnG7J5/AA/pU1hcTPql6l1GsSRwqI9rZ3gnnP5Uacge6uGMYaQcgNwB/nigCOUBrwhsgSNuZsfeIG0DA7DFcz48u5bcW0eoRRtHGjPEIz8rdB83fuPzrt/D9tb3V/jVpZbWNx8skADFBye4PXPpWP8Q9A0u303ULiymkv2MYRZpjyBnnjt3oA434k6fLN8NfDGsXU/mytugRVyQiL06ivJa9z8dRSTfs/eGpWTCxXEiqR0x614ZQB+mnw9/5EHw1/2DLb/wBFLW/WB8Pf+RB8Nf8AYMtv/RS1v0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfEH7ZP8AyVyH/sGQ/wDoclfb9fEH7ZP/ACVyH/sGQ/8AoclAHhVeiwzNf/BqCMjP9na0gDHoqyxtn9UWvOq9G+F6/wBseH/FnhvcxlurL7VbIOd00JDgfUgEfjQB2ESs0KGRTtKAlV6YPrj2q1cz2ht0jjiMbrj3BrM02f7boOm3CttZoQpYHHI4/pUq287KW3oVUEnaaAHXU8l5c8DLbecc9KZFPHFayfcMmDsA5OcVSvL19PubKRYbia3klKyJBwxGOme3X9KSxtJGh8iV23Ek785wSemfbgUAT6C7w2bW13KJG3Fkcdskkj9akmSTa21cr1wKzfDtoYNOku5X3O8zBVByBg806LUZLK8+yyXFz5lzKPLQJlDGR69jnPFAGn5x8jptHf1b61FBCzfdVVDenX86kEBllMasFABJzx0qxbW67wGAZecjPFAGPBH5/wAUtEikw1pZr9tdf7iICzZP/Aa8o1O8l1DUbq8nJaa4laVyTnJY5P8AOvS4bs2eheLPERjVJLiMaTa9sGTJk2/SMN+LV5XQB9a/sOf8grxd/wBdrb/0GSvnX4sf8lT8Zf8AYavf/R719FfsOf8AIK8Xf9drb/0GSvnX4sf8lT8Zf9hq9/8AR70AdH8FiZLbxjbgkFtGmcEdiMGl8JQqdIB/5aOxB+mP/wBdVvgTMp8bPpzsAup2c9kM/wB50IX9cVqeFUlTTp7F0Md3aSMmcZ5BIOf8KANJVYeSFeQoBznHPtmrLnETdDnpUc8rCS3jC4hIJdz1B7CopZDgK4Zdxzn1FAGpashWYOirFghs9wBzT72NQ8r7cs4yjj0xVdmaOznYfPIFY+XkdKmnmO+OJkKh1xtI6E+h6UAQlsoCvX3qnPG5YtIkeOg5OB+OKckuEYk429cDoPWr0dzhUBSJ2cHGQDjA64PvQByfi6KSXTUmR2WKMngnCt/j3pPjG5tdA8D6WSQ1vpKO6+jP839a078S+JfE1j4ct42Z57lIi2M8cbjj0AzXM/G/VItU+Imoi2I+zWuLaLH91BgfyoA6v9kP/kstt/15T/yFXP2x/wDkr0Hb/iWQ/wDoclU/2Q/+Sy23/XlP/IVb/bJ/5K5D/wBgyH/0OSgDU/ZMRZ38SwL/AK17N8e4xXO+Gw9g10WYrbrcPFIp6DGSG9uePxpP2W9fTRviNHbzMqw3qGBtx456frXReIbKTQPiDrmj3KLEJZzPD6Nu5GPY0AXIriMqJEx5uMo3UAetK0gF0ZY/mB6dsCsWO3eCScrL5NrjcqY+6T9457DPb3q7GJBKrtcmWNsrtABHT1HQ0AMUQTeIZBHNibyszQ5yW5GAP1rRt5DDO8nK7xgr74qokSNqjXBjAkWAEPjo27BNStHLKiDLRMTuOCCzD3PYfrQA+ScAyFdx6sqk9PpXG+IYtSmga5jlWCzuQubZWJ3ZHU9hkHtXVG1VLwo7eZJKp4Y5VgPTgDqee9M0yxk8S+KtK0WGFseaHlUEHYB1/QUAL8W0XSfgZ4a0uQgTO5mIxggHtXzufavaP2mfEEOo+Ll0uxfNrYIIVUdOB/jXi5OTmgD9NPh7/wAiD4a/7Blt/wCilrfrA+Hv/Ig+Gv8AsGW3/opa36ACiiigAooooAKKKKACiiigAooooAKKKKACviD9sn/krkP/AGDIf/Q5K+36+IP2yf8AkrkP/YMh/wDQ5KAPCq3fA+tP4d8V6ZqiYxbzq7A9CueQfwrCpaAPeru2t9G8S6jploR9huiNQ00n7pgkBbC/7pyv4UyWJpAu+5ZVHUbaq+A7L/hYngFtKtpAnijw/uuNPYnBmi6tDn9R+NSRzfbNOinhDElSJkxyjDquOx4xQBJFMrwmMHG7kGpoym0RgkADp2zVF9xkXKhVHHHb6VYQKZh5jPjBxt/rQBLbbIraNXwUBf5Vxzljxz/So2WIQqZEUlXLIW6r71CuTHHufK9s9+TTyVdsZ3E8Hd6UAPiWB4wRnzBwzA8n86pa7qbadBi1+a+nxHHFg/MTwCBVy2xarISVWFPn3PxgelWvCtvBY2zfEbxSFjsLNWTRrWX711PziTH90HnPqPrQByPxnVdDttB8JI6tPp8BuL4gYzdS4ZgfoNo/CvLava1qVxrGq3WoXjmS4uJDI7HqSTVGgD61/Yc/5BXi7/rtbf8AoMlfOvxY/wCSp+Mv+w1e/wDo96+iv2HP+QV4u/67W3/oMlfOvxY/5Kn4y/7DV7/6PegDF0DUptI1qx1C3bbLbyrIp9MGvcvHUVvZa9Y+LLLI0bxDEHYr92K4H31P48/jXz7Xtvwd8VaZqmgXPgnxU2NNuTuhlPWCTtIp9u4oAZqKOEWI5+eQZl3fdHXPv7CnKVO1WLHYMZJzn3qXxb4Z13wfJHDqKm50sOGgv4vmilTsCex+tVVDSX0PkMPJeBnwGBJYkdcegNAF11za3Kj5iYm4U4J49afM7FkUr9xQfmP3SPU/56VUmuo7SxluJ2CxoNgBPOc4/lV6ZQx3ocowzx3PvQBTaIl0CZARlbnjPPIP4U+7v4LM3MzA+ZGPlBXG4/4VFPfWVids1yHlIOETlifTHrXS+Dvh9ceIC3iLxmzaV4ct8OIn+V5wOwHvigCl4TjXwh4Q1Hx7q4xqN6j2+lpJ97nhpMfoK8Au53ubmWeQkvIxY/jXo/xs8djxXrgttPUQaPZqIbaBD8qqOBxXmVAHtX7If/JZbb/ryn/kKt/tk/8AJXIf+wZD/wChyVU/ZD/5LLbf9eU/8hVv9sn/AJK5D/2DIf8A0OSgDx7w3qL6XrdndxkgxSA5H1r6x+IWlf8ACwfAem+LtJVX1OzTFwidWA7/AMjXx3XtPwN+KsvhWcWV+fNsZPleNjwRQBa0+/iis2vdTvhJJG2VQqB5ZHcqOpz07CuhW1eZJTbScSZcSIRwSF5Gf90fma6Xxd8OdP8AFCp4j+H8kErOC81izDr3wM157JdvpYksdX0aa0ulbBOxlI47CgDVtrG5tLohZ5rrfCzOr4XGCMAfnjn0p6vcf2fcXM9qIJYRI6xlsgAL8pJHXJzn8K5+w8Xz2WueY8U8tsLXyuIyXOSR6dQD1q/bNqvia3k03RdK1y8dyNxkQRjnjng/zoA2/EuqWVh4bMSr5s9wn7rbx8x6FR69+K6fw1Yp8OvhvqPinVjs1e/h226P99AR2zUngz4baZ4HtIta8f3sUtxCPMhsd+/Y3Xknr/KvGPjr8UJ/GmqfZrUiPT4PkVF6YoA8u1e9k1HUZ7qZizysWyapUp5NFAH6afD3/kQfDX/YMtv/AEUtb9YHw9/5EHw1/wBgy2/9FLW/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8Qftk/wDJXIf+wZD/AOhyV9v18sftL/Cnxp40+IsWqeGtG+22K2MUJl+1Qx/OGckYdwe47UAfKVFeq/8ADPnxP/6Fn/yftf8A45R/wz58T/8AoWf/ACftf/jlAHCeEfEmoeFdbt9U0qZoriI5GO49DXr0utaP8RbmS90W6j8O+LJ0xcWshC2t+fUHojn16e9c5/wz58T/APoWf/J+1/8AjlOX9n74oIwZfDRVh0I1C1/+O0Aal6LnTL02uuWlxptxHj5Zx8h5/hfowPYg0l1e28FuZDLHsILL8w+bjIrc0XwH8ctLtltDoovLEf8ALreXlpNHj/daQgfhV+P4eePWkEl38J9ClbOTtvokB/AXFAHD6NrMM1lDHePGlwuWO5sdc9KtQ38d1cxQaZHJf3kmFjhtU3ufTIHT8a7m58EfEBotkHwk8PIQMKWuoWI/OesKf4e/G020ttY6BDp1tKMMllc2cJYehZZASPYmgDO1KHS/DkUV94+uob2+jYGDw/Zy5BI5BuHHA7fKOfpXmXjjxhqXi/U/tWoMkUKDbDawjZFCvZVUcAV2cnwA+KMjFpPDbMx6ltQtif8A0bTP+GfPif8A9Cz/AOT9r/8AHKAPK6SvVf8Ahnz4n/8AQs/+T9r/APHKP+GfPif/ANCz/wCT9r/8coA9g/Yc/wCQV4u/67W3/oMlfOvxY/5Kn4y/7DV7/wCj3r6y/ZV8BeJfAth4ij8Vab9ge7lgaEefFLvCh8/cZsdR1rxf4hfA34i6v4+8S6lp/h7zrK81O5uIJPttsu+N5WZTgyAjII4IBoA8KqSGV4ZFkico6nIIOMV6j/wz58T/APoWf/J+1/8AjlH/AAz58T/+hZ/8n7X/AOOUAR+CfjFregxfYr4R6jpTjbJbXK70ZfoeldImpfDfxBKJ7abUPC94SW2wnzYCe+FPIrn/APhnz4n/APQs/wDk/a//AByl/wCGffif/wBCz/5P2v8A8coA6OPwt4evmxc+PrL7KrbsfZW3n8PX8auXOh+B4pTLJ4/1DLD5mW1B3DPrmuR/4Z++KH/QtH/wYWv/AMdpD+z98UD18NE/XULX/wCO0AdbH42+Hfgch/Dmly61qmMm+vzuwfZOlec+P/ihr/jKUi9uWS3z8sScKB6Adq2P+GfPif8A9Cz/AOT9r/8AHKP+GfPif/0LP/k/a/8AxygDysnJyaSvVf8Ahnz4n/8AQs/+T9r/APHKP+GfPif/ANCz/wCT9r/8coA1f2Q/+Sy23/XlP/IVb/bJ/wCSuQ/9gyH/ANDkrsP2cvhL428H/EuDVfEei/Y9PW2mjMv2qCTDMBgYRyf0qx+0v8KfGfjP4ix6p4a0b7bYixihMv2qGP5wzkjDuD3HagD5TNAr1T/hnz4n/wDQs/8Ak/a//HKP+GfPif8A9Cz/AOT9r/8AHKAOS8M+ONc8OzJJp17JHt9DXptl+0Jq77f7WtLS+2Djz4Ff9a5//hnz4n/9Cz/5P2v/AMco/wCGfPid/wBCz/5P2v8A8coA7Kb9ouePcbLS7WIsBkrEoJIH06VTu/2j/ED2zx26iEkYGxFH64rmf+GfPid/0LP/AJP2v/xyj/hnz4n/APQs/wDk/a//ABygDlfFXjvXfEsrNqF5KwJzjd1+prlc88816p/wz58T/wDoWf8Ayftf/jlH/DPnxP8A+hZ/8n7X/wCO0AeV0V6p/wAM+fE7/oWf/J+1/wDjlH/DPnxP/wChZ/8AJ+1/+OUAfcHw9/5EHw1/2DLb/wBFLW/WP4Ns59O8IaHZXkfl3VtYwQypkHa6xqGGRweQelbFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXz38d/jlrfw68bR6LpemabdW7WkdwXuA+7LMwI+VgMfKK+hK+IP2yf+SuQ/wDYMh/9DkoA1f8Ahq7xV/0AtE/KX/4uj/hq7xV/0AtE/KX/AOLr51ooA+iv+GrvFX/QC0T8pf8A4uj/AIau8Vf9ALRPyl/+Lr52xXR+GPBur+IsvZwBLUHDXEp2oD6Z7n2FAHs3/DV3ir/oBaJ+Uv8A8XSj9q3xWTgaDohPsJf/AIusLTfhRp+mKJtbi1bUGHPl28Bhj+hdhn/x2o/FXi3RvDY+weG/D+lWNzGo3TPELiQH0y5Iz+FAHSt+1P4vVdzeHdHC+pSb/wCLqP8A4au8Vf8AQC0T8pf/AIuuWs/jjrT2qWl3ovh68jQYDT2K5x7gcfpUel+OdC1u/C+IfC2htE+R/o0RgYfk1AHWf8NXeKv+gFon5S//ABdH/DV3ir/oBaJ+Uv8A8XWP4h+GvhW+hafRr+60W6ZA62t/GzxPn+7IBn8xj3ry3xP4S1jw3Io1O1KRP9yZCHjf6MODQB7V/wANXeKv+gFon5S//F0f8NXeKv8AoBaJ+Uv/AMXXztSUAfev7PHxS1T4m2etzatY2Vo1hJEiC23YYOGJzuJ/uivLfGv7THiXQfGOvaPbaNo8kGn389pG8gl3MscjKCcNjOBWl+w7/wAgvxd/12tv/QZK+dfix/yVPxl/2Gr3/wBHvQB6/wD8NXeKv+gFon5S/wDxdH/DV3ir/oBaJ+Uv/wAXXzrRQB9Ff8NXeKv+gFon5S//ABdH/DV3ir/oBaJ+Uv8A8XXzsATXfeBfhR4m8ZKJ7C1EFhnDXdwfLjH4nrQB6X/w1d4q/wCgFon5S/8AxdH/AA1d4q/6AWiflL/8XUEHwv8AhtoGyLxN4z+36h0NrpieYc+nGTV688D/AA5e1zH4f8YQRHpdbFYDP+z1oAg/4au8Vf8AQC0T8pf/AIuj/hq7xV/0AtE/KX/4us1/g14Z8RKw8DeM7Wa8Gf8AQtQXyJfpg15X4y8Fa94Ovza6/YS2zfwyYyjj1VuhoA9m/wCGrvFX/QC0T8pf/i6P+GrvFX/QC0T8pf8A4uvnbpR2oA+yPgf8eNd+IHjyLQtT0vTLa3e3klMluJN+VGQOWIqf47/HLW/h142TRdL0zTbq3a0juN9wH3ZZmBHysBj5RXjP7If/ACWW2/68p/5Crf7ZP/JXIf8AsGQ/+hyUAav/AA1d4q/6AWiflL/8XR/w1d4q/wCgFon5S/8AxdfOtFAH0V/w1d4q/wCgFon5S/8AxdH/AA1d4q/6AWiflL/8XXzrWz4e8L654im8rQ9KvL5/SCItigD3H/hq7xV/0AtE/KX/AOLo/wCGrvFX/QC0T8pf/i64SX4HeOIIbeS706G38+RY1WW4QMCemRnIFSaj8BvHtnEXi0uO9A6i0nSUj8Ac0Adv/wANXeKv+gFon5S//F0f8NXeKv8AoBaJ+Uv/AMXXgeraVf6RdtbapZz2k6nBSZCp/WqNAH0V/wANXeKv+gFon5S//F0f8NXeKv8AoBaJ+Uv/AMXXzrRQB+oPhjUJNX8NaTqU6Kkt5aQ3Dqn3VLoGIGe3NadYHw9/5EHw1/2DLb/0Utb9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXxD+2T/wAlbh/7BkP/AKHJX29XxD+2T/yVyH/sGQ/+hyUAeFUdqSpIkeR1SMFnc7QB1JNAHWfDHwlJ4v8AES2rNssbdTPdSdljXr+J6CvZbLW7y9u10zwuo02wtZfs5miUecwBwUTI+X3Yck1raBpunfB/4YCbU1WTxFqaiZoCoz0OxGz/AAg/MfpjrivK/C/jK60vV/tP2Z5dj+ZKUxy2SSemOc0AfVOpeE7FdD05RZN9vlQ7hdTGWXfjAO5ie+DXx1rvhe51Dx5e6bA4MglPmSEcD1Nen6/8VfEmo3PmRxkmJDgHsDjn6jFZ/hK3Nq02oXuHu7smVmPPHbH40AcfH8OpotSFtcXqJG8JdGjBJ4wOfxNUNZ8Ey6LPFcPKktq74BTPFeqTfvLuSR1BMdtsHvuYHP6frUTQLq9gIGwGifq3bgcUAWNIuNA1aC3jkuJrHyoQokhuGRsjA7HH6Vb1SJtEtFTVJo9b8KXrLG85UebCW6bsf+hdfWvPL/w5draKsULtMzlAq/jz+Xeql9cazoulTaZfrKIrhQI95yrkEHAP4UAYHxS8HyeDPFUunhvNs5UW4tZgOJIm5B/p+FcgRXvF7JbfEz4afYUhMfiTQIDcW/H/AB8QD76j3xz9Qa8HIwcGgD60/Yc/5BXi7/rtbf8AoMlfOvxZ/wCSp+Mv+wze/wDo96+iv2HP+QV4u/67W3/oMlfOvxY/5Kn4y/7DN7/6PegDlacq5HcsTgAU3FepfCzRbLR9FvfHfiO3WazsnEWnWsg+W6uT0+qr1NAFvwz4S0nwbpVt4h8eQm4vbhd+naIDh5vR5P7q/wA6r+JfiD4g8YzrZSyYt1/1WmWf7u2iUdiB978azFk1Pxl4jutT1S5eS5kP72ZjwmcYVR6AdAK6Hw1oq6BeXZQiQS4xKRzjrigDntL0LWJmCxiCx5G6TjgH0xVvVrvWrbWoNDbUxIPl24YgOSoOWrqbcTTgGJlT59uT/D747msCPw9DJ4o1CG6unlmQbkcjByQM/lQBW14XOk2UUmsW9veQs2xZovvIe3PBFdHo3j6ZdHTTdcz4j8NsP3tle83FuP70Uh5yOvNSSLbybbWYG4WPa22QdWXgE1keJNLubzWIrm3McSrDgBQMsVyefzoA534j+CE0OK21rQZzf+GdQy1tcgcxn/nm4/hYelcHXrvgDxBbafcTaPrCiTwxrDCG7hI/1Eh4WZR2IOM+1cF488Nz+E/FV9pFzyYH+R+zoeVYfUUAelfsh/8AJZLb/ryn/kKtftk/8lch/wCwZD/6HJVX9kP/AJLLbf8AXlP/ACFWv2yf+SuQ/wDYMh/9DkoA8KpevSkr1j4J+EdOnS98Y+LRt8N6Nhyp/wCXmX+GMevvQBN4N8C6ToOgW/ir4iLL9nuD/wAS7SYyFlvT6n+6nvW1r3xdv4bQabp08GiWK5C2ejoF2DtufGSR3IxXnfxC8bah4y8TXOsXI8pCNlrAo+S3hB+UKPwroPCmj2+m21vPdWMt3dXSh/kj3hFPP1z70Acnqfii91C9+03BludmMG6uHlOcdyT+lbenfEC90nUjPbLLYScfPYTsq9u2SrfjXW3vhGyvPD2psLZbSCANcvMV+bPoSeg9q5a08PWVz4Z02e3g33DxGR4yx3OQxzjtnAoA9HsPi/pfiWH+z/iFpVvrmnbSBerCEuYge/H9MV558VPh3BoFrbeIfC1ydS8J3x/cXHVom/uP6HjrXE3yx217u08zgDlo5E2lfY16z8I/FtjCr6DrsXm+GdZbyLpP4YJDwsg/u8kZoA8RorqviZ4RufBPi+90i4+aNG3wSdpIj90/lXK0Afpr8Pf+RB8Nf9gy2/8ARS1v1gfD3/kQfDX/AGDLb/0Utb9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXxD+2T/AMlbh/7BkP8A6HJX29XxD+2SP+Ltw/8AYMh/9DkoA8KHXFem/s/eHrbXPiBbTakANN05Gvbhm+7hBnB+przLtXs3w/J8PfCnUr1CEvNcuPsqtkgrbx4Mh9CMlRQBH8WvFkviTW9TuZmYOZQsMbDlQOgHoAMZHqTVnwPYpFoiXDQAyPlSCMZwa4nTY31K/uboxu0aSbUDc5Puf1JrvtA/tO/t5LXT1tI7a3fa73BLEnqQAKAL+lWiWRcgibzFAfAB24/mOf0qVn+0XohCqiriIBfXOafPbTKqrJ5JvScD7OCBj3pLKwuBKH2/vkkDEe31oA3I7SNmMUrgNGMEAdjXPebFDrV4yEmBTgZ43e9XYHu38UasTGXtVt40BH9/kgD/AD3qheabLEUYcyZJcCgDQkneYuedpUEEA8fjWVfWVtrSLb38QzGMxFpMbfUgVantXRImtLWS5LAFismzH0B61j6vqVtaWvny2c8hRiv7xdu3sRQByXhfWpfCfjW3u4LhJRbXO0kN8rpnDA+xBOfqaofF3QYPD/ju/gsSG0+423dqw6GKQblx+dRQ2tnqN9eT2MsVtGXDLHIcDGO344/Ouh+KH/Ez8EeENYcu9xCk2lzyHkExsGXH/AXx+FAHsv7Dn/IK8Xf9drb/ANBkr51+LH/JU/GX/Yavf/R719FfsO/8grxb/wBdrb/0GSvnb4sf8lT8Zf8AYZvP/R70AYvh/SrjXNastLs13T3UqxL9SetenfE3ULabWtK8JaQ+dH0SPyNydHm/jf3JNUvg5b/2RpmveL5QA1jD9ls9w4M8nAP4DJrB8MFjqzalPF5iOxUZGfmJ4OKAOw8O2drYWskYikDNIX8xs49s46fjWmWeN3STgEZAzx9QaS6CqQ+0JJ1IU4P41Ars0xc5IGOpzQBb0uAMHkBAcMFUHpn1qW1ii0/Ub+KeTzZHZJDJLjqVGR+dJp8y+bFCv8T5JqXKXC38pA82O6dM+w6A/hQBS1ZlbUlk24+6GA71mX9tPeanFDLJJHB1ZlO0kegPYVf1U+ZOcALhFyPTiqrXDtsRwTtG38KAOc8XaUumSNPAxaynXawLFmU9iSa1PiF/xVXw18P+KAA1/Y/8Su+YdW2j5GP1HH4VtS26Xunz28sDSeahQADv2Ncz4BvYh4c8Y+Hr8OWuIRLChHIlRsfyJoA3f2Q/+SyW3/XlP/IVa/bJ/wCSuQ/9gyH/ANDkqt+yKNvxntweos7gfoKs/tk/8lch/wCwZD/6HJQB4lYWst9fW9pbqXmmcRoo7knAr2H4736eHtP0L4eaU2LfS4FlvlT/AJaXLjJz64/wrA+AulRXfjZNSvE3WekxteSHGRlfu/riqel3d74o8fX+uzwfalknaaR3OAoz8v44A4oA0fC3hKzk0cPqUDM1wu5QSVYVp6PMdP8AC4P2liUdvJU5DpgkCNvU1Z1nUJIbG6ljK/aIyCrDnBLYAPqMVW1K2MEi2aOzzSSmWVioAyVxj6Dn86AO4tdYsV+F+twXVuxmkgkYBRkkkcHH9a4PS2S58I2M9s4WW1UGRMbWwO49qXxDeRRaRHaieVbqVo4zHGDtZQQCOn1q/wCKSFCCBQsEm0mNV25HYUAUNZi024jt573TxMJ38pJoTg5I4zg9Pwrh9csW0HVZbLLrbzAMmTwOe/0r1Brj7JE6FcvvwhkOOwOB6AZx+Fcx410S+16JL6B43eIbUt0547/N3NAG14ulPj34QQa8679W8PSJZ3Dg5LwngMe+OleK16x8B5vO1DxJ4avBiPVtNli2N1EiDcpx68GvKpUMcro3VSVP4UAfpl8Pf+RB8Nf9gy2/9FLW/WB8Pf8AkQfDX/YMtv8A0Utb9ABRRXhXxetrLVfjb4N0rW7+4tNHn0+6eby7xrZSyglSWVh3AoA91or5r8M+N9Q0PTPFun6b4lnvNItdbttN0PUriA6jLO8ocvbp86iQrtGCWAweuMCtKx+KXjKHwX4j1K+tLeS78M6vDFfJJbCKSWzON+USR1SQZzkMwAzxxQB9BUVwvwq8VX/jODXNYfyBoRv5LfSSiENLDH8plYk8hmzjpjbXkX7QOk6fpc0vijTLwo8d9Eb3U7fWXa8tm8za0MFtuEZwMcEgjnI4JoA+l6K+ZvjPpd1aeK/EXjG6urHUtBt4bZW0xdcms7qI7EzhEGAxDAgMckHOOa+ifD08V1oGmXFtHLHBLaxSRpMcuqlAQG9wOtAGhRRRQAUUUUAFfEP7ZP8AyVyH/sGQ/wDoclfb1fEH7ZP/ACVyH/sGQ/8AoclAHiNtA9zcRQQgtJIwVR1yTXqvxfc6IujeGLeZvK0iwjSdQMYuHy79PdgP+A1wHgeeO08XaTPOoMcdyhIP+8K774vacg+MeqacGyj3nmN9GAfA/wC+qALXw9sZ9NsozcSKEnAIj6nJ5/wrotEMNhrE9rd+VFLcuZbd14Eq9MY7EYrJijM93KUeSNbZdioRzn+99K0bG4juvFSRybN8NuXQHruJHI/KgDTeYQXUpY5K/wAqi0rUjNrBCqfKZTj1YjpWbqTPJLIF3Aljn2qKwHlPlckgZGT3oA6Ky1WKa61GSKSBy+Nyx8+XsTPP1JxWdYal9oklaUYYjAXPQVRh0230trqa2jO+8bzZOeBx90fjk1WWNjMskLZx1HtQB0lokk8VxHBN5Ep5DkbgB/SsK/tLfWrRY7qGNraOQqsgb/WEHBx36+taGm75re6tyP8AWJsBJI696ybXULW2t5dPt1d3sH8rCrw3GTz9aAOa+IGnWdlHZNYWy24AMcjRj5SewJ9aWWaTU/gjexeX8umalDKpC8AOrqcn1Jx+XtWh48ivbjw5EYo1aFWM0pByVwOOKpeDmaf4T+N7UZKiOCcZ6ArKo/kxoA9i/Yd/5BXi7/rtbf8AoMlfOvxY/wCSp+Mv+w1e/wDo96+jP2HwP7K8WnPPnW3H/AZK+dfisR/wtbxhnp/bV5n/AL/vQB13iR/7E+Dfh3SzG8U19I99ISuFcfdXn2weKZ4Yu9Ns9HgtbhJIbncXJZCA3oQenYVrfHORJtA8AG2I8h9Kj2kDGDuOR+dXLNnttOtY5CANn1HSgCNhuj82C5eQN0OVIx+VSygeaqqDhlUkjvxUiIC3yiNFK5JAA/UUjSK9wHDegHPSgCGCMJqsOGxjng8U+WUxi9KkLi7bOOh4H9MU6ID7fGVBycnFVpIikd0z8Ga6Zh7jp/SgAZMpJJk5Y96jhiWS4O4fe71ZmQiNdp5x681YjKiEtH5e9RjB4wf60AVJZnsX3MFjjByXJ4NYXwllgl+K1vA9sl3Hc+bFkYO4sD8xz6dfwrXfT4L+dZNRla5I5VCNsaj6d6yfAYgg+OGk/YRGkIufLXy+B0wcfnQB0n7NNuLT9oW4gAwI4rpQKrftk/8AJXIf+wZD/wChyVufA63+zftPahHjGIrr+QrE/bIGfi7CP+oZD/6HJQBleGLe40D4Fa7q8aGOTU51tlmx/AOoH1NVPA9v9k8MpcI2PtLH936kcda6j4j2r6J+zv4UtFXcl7N5pYY+XknB79RWB4bhurfwvaRM9rNGV3KCShXPOCQDmgC9FYzNv89o5I5AWaN+QAO9JqEouTbKgAZRtRue/bP+NOtZ7mJ1CSJ83y7AxdfYgnH5VLqs0sj28UYxcFlI+XHTnigCPxIxksLaxIklkmkRfMPABB6/Wk8Qxi3tlh3EmIgBzySBwKzvEurxmO18qRZLyG6QJGh4LZ5yfpmtHWt8kbF18uQvjacE0ANmmu5rKPKpHcb0zIg3YU43F89Pl7VH9qslQNqcsSWUmQPMB2nHUZHerEmwWWyURs4GG2Hqcen5VC6T2MEkEtjdXoccRiE+WeP7x49KAOV8D6xDo/xOtNUs8ywC6McasCxdWBH1PWuV8WWs1n4l1OC5i8mVbh8x/wB3Jz/Wui8D2k+mfFDQUnUW0n22N9jfwAtxUfxlAHxP8R4OQbtiDQB+gPw9/wCRB8Nf9gy2/wDRS1v1gfD3/kQfDX/YMtv/AEUtb9ABWD4j8H+HfEs0M3iDRbDUpYVKRvcwrIUBOSBmt6igDBvvB/hy+8Prod1oenPo6MGSzFuqxIw7qoA2nk8j1NUNR8B6QPCOt6F4etLLQ49Vga3mktrVcYZdhJTgE7SQK62igDH8H6Ba+FvC+maHp+TbWMCwqxGC5A5Y+7HJPuazbj4deD7jXzrc/hzTJNUMnnG4aAEl853kdC2ec4znmuqooA5fWPh94S1rW/7X1Xw7pt3qWVLTzQBmcqABu7NgADnPAFdQBgYHSiigAooooAKKKKACviD9sn/krkP/AGDIf/Q5K+36+If2yf8AkrcP/YMh/wDQ5KAPEtPYJf27k4AkUk/jXr/izZN8aJppDuj+zwSKzDPW2jwa8ZU7WU59+K9p10mTxR4L1dlXyNW0uOIk87pYiU/PASgDYdJJWCxlI2U/LI2Tx6GnXWnpFqVnfqR5sR2lgeGU9VP9KbPJ5ExGNoPGV5DexFRLOHlI3ZUdB1FAFi9kSO5fyiCrndn61Fp8K5DOw9T6fnVG5u47byjIrSSzSeVGgPU9+fSqsdybqOR5YxHEWKpGOnHGSe9AF3QtVj1gXiZxJDMdmT1j7H/PrVlP3LyDgDHOOKwNOubedpTAqoYiULIm3afb1FPXxGJdWttLe2b7RI2yR+APY49xigDcvJpoLONbFwtxcP8AfYEiNAfvY71BbWtnZIyTxtvkOZJgT87HqTirUa74z5eGK9vb/JqnC6eSzrKq+UNrBxnH49utADPFU8dj4XvfILEOnkoG6ktx/WsDSp00X4L61M5H2jWbtLOEZwdkfzyHHpkoKXxu0EmjpcK372N1IjBODnjPp+VUvisr6XonhHQGKK9tp4uZkX+GSZi3Pvt2flQB7d+w8c6X4uJ6+dbf+gyV86fFkEfFPxj76ze/+j3r6K/Yd/5Bfi7/AK7W3/oMlfOvxZ/5Kn4y/wCw1e/+j3oA7j4gjzvAPw5lI3KbaWPHriQ1NaD93HEi3VtKo4EucEe2cg03XpRqHwW8CyRf6y2vbi1Zsfd3bSP51rXPzBImc/LjLDjIxzQBShMjTMjwOo6GQY2n+tW44xnOMd/Q5psyqjhQ+GZgFHUZIzj9KjMhWIrnnH40AW7dG+2wSBcoW5pLuIuLZV+YEs2fXnrU1uP9JwQVdWHXtxxToXMlpHJIQGIzuHAAoArSRh+W4KnBHpVeRU8osD3xgHGasM/l3Eij1potY7oghVLDvmgDKlge9dYZWKW33jFGeX+ppvwrSG9+NWi/Z4fLhhnkJQADASM84/CtqPS5xITsjgI7u4YkfQf1qn8J4Y7DxP4h1qRGMGlabPIH/wCmkh2Kf50AbnwGulvf2lLu4UkmSK6PPbpWN+2P/wAleg/7BsH/AKHJUf7KUxuPjkJWGC9tct+YFP8A2yP+SuQ/9gyH/wBDkoA0vj1ui+DXw6iPDOhbZ7beP6fnXDWerxRabYLcxSWsqgJlkO1u2QR/Kuw+MXn6v8Dfh9qsLB7e0DW0w6kPjg/TAx+NcPDe6dq9laW6uS67TsVSGRwOuelAHRiQzHacbjyCBgiicb7iNFkaIoRlzyRWANQms9Q8m8VmjfOy5UH5uM4IHfmtOG9gncjzHZm5yVOD+NAFXxd9kggtXMarJ5qDzVXnOcknHSrhmnurBJrgjzo5Qh2d1I4JrN1y7uIxp8cEKSqblP3T/wAZHIH8q2nzNKUYuxxlgx4U/WgC7epGziZ1B3KFzjOD15/lU0+vS6ZpMjSwGSBF3SASZOPbIFYN1rEFvCVFwHz8oVBkk59PSq2paf8A2leK1356Wix/Mm8hXbIx8vsOaAE8HXsXiT40aBcW28x/aI+CuMBTmsj44JEnxS8QCE5Q3BPWu+/Zv0JG8ZatrzL5dlpETPuPQHBxg/hXkXjbU21jxXql85JM07Nz9aAP0Z+Hv/Ig+Gv+wZbf+ilrfrA+Hv8AyIPhr/sGW3/opa36ACiiigAooooAKKKKACiiigAooooAKKKKACviD9sn/krkP/YMh/8AQ5K+36+If2yf+SuQ/wDYMh/9DkoA8Kr1nRJv7Y+ESyxBW1DwxfrdgZO428mFf8AQh/OvJa9K+A+oW0Pi9tL1Jsadq0D2U4zgEOpXJ+mc0Ad3IyXMEN3GE8ucBxvXPynn1GKZI9ukbJEEExxhlHT1rK02e40HW73wnrcZXUNPdoo5HGBIg+6Rn1GD9K2boMsQJCFmOFG3BJP9B1oAq3+lw3kETTeYXhl3qY2KnJ96fFYpGYugQNtKqBhfbFOWRtnyOcAAkngY9RVpZlEoEpba6Z3dsj1oAy9Kt86TMZAgMtzKfmHRA2Bz+BqzaafCLlJriNfMiGQ46kf4VJYvHNGjIVeP53jcHp8zdu/XrUspllWTaNzqvc4oAquP3yKrbDnrT5IXUqJYoXZmGGZec9M470yxdZY2VkL5b7wHIpNb1caPpz3cyiREOE56sen4UAUZLBPFvjzSdDLBbKyJub6fIGxFG5/bgD8zXm3xK1z/AISLxtqmogARySlYwP4UHCj8AAK9RME/hH4O6n4h1HCa14ql8uHsy2wOT+DED8APWvCWJYknqTmgD6z/AGHf+QV4u/67W3/oMlfOvxY/5Kn4y/7DV5/6Pevor9h3/kF+Lv8Artbf+gyV86/Fj/kqfjL/ALDN7/6PegDuvAMb+IPgt4l0uFs3ej3MWqwqBkkDKv8Ahjn8KtaVerq2lQ3MaENyHbdwCB1ArnvgB4mTw745ijuwrWF6ptrhH6MjcEGt/wAW6NcfDzxrc6ZtE2i3rCazkY4VomPBU/3hnBHtQBYlaAWxnJJEe51JGW9N2KggInt1lXftJPDjnGeKW/2izeWLcUZkeL5vvkkAAn0yRxTmLCRRI6+ZjOB0YjrgelAFuK4cmZ9rMCp3BeT9RUeluk+hWyRvv+QgmTknHUE+1Ptpss2/KqV3cdcc/wCNRWMLwafax+YzFV3lmGSA3b8KABmInRmzgINwPbjn+tFrJujLMkksRxtaPGWHbOO49acgyQB8p3bgT1x6n60y4dtJ0gSxpG0CS8q7Y4Y9B1zQBU8RalcWnhxUkkdbiRVj37gWKrySfw/nWjqkZ8H/AATMlzlNW8RzCfYeot04TP16/jS/Dvww/j3xQ97qSiLQdOAmu5OdpUciME+veuN+OPjH/hKvF0/2XC2Ft+5gjQYVUXgDH4UAdF+yKSfjNbk97O4/kKs/tk/8lch/7BkP/oclVf2RP+Sy23/XlP8AyFWv2yf+SuQ/9gyH/wBDkoA0/hE3/Cc/B7xD4NfD3lupubMZGdw56da8QEz2UUqgvBqEMm1xjkgdfpitr4S+LpvBvjSx1KNj5W4JKvZlPXNeofHrwOtjqcPjjwzD5+hakA86qciNj1yPQ96AOMsL2G7tLeSKQXc5Vd8SH5gTwSx/hFacxRDww8k4+bPykfNk89MbfWuW0bU7OztTbWNhM91JmMuuCsnzcZOeOg7V0VtcT21uv9oWNwJlAOYQrDOOoHb6UAZJ1WyuNU0+KF/MkhvA5J5VlweQa6IQ790rb2GOFzhTjrn1+npVGW3sLxdKjjhVRcziRGVQr4AOR+fGK0IdHmtNUlE92ZowrxCCTCmEnrj+Rz2zQA+K0eW0drVNzrypkyqkf3fauU8U3soeK3tJplux8s1owwcnp9evbrWrB4isNPuNYle5je6il/cqWYlxtHC9sAg13XwG8DT+KdcuPGnitFi0m1YNH5w2+YV5GPYUAWPEB/4Vj8CILFx5eua6RLKM4ZEIHFfM5JJJPJNemfH7xy3jTxvO8MhOn2hMUCg8YHevMqAP01+Hv/Ig+Gv+wZbf+ilrfrA+Hv8AyIPhr/sGW3/opa36ACiiigAooooAKKKKACiiigAooooAKKKKACviD9sn/krkP/YMh/8AQ5K+36+If2yf+StQ/wDYMh/9DkoA8Kqzp909ldw3MJw8bBvyNVu1FAH1Hq1tF8TvCOleLfDyxy+L9FRVurUHD3cK+3cj/H2rlP7QtdZsxc28wSQtseNziSM85XHrXkvhDxXqnhXVYb7Sbl4njOduTg17BFe+F/iRerqun3cHhfxnw0pl4tbtu5bH3SfXpQAmcO275Q2eB+lMZRv+bBVhg89qTUdN8SaIr/254fuTGhBS5tB50D8dnBxzXN6n4hZbZxa2tws7DGTEfkP4igDqLMCOztUtiojw2BjACgnvUsbu8xfcSxYBsHPQf5FcPoOr31jZxQGzubny+SEjJx3610lnYeKtYaCXw94b1Rdx/wBbMhSNT6kngfiaANNpYdKhnmuZBHEAMsenWq3gXwwvjbUrnxL4oeSw8FWDb3MrbRO4/wCWae57kVT1/SLHw6Ibv4i6xHqF0vK6JpsgbLD/AJ6SD5VH0yea4/4g/EjUfFkVtYxQxabo1qgjt7C2OI0X39T70AXvjZ49/wCEz8QJHZr5OkWKCC1hXoqDgV5qeaUkmkoA+tP2Hf8AkFeLv+u1t/6DJXzr8Wf+Sp+Mv+wzef8Ao96+iv2HP+QV4u/67W3/AKDJXzr8Wf8AkqfjL/sNXv8A6PegDmIJWhkWSM4dTkGvorwH4n0P4ieE08LeMrgwXUJzY32fmt3x6+h9K+calt5pLeVZIXKOOhFAHtHi/wAOa/4QsVstZt/tGnE7rXUbb542Gcgkjpj0NZVhqTX2oQGRoxH5JTercGRsHBz0qPwT8Zdc8PoLW5ZLzTiMPbTqHRh7g11c+ofCjxX+/kt7zw7fv942jboifXYen4UAZN/fw2FvfSTSgtGv7tV64IAH61ftbqGezsi5SOd4wTG7AZOPSnR+E/Asql5/Hl40CjPlLa/MQO3LYqWHSvhHdLITruvRSIeXZlOfyoAzNQ13TdMZ1nLSXWAFijGd30rb8K+A9e8fyi81JG0bwzGSxnnG1mUddoPeqv8AwmHw18Fyed4Z0STVNSUfu7rUH8zacdQvT864nxh8X/FHiYulzeNHAc4jThQPoKAPSfi14/0Xw14YHg7wHiK0QkSyg5aVu5J7185SOXcsxJJOSaWaWSaRpJWLu3JJPWmUAe1fsh/8lltv+vKf+Qq1+2T/AMlch/7BkP8A6HJVT9kP/kstt/15T/yFW/2yf+SuQ/8AYMh/9DkoA8Kr2v4QfGZ/DlkdC8SQi/0Ob5HjkG4KD1rxSigD6a8TfCWx8QpNr3wh1a3kWYb5NOaQAg9flz/I15gx8W+F5Gsta0W+QgjJkjYnr1B6Vxeg+I9X0G5SfSL+4tnQ5GxyB+Venab+0L4ut4VivWt70KOsyAnNAHHxQa9catHdWOj6gUjl83y0ibjofTjkV1C6R418RXcl3B4KzeXTEyXEluwBPcgcAH1q1fftEeL5CPsItLJSMMsUQ+b8etYmt/G3xrq0Dwy6m0UT8FYsrx6ZHNAHonhf4Q6F4YA1z4oanaoyEOumQNkk9g1Yfxe+NUuu2a6J4ZjSw0aMBVjhwAQPpXi17qN5fSNJeXU87t1Mjk5qpQApOTk9aSiigD9Nfh7/AMiD4a/7Blt/6KWt+sD4e/8AIg+Gv+wZbf8Aopa36ACiiigAooooAKKKKACiiigAooooAKKKKACvij9sOzuZ/izC8FvNIn9mQjciEj78lfa9FAH5bf2dff8APnc/9+m/wo/s2+/587n/AL9N/hX6k0UAflv/AGdfY/48rn/v03+FA0+/VsraXQI7iNv8K/UiigD83/D/AIs8aaAAumXeqRRgg7AHx+VdTB8YviIkgeSSeXnkPag5/wDHa+96KAPg+6+NPxGmiCRSXEIzn93bBf5LXM6/478d66pW/vNTaM9UVXCn8K/RaigD8upbPUZnLy2127k5JaNif5Uw6be54srn/v03+FfqRRQB+Ww02+/587n/AL9N/hSnTr4/8uVz/wB+m/wr9SKKAPmX9iS3nt9L8WC4hkiJmtsb1K5+WT1r55+K2n3j/FDxgyWlwytrN4QRGSCPPf2r9IKKAPy2/s2+/wCfK5/79N/hR/Zt9/z5XP8A36b/AAr9SaKAPy3/ALNvuv2K6x/1yb/CkGnXw6Wdz/36b/Cv1JooA/LkWGoAf8et2PpG1N/s6+/587n/AL9N/hX6kUUAflt/Zt9/z5XP/fpv8KX+zb7/AJ87n/v03+FfqRRQB+W39m33/Plc/wDfpv8ACj+zb7/nzuf+/Tf4V+pNFAHw7+yTZ3UHxhtnmtpo0+xzjc6EDoKtfthWdzP8WYXgt5pF/s2EbkQkffk9K+2KKAPy2/s2+/58rn/v03+FH9m33/Plc/8Afpv8K/UmigD8tv7Nvv8Anyuf+/Tf4Uf2bff8+Vz/AN+m/wAK/UmigD8tv7Nvv+fK5/79N/hR/Zt9/wA+Vz/36b/Cv1JooA/Lb+zb7/nyuf8Av03+FH9m33/Plc/9+m/wr9SaKAPy2/s2+/58rn/v03+FH9m33/Plc/8Afpv8K/UmigDA+H6lfAfhtWBDDTbYEHqD5S1v0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    FLAIR images obtained at multiple levels at time of presentation (top row), on day 14 (second row), on day 28 (third row) and on day 35 (fourth row) from a 28 year old woman with recurrent partial seizures associated with a mitochondrial disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cole, AJ. Status epilepticus and periictal imaging. Epilepsia 2004; 45 Suppl 4:72. Copyright &copy;2004 Blackwell Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15158=[""].join("\n");
var outline_f14_51_15158=null;
var title_f14_51_15159="Fetal fibronectin for prediction of preterm labor and delivery";
var content_f14_51_15159=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fetal fibronectin for prediction of preterm labor and delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/51/15159/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/51/15159/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/51/15159/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/51/15159/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/51/15159/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/51/15159/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/51/15159/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm delivery (PTD) is the major obstetrical and neonatal problem of the developed world. Traditional methods for predicting women destined to deliver preterm relied upon obstetrical history, demographic factors, or premonitory symptoms that were neither sensitive nor specific [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The development of various biochemical and biophysical tools has helped to distinguish between women who will and will not deliver preterm. However, even after caregivers have made an accurate diagnosis of preterm labor, the lack of effective interventions to prolong pregnancy remains a problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of biologic markers in serum, amniotic fluid, and cervical secretions have been evaluated for their potential to predict PTD. The most commonly used biochemical approach for differentiating women who are at high risk for impending PTD from those who are not at high risk is measurement of fetal fibronectin (fFN) in the cervicovaginal secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/5-14\">",
"     5-14",
"    </a>",
"    ]. The test is performed alone or in conjunction with sonographic assessment of cervical length.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FETAL FIBRONECTIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibronectins are large molecular weight (450 kD) glycoproteins found in the plasma and extracellular matrix. A unique epitope generated by differential glycosylation of adult tissue fibronectin has been termed fetal fibronectin (fFN). It has been identified in amniotic fluid, extracts of placental tissue, and malignant cell lines, and is recognized by the monoclonal antibody FDC-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    fFN is thought to be a \"trophoblast glue\" that promotes cellular adhesion at uterine-placental and decidual-fetal membrane interfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/15\">",
"     15",
"    </a>",
"    ]. It is released into cervicovaginal secretions when the extracellular matrix of the",
"    <span class=\"nowrap\">",
"     chorionic/decidual",
"    </span>",
"    interface is disrupted; this is the rationale for measurement of fFN as a predictor of PTD.",
"   </p>",
"   <p>",
"    The fFN assay has been used in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To predict the risk of PTD in symptomatic patients, given identifying women with preterm contractions who will go on to deliver prematurely is an inexact process (30 percent of preterm labors spontaneously resolve and 50 percent of women treated for preterm labor deliver at term) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To identify asymptomatic women who are most likely to deliver preterm. Screening asymptomatic women is usually reserved for those in a high risk group (eg, previous preterm delivery, multiple gestation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SAMPLE COLLECTION AND RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidates for testing should meet the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intact fetal membranes",
"     </li>",
"     <li>",
"      Cervical dilatation less than 3 cm",
"     </li>",
"     <li>",
"      Gestational age 22 and",
"      <span class=\"nowrap\">",
"       0/7ths",
"      </span>",
"      to 34 and",
"      <span class=\"nowrap\">",
"       6/7ths",
"      </span>",
"      weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since fFN is normally present in the cervicovaginal discharge prior to 20 to 22 weeks and is always present in the amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/17\">",
"     17",
"    </a>",
"    ], testing in the first half of pregnancy or after rupture of the fetal membranes is not useful for predicting impending premature birth.",
"   </p>",
"   <p>",
"    Samples are collected from secretions in the posterior fornix or external cervical os during a speculum examination using a swab from the manufacturer's kit. The so-called \"blind\" sampling of the posterior vaginal fornix without a speculum also appears to be an effective sampling technique [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to obtaining the sample, manipulation of the cervix (digital or ultrasound examination) and introduction of intravaginal substances (eg, lubricants, medications) should be avoided because these actions can lead to a false positive or negative result [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/20\">",
"     20",
"    </a>",
"    ]. False positive results can also be caused by semen or sperm from coitus within the previous 24 hours or from a grossly bloody specimen.",
"   </p>",
"   <p>",
"    A sterile speculum examination is performed and the Dacron sampling swab is completely submerged for 10 seconds in the vaginal secretions that pooled in the posterior fornix. We obtain only one specimen from this site and do not simultaneously sample the cervical os. A fFN concentration of 50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is the threshold for a positive test result.",
"   </p>",
"   <p>",
"    Various methods for \"blind\" sampling have been described. In one method, the posterior vaginal wall is depressed with an unlubricated, gloved finger and then the polyester swab is passed along the finger toward the posterior fornix until resistance is felt [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/19\">",
"     19",
"    </a>",
"    ]. In another method, the labia are held apart and then the swab is blindly inserted into the vagina and directed toward the posterior fornix [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/18\">",
"     18",
"    </a>",
"    ]. In both methods, the swab is left in the posterior fornix for 10 seconds and then placed in the holding medium. The advantage of blind methods is that they can be performed by a nurse or other personnel not experienced with speculum examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     USE IN SYMPTOMATIC WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of fFN testing in symptomatic women was illustrated in a systematic review of 32 cohort studies that evaluated cervicovaginal fFN for predicting PTD within seven days in women with signs and symptoms of preterm labor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/21\">",
"     21",
"    </a>",
"    ]. Pooled estimates showed that 76 percent of symptomatic women who went on to deliver within the next seven days had a positive test (95% CI 69-82), and 82 percent of symptomatic women who did not deliver within seven days had a negative test (95% CI 79-84). The likelihood ratio of a positive test was 4.20 (95% CI 3.5-5.0); the negative likelihood ratio was 0.29 (95% CI 0.22-0.38). Among women in this systematic review, the overall pretest probability of delivery within seven days of testing was 7.7 percent, and based on negative or positive fFN results, the posttest probabilities were 2.4 and 25.9 percent, respectively. Of note, there was a wide range in the prevalence of preterm birth within seven days of sampling (1.8 to 29.7 percent) among the studies included in this meta-analysis. The test will have higher positive predictive values in high prevalence populations and high negative predictive values in low prevalence populations.",
"   </p>",
"   <p>",
"    Other systematic reviews have reported similar findings (",
"    <a class=\"graphic graphic_table graphicRef73381 \" href=\"UTD.htm?30/6/30827\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52380 \" href=\"UTD.htm?24/24/24971\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a comparative study showed that the fFN assay was superior to the usual clinical assessments for predicting PTD in symptomatic women (",
"    <a class=\"graphic graphic_table graphicRef64332 \" href=\"UTD.htm?11/21/11611\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     fFN alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest using the fFN test in the evaluation of women with preterm contractions in whom the diagnosis of preterm labor is uncertain. A negative test together with other reassuring factors (eg, no signs of intrauterine infection or active abruption, and no progressive cervical change or increase in uterine contraction intensity) can be used clinically to avoid unnecessary or expensive interventions (eg, admission to the hospital, tocolysis, glucocorticoid administration). Indeed, the principal utility of the fFN assay lies in its high negative predictive value. In one seminal study, 99.5 percent of pregnant women presenting to their physicians with signs and symptoms of preterm labor, and who subsequently had a negative cervicovaginal fFN test, failed to deliver within seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/9\">",
"     9",
"    </a>",
"    ]. Moreover, 99.2 percent of the fFN negative women remained undelivered for 14 days. However, a limitation of this study is that the very high negative predictive value reflects, in part, the low prevalence of preterm birth within seven days (about 3 percent) in the study population.",
"   </p>",
"   <p>",
"    In one cost analysis, the use of fFN reduced the costs of managing patients with suspected preterm labor by 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/22\">",
"     22",
"    </a>",
"    ]. A second study, involving nine referral centers and one university maternal-fetal medicine unit, collected data on maternal transport costs with a negative fFN [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/23\">",
"     23",
"    </a>",
"    ]. One hundred fifty-one patients had a presumptive diagnosis of threatened preterm labor. Ninety percent of the patients admitted to a referral hospital with threatened preterm labor who had a negative fFN result were not transferred, leading to a cost savings of $30,297 for road and fixed-wing transport.",
"   </p>",
"   <p>",
"    By comparison, a third study of women with presumptive preterm labor between 24 and 34 weeks of gestation compared costs when fFN results were or were not made available to clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/24\">",
"     24",
"    </a>",
"    ]. Knowledge of the fFN result did not lead to significant reductions in initial length observation (median, four hours versus three hours), rate of hospital admission (28 versus 26 percent), use of tocolysis (18 versus 16 percent), cessation of work (27 versus 26 percent), or total health care-related costs. We interpret these findings to mean that fFN is cost effective only when clinicians are comfortable using the results to alter patient care.",
"   </p>",
"   <p>",
"    While the positive predictive value of fFN (less than 30 percent in most populations) is far higher than other clinical assessments (eg, risk scoring systems, tocodynamometry, digital cervical examination) or other biochemical markers (eg, salivary estriol, cervical interleukin-6) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/25\">",
"     25",
"    </a>",
"    ], its high false positive rate makes it less than optimal for predicting PTD and management decisions. Moreover, no interventions (eg, antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/26\">",
"     26",
"    </a>",
"    ]) in fFN positive patients have been proven effective for preventing PTD. There are currently no data on the use of progesterone supplementation in fFN positive women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of spontaneous preterm birth\", section on 'Supplemental progesterone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, a positive fFN test should prompt consideration of administration of glucocorticoids to accelerate fetal lung maturation since these drugs are most effective if administered once, at least 48 hours before, but within seven days of, delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cervical length combined with fFN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative risk of PTD increases as cervical length decreases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women with preterm contractions, sonographic cervical length assessment, followed by fFN if the cervix is short, improves the ability to distinguish between women who will and will not deliver within seven or 14 days. Many referral centers now use a combination of these two tests in the evaluation of women with preterm contractions to help in management decisions (eg, use of tocolytics, use of glucocorticoids, follow-up).",
"   </p>",
"   <p>",
"    In combined testing, we order a fFN test only in women with a cervical length measurement of 20 to 30 mm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5608?source=see_link\">",
"     \"Overview of preterm labor and birth\"",
"    </a>",
"    .) Support for this approach was derived from the following lines of evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study showed that women with a cervical length &ge;30 mm were unlikely to deliver preterm and that measuring fFN did not enhance the predictive value of ultrasound examination in these women [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/27\">",
"       27",
"      </a>",
"      ]. By comparison, if the cervix was &lt;30 mm in length, the risk of delivery within seven days with positive and negative fFN results was 45 and 11 percent, respectively; the risk of delivery within 14 days was 56 and 13 percent, respectively. Delivery within seven days occurred in 75 percent of women with a cervical length &lt;15 mm and positive fFN.",
"     </li>",
"     <li>",
"      A prospective blinded study found that fFN was most useful in symptomatic women with a cervical length between 16 and 30 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/28\">",
"       28",
"      </a>",
"      ]. In this study, ultrasound cervical length and fFN data were collected in symptomatic patients, but the results were blinded to the physicians. A fFN &ge;50",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      was significantly more reliable than an ultrasound cervical length determination &le;25 mm for identifying patients who would deliver preterm. The sensitivity, specificity, and positive and negative predictive values of cervical length &le;25 mm for PTD were 75, 63, 24, and 94 percent, respectively, while the corresponding figures for fFN &ge;50",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      were 63, 81, 33, and 93 percent, respectively.",
"      <br/>",
"      <br/>",
"      The authors went on to determine whether selective use of fFN after cervical length measurement could decrease the number of fFN tests ordered. As noted above, women with a cervical length &gt;30 mm were unlikely to deliver within seven days and the addition of fFN testing did not significantly improve the predictive value of cervical length measurement alone. Cervical length &le;15 mm or fFN &ge;50",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      plus cervical length 16 to 30 mm were predictive of PTD and the sensitivity, specificity, and positive and negative predictive values (67, 81, 36, and 94 percent, respectively) were not significantly different from those of using fFN alone. Limiting fFN testing to women with intermediate cervical length avoided 200 tests in this population.",
"     </li>",
"     <li>",
"      Others have also found that it is possible to use fFN testing selectively. One such study reported that only positive fFN testing and functional canal length &lt;20 mm were independently associated with PTD [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/29\">",
"       29",
"      </a>",
"      ]. The authors proposed two-step testing: first, sonographic assessment of the cervix is performed with functional canal length &le;20 mm as a positive result and &gt;31 mm as a negative result. fFN testing is then performed only in patients with a cervical length of 21 to 31 mm. Two-step testing had overall sensitivity, specificity, positive and negative predictive values of 86, 90, 63, and 97 percent, respectively, for predicting delivery within 28 days. The combined use of the cervical sonography and fFN testing predicted PTD with higher sensitivity and negative predictive value than either of the methods alone.",
"     </li>",
"     <li>",
"      Another study found that a policy of contingent use of fFN when sonographic cervical length is between 16 and 30 mm gave sensitivity, specificity, positive and negative predictive values of 80, 61, 17, and 97 percent, respectively, for delivery within two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/30\">",
"       30",
"      </a>",
"      ]. The authors noted that contingent use decreased the number of women needing fFN screening after cervical length measurement by one-third.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to note that when fFN and sonographic determination of cervical length are to be used together, the Dacron fFN swab should be obtained prior to cervical sonography and placed in the carrier buffer. It can then be sent for assay, depending on the cervical ultrasound findings. Both sonographic cervical length and fFN determinations are supported by the American College of Obstetricians and Gynecologists (ACOG) and the United States Preventive Services Task Force (USPSTF) to differentiate true preterm labor from Braxton Hicks contractions in preterm symptomatic women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with American College of Obstetricians and Gynecologists (ACOG) guidelines that recommend against obtaining fFN levels to screen pregnant women for risk of preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/31\">",
"     31",
"    </a>",
"    ]. Although the prediction and prevention of prematurity are major goals of prenatal care, the utility of fFN testing for predicting preterm delivery is low in asymptomatic women, and few potentially effective interventions are available. Nonetheless, a number of studies have examined its value in this setting.",
"   </p>",
"   <p>",
"    In asymptomatic women with a short cervix (&lt;25 mm), the combination of a short cervix on ultrasound examination and a positive fFN result is predictive of an increased risk of PTD, especially in women with a previous PTD, while two negative tests are reassuring (less than 1 percent chance of PTD in the next week or two) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. However, although women with positive tests are at increased risk of subsequent PTD, most do not deliver with the next seven days. Since antenatal glucocorticoids for fetal lung maturation are best administered only once, 48 hours to seven days prior to a PTD, the value of fFN in this setting is debatable. If fFN testing is carried out in this setting, consideration should be given for steroid administration in a patient at or beyond 24 weeks of gestation who has a positive fFN result and short cervical length and additional risk factors for PTD (prior spontaneous preterm birth, multiple gestation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is evidence from randomized trials that progesterone supplementation is useful in preventing PTD in women with a short cervix, but this intervention has not been evaluated in the subgroup of women who have a positive fFN result. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of spontaneous preterm birth\", section on 'Supplemental progesterone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of cerclage in women who are incidentally identified to have a short cervix on ultrasound examination is of marginal benefit, in both fFN positive and fFN negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15159/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of spontaneous preterm birth\", section on 'Supplemental progesterone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"       \"Patient information: Preterm labor (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal fibronectin (fFN) is thought to be a \"trophoblast glue\" that promotes cellular adhesion at uterine-placental and decidual-fetal membrane interfaces. It is released into cervicovaginal secretions when the extracellular matrix of the",
"      <span class=\"nowrap\">",
"       chorionic/decidual",
"      </span>",
"      interface is disrupted. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Fetal fibronectin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal utility of the fFN assay lies in its high negative predictive value (over 99 percent in symptomatic patients in populations with low prevalence of preterm birth within seven days); the positive predictive value is much lower. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'fFN alone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not obtaining fFN levels to screen pregnant women for risk of preterm delivery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although the prediction and prevention of prematurity are major goals of prenatal care, the performance of fFN testing for predicting preterm delivery is low in asymptomatic women, and few potentially effective interventions are available. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Asymptomatic women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest obtaining a cervico-vaginal Dacron swab sample for use in possible fFN analysis and then conducting sonographic measurement of cervical length in women with preterm contractions and cervical dilatation less than 3 cm on visual inspection at sterile speculum examination. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cervical length combined with fFN'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We do not send the sample for fFN testing when the cervical length is over 30 mm or under 20 mm. Women with cervical length over 30 mm are unlikely to deliver preterm, while preterm delivery is likely if the cervical length is less than 20 mm.",
"     </li>",
"     <li>",
"      In women with cervical length 20 to 30 mm, we suggest selective use of fFN analysis to support or exclude the diagnosis of impending preterm birth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After testing, women found to be at low risk of impending delivery (negative fFN or cervix longer than 30 mm) can be discharged from the labor unit, whereas administration of antenatal glucocorticoids with or without tocolysis should be considered for women at high risk (positive fFN or cervix less than 20 mm). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cervical length combined with fFN'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/1\">",
"      Main DM, Gabbe SG, Richardson D, Strong S. Can preterm deliveries be prevented? Am J Obstet Gynecol 1985; 151:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/2\">",
"      Newman RB, Gill PJ, Wittreich P, Katz M. Maternal perception of prelabor uterine activity. Obstet Gynecol 1986; 68:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/3\">",
"      Lockwood CJ, Dudenhausen JW. New approaches to the prediction of preterm delivery. J Perinat Med 1993; 21:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/4\">",
"      Copper RL, Goldenberg RL, Davis RO, et al. Warning symptoms, uterine contractions, and cervical examination findings in women at risk of preterm delivery. Am J Obstet Gynecol 1990; 162:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/5\">",
"      Lockwood CJ, Senyei AE, Dische MR, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991; 325:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/6\">",
"      Morrison JC, Allbert JR, McLaughlin BN, et al. Oncofetal fibronectin in patients with false labor as a predictor of preterm delivery. Am J Obstet Gynecol 1993; 168:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/7\">",
"      Bittar RE, Yamasaki AA, Sasaki S, Zugaib M. Cervical fetal fibronectin in patients at increased risk for preterm delivery. Am J Obstet Gynecol 1996; 175:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/8\">",
"      Iams JD, Casal D, McGregor JA, et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 1995; 173:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/9\">",
"      Peaceman AM, Andrews WW, Thorp JM, et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997; 177:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/10\">",
"      Rozenberg P, Goffinet F, Malagrida L, et al. Evaluating the risk of preterm delivery: a comparison of fetal fibronectin and transvaginal ultrasonographic measurement of cervical length. Am J Obstet Gynecol 1997; 176:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/11\">",
"      Bartnicki J, Casal D, Kreaden US, et al. Fetal fibronectin in vaginal specimens predicts preterm delivery and very-low-birth-weight infants. Am J Obstet Gynecol 1996; 174:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/12\">",
"      Parker J, Bell R, Brennecke S. Fetal fibronectin in the cervicovaginal fluid of women with threatened preterm labour as a predictor of delivery before 34 weeks' gestation. Aust N Z J Obstet Gynaecol 1995; 35:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/13\">",
"      Leitich H, Kaider A. Fetal fibronectin--how useful is it in the prediction of preterm birth? BJOG 2003; 110 Suppl 20:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/14\">",
"      Honest H, Bachmann LM, Gupta JK, et al. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ 2002; 325:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/15\">",
"      Feinberg RF, Kliman HJ, Lockwood CJ. Is oncofetal fibronectin a trophoblast glue for human implantation? Am J Pathol 1991; 138:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/16\">",
"      King JF, Grant A, Keirse MJ, Chalmers I. Beta-mimetics in preterm labour: an overview of the randomized controlled trials. Br J Obstet Gynaecol 1988; 95:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/17\">",
"      Gaucherand P, Guibaud S, Awada A, Rudigoz RC. Comparative study of three amniotic fluid markers in premature rupture of membranes: fetal fibronectin, alpha-fetoprotein, diamino-oxydase. Acta Obstet Gynecol Scand 1995; 74:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/18\">",
"      Roman AS, Koklanaris N, Paidas MJ, et al. \"Blind\" vaginal fetal fibronectin as a predictor of spontaneous preterm delivery. Obstet Gynecol 2005; 105:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/19\">",
"      Stafford IP, Garite TJ, Dildy GA, et al. A comparison of speculum and nonspeculum collection of cervicovaginal specimens for fetal fibronectin testing. Am J Obstet Gynecol 2008; 199:131.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/20\">",
"      McKenna DS, Chung K, Iams JD. Effect of digital cervical examination on the expression of fetal fibronectin. J Reprod Med 1999; 44:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/21\">",
"      Sanchez-Ramos L, Delke I, Zamora J, Kaunitz AM. Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients: a meta-analysis. Obstet Gynecol 2009; 114:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/22\">",
"      Joffe GM, Jacques D, Bemis-Heys R, et al. Impact of the fetal fibronectin assay on admissions for preterm labor. Am J Obstet Gynecol 1999; 180:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/23\">",
"      Giles W, Bisits A, Knox M, et al. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings. Am J Obstet Gynecol 2000; 182:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/24\">",
"      Grobman WA, Welshman EE, Calhoun EA. Does fetal fibronectin use in the diagnosis of preterm labor affect physician behavior and health care costs? A randomized trial. Am J Obstet Gynecol 2004; 191:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/25\">",
"      Lockwood CJ. Predicting premature delivery--no easy task. N Engl J Med 2002; 346:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/26\">",
"      Andrews WW, Sibai BM, Thom EA, et al. Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. Obstet Gynecol 2003; 101:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/27\">",
"      Gomez R, Romero R, Medina L, et al. Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes. Am J Obstet Gynecol 2005; 192:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/28\">",
"      Schmitz T, Maillard F, Bessard-Bacquaert S, et al. Selective use of fetal fibronectin detection after cervical length measurement to predict spontaneous preterm delivery in women with preterm labor. Am J Obstet Gynecol 2006; 194:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/29\">",
"      Hincz P, Wilczynski J, Kozarzewski M, Szaflik K. Two-step test: the combined use of fetal fibronectin and sonographic examination of the uterine cervix for prediction of preterm delivery in symptomatic patients. Acta Obstet Gynecol Scand 2002; 81:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/30\">",
"      Audibert F, Fortin S, Delvin E, et al. Contingent use of fetal fibronectin testing and cervical length measurement in women with preterm labour. J Obstet Gynaecol Can 2010; 32:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/31\">",
"      Committee on Practice Bulletins&mdash;Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol 2012; 120:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/32\">",
"      Goldenberg RL, Iams JD, Mercer BM, et al. The preterm prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am J Public Health 1998; 88:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/33\">",
"      Iams JD, Goldenberg RL, Mercer BM, et al. The preterm prediction study: can low-risk women destined for spontaneous preterm birth be identified? Am J Obstet Gynecol 2001; 184:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/34\">",
"      Mercer BM, Goldenberg RL, Meis PJ, et al. The Preterm Prediction Study: prediction of preterm premature rupture of membranes through clinical findings and ancillary testing. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 2000; 183:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/35\">",
"      Goldenberg RL, Iams JD, Das A, et al. The Preterm Prediction Study: sequential cervical length and fetal fibronectin testing for the prediction of spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 2000; 182:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/36\">",
"      Iams JD, Goldenberg RL, Mercer BM, et al. The Preterm Prediction Study: recurrence risk of spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1998; 178:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15159/abstract/37\">",
"      Keeler SM, Roman AS, Coletta JM, et al. Fetal fibronectin testing in patients with short cervix in the midtrimester: can it identify optimal candidates for ultrasound-indicated cerclage? Am J Obstet Gynecol 2009; 200:158.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6823 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15159=[""].join("\n");
var outline_f14_51_15159=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FETAL FIBRONECTIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SAMPLE COLLECTION AND RESULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      USE IN SYMPTOMATIC WOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      fFN alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cervical length combined with fFN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ASYMPTOMATIC WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/6/30827\" title=\"table 1\">",
"      fFN and risk of preterm birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/24/24971\" title=\"table 2\">",
"      fFN perform sx and asx women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/21/11611\" title=\"table 3\">",
"      Performance of fFN vs clinical assessment for predicting PTD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5608?source=related_link\">",
"      Overview of preterm labor and birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=related_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=related_link\">",
"      Prevention of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=related_link\">",
"      Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_51_15160="Rifapentine: Drug information";
var content_f14_51_15160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rifapentine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/2/27684?source=see_link\">",
"    see \"Rifapentine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Priftin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Priftin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitubercular Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tuberculosis:",
"     </b>",
"     Oral:",
"     <b>",
"      Rifapentine should not be used alone",
"     </b>",
"     ; initial phase should include a 3- to 4-drug regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial phase of short-term therapy:",
"     </i>",
"     600 mg twice weekly (with an interval &ge;72 hours between doses) by direct observation therapy for 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuation phase of short-term therapy:",
"     </i>",
"     600 mg once weekly by direct observation therapy for 4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Latent tuberculosis infection (unlabeled use):",
"     </b>",
"     Oral: 900 mg once weekly for 3 months;",
"     <b>",
"      Note:",
"     </b>",
"     Must be administered under direct observation therapy and given in combination with isoniazid (Sterling, 2011; CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternative regimen based on weight (CDC, 2011):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25.1-32 kg: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     32.1-49.9 kg: 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;50 kg: 900 mg",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F15682466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Latent tuberculosis infection (unlabeled use) (CDC, 2011):",
"     </b>",
"     Children &ge;12 years and Adolescents: Oral: Use once weekly for 3 months;",
"     <b>",
"      Note:",
"     </b>",
"     Must be administered under direct observation therapy and given in combination with isoniazid (maximum dose: 900 mg):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     10-14 kg: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     14.1-25 kg: 450 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     25.1-32 kg: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     32.1-49.9 kg: 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;50 kg: 900 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Priftin&reg;: 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15682469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pulmonary tuberculosis; rifapentine must always be used in conjunction with at least one other antituberculosis drug to which the isolate is susceptible; it may also be necessary to add additional agents (eg, streptomycin, ethambutol) until susceptibility is known.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F15682241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of latent tuberculosis infection (LTBI) in combination with isoniazid",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Rifapentine may be confused with rifampin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F218470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency may vary based on treatment phase; adverse reaction data is based on rifapentine combination therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia (&le;32%; most likely due to pyrazinamide from initiation phase)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Hematuria (10% to 18%), pyuria (11% to 22%), urinary tract infection (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (6% to 13%), lymphopenia (3% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (3% to 6%), edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system:  Fatigue (&le;1%), fever (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (&le;3%), maculopapular rash (2%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (5% to 10%), hyperglycemia (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (3%), nausea (1% to 3%), abdominal pain (1% to 2%), constipation (1% to 2%), diarrhea (1% to 2%), hemorrhoids (1%), hyperphosphatemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary casts (4% to 8%), cystitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytosis (&le;6%), leukopenia (4% to 6%), leukocytosis (2% to 3%), neutrophilia (1% to 3%), thrombocytopenia (1% to 3%), polycythemia (&le;2%), lymphadenopathy (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (2% to 7%), AST increased (2% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (4% to 7%), pain (3% to 6%), arthrosis (1%), gout (1%), tremor (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Hemoptysis (8%), cough (6% to 8%), bronchitis (3%), pharyngitis (1% to 2%), epistaxis (1%) pleuritis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (3% to 8%), injury (1% to 5%), infection (1% to 3%), diaphoresis (2%), herpes zoster (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, anxiety, bilirubinemia, bronchospasm, BUN increased, diabetes mellitus, dyspnea, dysuria, erythematous rash, hepatomegaly, hypercalcemia, jaundice, loss of taste, muscle weakness, orthostatic hypotension, palpitation, pancreatitis, pyelonephritis, seizure, somnolence, syncope, tachycardia, urinary incontinence, weight gain/loss, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F218436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rifapentine, rifampin, rifabutin, any rifamycin analog, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Patients with abnormal liver tests and/or liver disease should only be given rifapentine when absolutely necessary and under strict medical supervision. Monitoring of liver function tests (eg, serum transaminases) should be carried out prior to therapy and then every 2-4 weeks during therapy. Combination therapy should be discontinued if ALT is &ge;5 times the upper limit of normal (ULN) even in the absence of liver dysfunction symptoms or &ge;3 times ULN in the presence of symptoms (CDC, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use is not recommended in patients with porphyria; exacerbation is possible due to enzyme-inducing properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV-seropositive patients: Use of rifapentine during the",
"     <b>",
"      initial phase",
"     </b>",
"     of treatment in HIV&ndash;seropositive patients has not been evaluated. Rifapentine should not be used during the",
"     <b>",
"      continuation phase",
"     </b>",
"     of treatment in HIV-seropositive patients; rifampin relapse and resistance have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use with caution in patients with cavitary pulmonary lesions and/or positive sputum cultures after initial treatment phase and patients with bilateral pulmonary disease; higher relapse rates may occur in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Compliance: Compliance with dosing regimen is absolutely necessary for successful drug therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lenses: Remove soft contact lenses during therapy since permanent staining may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Red/orange discoloration: Urine, feces, saliva, sweat, tears, skin, teeth, tongue, and CSF may be discolored to red/orange.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Rifamycin Derivatives may decrease the serum concentration of Alfentanil.  Management: Monitor closely for decreased alfentanil effectiveness.  Increased alfentanil doses will likely be needed.  Alternatively, changing from alfentanil to a different opioid anesthetic (e.g., sufentanil) may also be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Rifamycin Derivatives may increase the metabolism of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Rifamycin Derivatives may increase the metabolism of Angiotensin II Receptor Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Candesartan; Eprosartan; Olmesartan; Telmisartan; Valsartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiemetics (5HT3 Antagonists): Rifamycin Derivatives may increase the metabolism of Antiemetics (5HT3 Antagonists).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dolasetron; Granisetron; Palonosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Rifamycin Derivatives may increase the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Rifamycin Derivatives may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Rifamycin Derivatives may increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Rifamycin Derivatives may increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Rifamycin Derivatives may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Rifamycin Derivatives may decrease the serum concentration of BusPIRone.  Management: The degree to which rifampin alters buspirone concentrations warrants the consideration of an alternative to buspirone that is not metabolized by CYP3A4.  If these agents are used together, buspirone dose adjustments may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Rifamycin Derivatives may increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.  Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Rifamycin Derivatives may enhance the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Rifapentine may decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Rifamycin Derivatives may increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Rifamycin Derivatives may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Rifamycin Derivatives may increase the metabolism of Dapsone (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May decrease the metabolism of Rifamycin Derivatives. Rifamycin Derivatives may increase the metabolism of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Rifamycin Derivatives may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Rifapentine may decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Rifamycin Derivatives may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Rifamycin Derivatives may decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Rifamycin Derivatives. This appears only affect rifabutin. Rifamycin Derivatives may increase the metabolism of Fluconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Rifamycin Derivatives may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Rifamycin Derivatives may increase the metabolism of Gefitinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Rifamycin Derivatives may decrease the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Rifamycin Derivatives may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with the rifamycin derivatives when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Rifamycin Derivatives may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Morphine (Systemic): Rifamycin Derivatives may decrease the serum concentration of Morphine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Rifamycin Derivatives may decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Rifamycin Derivatives may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: Rifamycin Derivatives may increase the serum concentration of Pitavastatin.  Management: Limit pitavastatin dose to a maximum of 2 mg/day with concurrent rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Rifamycin Derivatives may decrease the serum concentration of Propafenone.  Management: Monitor propafenone serum concentrations closely with rifamycin initiation/dose adjustments/discontinuation. Propafenone serum concentrations/therapeutic effects  may decrease with rifamycins. Propafenone dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.  Management: Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased quinidine concentrations/effects with initiation/dose increase of any rifamycin derivative.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Rifamycin Derivatives may increase the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Rifamycin Derivatives may increase the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Rifamycin Derivatives may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Rifamycin Derivatives may increase the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: Rifamycin Derivatives may increase the metabolism of Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Rifamycin Derivatives may decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus.  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as rifampin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Rifamycin Derivatives may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zaleplon: Rifamycin Derivatives may increase the metabolism of Zaleplon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Rifamycin Derivatives may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Rifamycin Derivatives may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F218451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: High-fat meals  increase AUC and maximum serum concentration by 43% and 44% respectively as compared to fasting conditions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. Postnatal hemorrhages have been reported in the infant and mother with rifampin (another rifamycin) administration during the last few weeks of pregnancy. Due to the risk of tuberculosis to the fetus, treatment is recommended when the probability of maternal disease is moderate to high. The CDC does not currently recommend rifapentine as part of the treatment regimen due to insufficient data in pregnant women (CDC, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F218463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F218441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor breast milk",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Priftin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (32): $145.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F218430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with pre-existing hepatic problems should have liver function tests monitored (eg serum transaminases) prior to therapy and then every 2-4 weeks during therapy. In treatment of latent infection with rifapentine and isoniazid combination therapy, patients with HIV infection, liver disorders, immediate postpartum (&le; 3 months after delivery) or regular ethanol use should have liver function (at least alanine aminotransferase [ALT]) monitored prior to therapy and then at subsequent clinical visits whose baseline testing is abnormal or for others at risk for liver disease disease (CDC, 2012).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F218442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Priftin (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F218419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA-dependent RNA polymerase in susceptible strains of",
"     <i>",
"      Mycobacterium tuberculosis",
"     </i>",
"     (MTB) (but not in mammalian cells). Rifapentine is bactericidal against both intracellular and extracellular MTB organisms.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: High-fat meals increase AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     by 43% and 44% respectively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~70 L; rifapentine and metabolite accumulate in human monocyte-derived macrophages with intracellular/extracellular ratios of 24:1 and 7:1 respectively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Rifapentine: ~98%, primarily to albumin; 25-desacetyl rifapentine: ~93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; hydrolyzed by an esterase enzyme to form the active metabolite 25-desacetyl rifapentine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Rifapentine: 12-15 hours; 25-desacetyl rifapentine: 11-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (70%); urine (17%, primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Tuberculosis,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR11):1-77; published erratum appears in",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 53(51):1203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/51/15160/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Recommendations for Use of an Isoniazid-Rifapentine Regient With Direct Observation to Treat Latent",
"      <i>",
"       Mycobacterium tuberculosis",
"      </i>",
"      Infection,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(48):1649-53; published erratum appears in",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61:80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/51/15160/abstract-text/22157884 /pubmed\" id=\"22157884 \" target=\"_blank\">",
"        22157884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grosset J, Lounis N, Truffot-Pernot C, et al, &ldquo;Once Weekly Rifapentine-Containing Regimens for Treatment of Tuberculosis in Mice,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 1998, 157(5 Pt 1):1436-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/51/15160/abstract-text/9603120/pubmed\" id=\"9603120\" target=\"_blank\">",
"        9603120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jarvis B and Lamb HM, &ldquo;Rifapentine,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 56(4):607-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/51/15160/abstract-text/9806107/pubmed\" id=\"9806107\" target=\"_blank\">",
"        9806107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keung AC, Eller MG, and Weir SJ, &ldquo;Pharmacokinetics of Rifapentine in Patients With Varying Degrees of Hepatic Dysfunction,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1998, 38(6):517-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/51/15160/abstract-text/9650541/pubmed\" id=\"9650541\" target=\"_blank\">",
"        9650541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keung AC, Eller MG, and Weir SJ, \"Single-Dose Pharmacokinetics of Rifapentine in Elderly Men,\"",
"      <i>",
"       Pharm Res",
"      </i>",
"      , 1998, 15(8):1286-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/51/15160/abstract-text/9706063 /pubmed\" id=\"9706063 \" target=\"_blank\">",
"        9706063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moghazeh Sl, Pan X, Arain T, et al, &ldquo;Comparative Antimycobacterial Activities of Rifampin, Rifapentine, and KRM-1648 Against a Collection of Rifampin-Resistant",
"      <i>",
"       Mycobacterium",
"      </i>",
"      Tuberculosis Isolates With Known rpo&beta; Mutations,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1996, 40:265-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sterling TR, Villarino ME, Borisov AS, et al, &ldquo;Three Months of Once-Weekly Rifapentine and Isoniazid for",
"      <i>",
"       M. tuberculosis",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2011, 365(23):2155-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/51/15160/abstract-text/22150035/pubmed\" id=\"22150035\" target=\"_blank\">",
"        22150035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tam CM, Chan SL, Lam CW, et al, &ldquo;Rifapentine and Isoniazid in the Continuation Phase of Treating Pulmonary Tuberculosis, Initial Report,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 1998, 157(6 Pt 1):1726-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/51/15160/abstract-text/9620898/pubmed\" id=\"9620898\" target=\"_blank\">",
"        9620898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10079 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15160=[""].join("\n");
var outline_f14_51_15160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218455\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218456\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218472\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218459\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682466\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218460\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682467\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682468\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218432\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218417\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682469\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218433\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682241\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218479\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218470\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218436\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218420\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218467\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218425\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218451\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218428\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218440\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218463\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218441\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218439\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218430\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218442\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218419\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218435\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10079\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10079|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/2/27684?source=related_link\">",
"      Rifapentine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_51_15161="Ependymoma";
var content_f14_51_15161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ependymoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/51/15161/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/51/15161/contributors\">",
"     Mark W Kieran, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/51/15161/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/51/15161/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/51/15161/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/51/15161/contributors\">",
"     Amar Gajjar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/51/15161/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/51/15161/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/51/15161/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ependymomas are an uncommon group of glial tumors that typically arise within or adjacent to the ependymal lining of the ventricular system [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/1\">",
"     1",
"    </a>",
"    ]. Ependymomas occasionally occur within the brain parenchyma or outside the central nervous system (CNS).",
"   </p>",
"   <p>",
"    Ependymomas account for less than 10 percent of tumors arising in the central nervous system (CNS) and 25 percent of primary tumors originating in the spinal cord.",
"   </p>",
"   <p>",
"    The clinical presentation and management of ependymomas arising in the brain will be reviewed here. Ependymomas arising in the spinal cord are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link\">",
"     \"Spinal cord tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age and anatomic location",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ependymomas is approximately equal in males and females. The median age at diagnosis in children is five years of age, and 25 to 40 percent of patients are less than two years old.",
"   </p>",
"   <p>",
"    The fourth ventricle is the most common infratentorial site and extension into the subarachnoid space occurs frequently, sometimes with encasement of the medulla and upper cervical cord. Supratentorial lesions can be either intraventricular, typically in the lateral ventricles, or parenchymal.",
"   </p>",
"   <p>",
"    The typical locations in which ependymomas arise differ depending upon patient age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, approximately 90 percent of ependymomas are intracranial, including 60 percent located in the posterior fossa, while the remainder arise in the spinal cord. Infratentorial ependymomas are most common in children under the age of three [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, approximately 75 percent of ependymomas in adults arise within the spinal canal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiologic factors responsible for the development of ependymoma are not known. A link to exposure to simian virus 40 was postulated based upon identification of the virus in tumor tissue. However, a causal relationship has not been confirmed, and SV40 is no longer considered either a risk factor or an etiologic agent in the development of ependymoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=see_link&amp;anchor=H20#H20\">",
"     \"Risk factors for brain tumors\", section on 'Viral infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is an increased association of intramedullary spinal cord ependymoma in patients with neurofibromatosis type II (NF2) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], although abnormalities in the NF2 gene have not been identified in the majority of sporadic ependymoma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the World Health Organization (WHO) classification of brain tumors, ependymal tumors are divided into four major subtypes: myxopapillary ependymoma (WHO grade I), subependymoma (WHO grade I), classic ependymoma (WHO grade II), and anaplastic ependymoma (WHO grade III) (",
"    <a class=\"graphic graphic_table graphicRef55058 \" href=\"UTD.htm?14/32/14861\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link\">",
"     \"Classification of gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1296274\">",
"    <span class=\"h3\">",
"     Ependymoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ependymomas are generally slow-growing tumors of children and young adults and are usually classified as &lsquo;classic ependymoma&rsquo; or WHO grade II and &lsquo;anaplastic ependymoma&rsquo; or WHO grade III. These tumors can occur anywhere in the ventricular system or spinal canal; they are most common in the fourth ventricle and spinal cord. Ependymomas are usually well demarcated with frequent areas of calcification, hemorrhage, and cysts. The tumor cells often form ependymal rosettes, which are diagnostic but not always present. Ependymomas are divided into cellular, papillary, clear cell, and tanycytic subtypes. Further classification of ependymomas into additional subtypes is probable, based at least in part upon advances in understanding the molecular biology of these tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is considerable controversy regarding the prognostic significance of ependymoma grade (grade II versus grade III). While some reports have indicated a poorer prognosis for anaplastic ependymoma (grade III), this has not been confirmed in most studies, the majority of which were performed retrospectively. Variability in the histologic differentiation of classic from anaplastic ependymoma between neuropathologists may account for these results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/8\">",
"     8",
"    </a>",
"    ]. In a large molecular analysis of 379 patient samples, nestin expression was correlated with a poor prognosis and was more accurate than histologic grading in predicting outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1296289\">",
"    <span class=\"h3\">",
"     Subependymoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subependymomas are rare tumors found in the fourth or lateral ventricles of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/6\">",
"     6",
"    </a>",
"    ]. Subependymomas are more common in males. These lesions are usually slow growing and histologically appear benign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1296296\">",
"    <span class=\"h3\">",
"     Myxopapillary ependymoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myxopapillary ependymomas are slow-growing tumors that typically are found in young adults and are more common in males. These tumors arise almost exclusively in the conus medullaris and filum terminale. Molecular analysis suggests that adult and pediatric tumors differ [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H10#H10\">",
"     \"Spinal cord tumors\", section on 'Myxopapillary ependymoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1296303\">",
"    <span class=\"h3\">",
"     Ependymoblastoma (ETANTR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ependymoblastomas are highly malignant tumors most commonly seen in infants. Although ependymoblastomas formerly were considered a variant of ependymoma, these tumors are now classified in the group of primitive neuroectodermal tumors (PNETs) and are referred to as embryonal tumors with abundant neuropil and true rosettes (ETANTR). Ependymoblastomas were included in some early series describing the natural history of ependymoma and accounted for many of the cases of leptomeningeal dissemination previously associated with this tumor (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=see_link&amp;anchor=H21#H21\">",
"     \"Uncommon brain tumors\", section on 'Ependymoblastoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic changes are common in ependymomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/11-21\">",
"     11-21",
"    </a>",
"    ]. One comprehensive genomic study has divided ependymoma into three distinct subgroups based upon site of origin (supratentorial, posterior fossa, and spinal cord) and suggests the presence of molecular subgroups within each anatomical location [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/22\">",
"     22",
"    </a>",
"    ]. Another group has documented two easily distinguishable molecular subgroups within the posterior fossa tumors that have prognostic implications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/23\">",
"     23",
"    </a>",
"    ]. Similarly, a gain in chromosome 1q25 has been reported to be associated with an increased risk of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/24\">",
"     24",
"    </a>",
"    ] and human telomerase reverse-transcriptase (HTERT) has been associated with a poorer overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective confirmation of these data is needed but an understanding of the molecular pathogenesis may eventually allow clinicians to specifically target therapies to distinct molecular subgroups of ependymoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of patients with ependymoma depends upon the location of the tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with posterior fossa lesions have evidence of increased intracranial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/27\">",
"       27",
"      </a>",
"      ]. As a result, headache, nausea and vomiting, ataxia, vertigo, and papilledema are common at presentation. Cranial nerve palsies are also common, especially involving cranial nerves VI to X. Brainstem invasion may occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizures or focal neurologic deficits are common presentations when the tumors arise in the supratentorial compartment.",
"     </li>",
"     <li>",
"      Tumors involving the spinal cord present with deficits due to involvement of ascending or descending nerve tracts or the exiting peripheral nerves. Specific abnormalities are related to the anatomic level of the tumor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link\">",
"       \"Spinal cord tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dissemination of tumor through the cerebrospinal fluid (CSF) is observed in less than 10 percent of patients at diagnosis when ependymoblastomas (ETANTR) are excluded [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/28\">",
"       28",
"      </a>",
"      ]. The incidence is higher with infratentorial ependymomas compared to supratentorial tumors (9.0 versus 1.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/28\">",
"       28",
"      </a>",
"      ]. Although historical data suggested a correlation between high-grade histology (classic grade II versus anaplastic grade III) and spinal seeding, more recent data have not confirmed this relationship. (See",
"      <a class=\"local\" href=\"#H1296274\">",
"       'Ependymoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for tumors that present in the posterior fossa includes medulloblastoma, astrocytoma, and brainstem or choroid plexus tumors. In the supratentorial location, glial tumors, PNETs, and choroid plexus carcinoma or papilloma should be considered.",
"   </p>",
"   <p>",
"    The appearance of these tumors on preoperative magnetic resonance imaging (MRI) or computed tomography (CT) may suggest the diagnosis of ependymoma. On MRI, these tumors have a hypointense appearance on T1, and are hyperintense on T2 or proton density images; gadolinium enhancement is usually prominent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70680 graphicRef73184 graphicRef80310 graphicRef59464 \" href=\"UTD.htm?13/28/13769\">",
"     image 1A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/29\">",
"     29",
"    </a>",
"    ]. Extension into the foramen of Luska is commonly observed. The CT appearance is often hyperdense with homogeneous enhancement; cysts and calcifications are common. The presence of calcifications within a tumor located in the fourth ventricle is highly suggestive but not diagnostic of ependymoma.",
"   </p>",
"   <p>",
"    A subependymoma should be suspected in adults who present with a long clinical history and evidence of a non-enhancing, well-demarcated, nodular intraventricular tumor that is isodense on CT, and isointense in T1 and hyperintense in T2-weighted images on MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of ependymoma requires histologic confirmation. Because gross total resection is so important, we favor open surgery and not stereotactic biopsy for most patients. Biopsy is recommended in adult patients where the diagnosis is in question.",
"   </p>",
"   <p>",
"    All patients should have MRI of the entire neuraxis to exclude metastatic disease, since up to 10 percent of patients have evidence of spinal seeding (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56153 \" href=\"UTD.htm?5/50/5921\">",
"     image 2",
"    </a>",
"    ). Cerebrospinal fluid cytology is important for staging for patients with posterior fossa lesions and those with anaplastic tumors. Ideally, CSF should be obtained from either the lumbar site presurgery, which often is contraindicated due to obstructive hydrocephalus, or one to two weeks postoperatively. The prognostic significance of ventricular or cisternal fluid is not well defined. Although uncommon, the presence of metastatic disease significantly affects both treatment and prognosis. One third of patients with metastatic disease may be identified only on the basis of positive CSF cytology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment for patients with ependymoma arising in the brain consists of maximal safe resection, which is usually followed by adjuvant radiotherapy. Chemotherapy does not appear to play an important role in the management of these tumors in adults and older children, but may in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/33\">",
"     33",
"    </a>",
"    ] or in patients with bulk residual disease.",
"   </p>",
"   <p>",
"    Until better molecular prognostic markers are available, current therapeutic approaches continue to focus on the degree of resection as the major determinant of treatment. Incompletely resected ependymomas of either grade (II or III) require a short course of chemotherapy followed by second-look surgery if there is residual signal, followed by conformal radiation therapy. Ependymomas of either grade that achieve a complete resection up-front should go directly to conformal radiation therapy. An exception to these approaches should only occur in the context of approved prospective clinical trials.",
"   </p>",
"   <p>",
"    Because of the complexity involved in these cases, patients with ependymomas should be referred to highly specialized centers whenever possible.",
"   </p>",
"   <p>",
"    Treatment of spinal cord ependymal tumors is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H8#H8\">",
"     \"Spinal cord tumors\", section on 'Ependymomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials evaluating the extent of surgery. Observational data indicate that patients undergoing gross total resection have a better prognosis than those in whom only a partial resection is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/34-39\">",
"     34-39",
"    </a>",
"    ]. Resection is particularly problematic for lesions of the posterior fossa, which are in close proximity to cranial nerves and the brainstem, where there is a significant risk of long-term neurologic dysfunction with gross total resection. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Prognostic factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebellar mutism, also referred to as posterior fossa syndrome, is a recognized complication of posterior fossa surgery and is most common when brainstem invasion is observed [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=see_link\">",
"       \"Epidemiology, treatment, and prognosis of medulloblastoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lesions invading the brainstem can be particularly challenging. Patients with incomplete resections do less well than those with gross total resection. As a result, many centers consider a second-look operation following chemotherapy in order to achieve macroscopic clearance. (See",
"      <a class=\"local\" href=\"#H2530398\">",
"       'Chemotherapy after partial resection'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Cerebellopontine angle lesions can often result in significant cranial nerve damage, although, at least in infants, recovery of function may follow successful resection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of adjuvant radiation therapy (RT) following surgery depends upon the anatomic location of the tumor, its histology, and the extent of resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ependymoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative RT is the standard of care following complete resection for most patients with posterior fossa and supratentorial ependymomas in order to reduce the likelihood of recurrence in the tumor bed. However, in young children, RT can cause severe neurocognitive impairment and other radiation-induced complications. Chemotherapy is being studied as a way to postpone or completely avoid the need for RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Retrospective data indicate that patients with supratentorial non-anaplastic tumors who have gross tumor resection with a wide margin of normal tissue may do well without adjuvant RT, and the role of adjuvant RT in this setting remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Because most recurrences are local, patients who recur can often be salvaged with further surgery and postoperative RT.",
"   </p>",
"   <p>",
"    The amount of normal tissue to be included in the RT treatment volume of posterior fossa ependymoma and anaplastic supratentorial ependymoma has been a source of controversy in the past. Data from observational series have now defined local radiotherapy, using contemporary techniques, as the standard of care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conformal techniques allow irradiation of the tumor bed and an adequate margin of adjacent normal tissue while sparing much of the brain. The current standard for a dose to the target is at least 54 Gy for lesions in the brain, and higher doses may be recommended for areas with residual macroscopic disease.",
"     </li>",
"     <li>",
"      Although prophylactic craniospinal irradiation (PCI) was advocated at one time for all resected ependymomas, local recurrence is the predominant site of failure and PCI does not appear to improve survival [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. More extensive radiation fields are indicated if there is evidence of tumor dissemination based upon neuroimaging or cerebrospinal fluid cytology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no randomized trials comparing adjuvant RT with observation in patients with ependymoma. However, the outcomes from adjuvant RT are illustrated by a single-institution series of 153 children with localized ependymoma (80 percent infratentorial), including 85 with anaplastic ependymoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/47\">",
"     47",
"    </a>",
"    ]. The median age was three years. All patients had undergone prior resection, which was complete in 125 (82 percent), and 85 (56 percent) had received prior chemotherapy. After a median follow-up of five years, the seven-year event-free and overall survival rates were 69 and 81 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Subependymomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with subependymomas often do well after complete resection alone, underscoring the different natural history of these lesions compared to other brain ependymomas. Whether RT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy significantly improve outcome for these patients compared with surgery alone is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of chemotherapy for patients with ependymoma has been based upon the demonstration of antitumor activity in children with recurrent or refractory disease.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    appear to be the most active agents, and higher response rates have been observed with more intense combination regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/48-53\">",
"     48-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who have undergone partial or gross total surgical resection, chemotherapy has been studied in a variety of settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2530398\">",
"    <span class=\"h3\">",
"     Chemotherapy after partial resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;One indication for the use of chemotherapy in ependymoma is in patients with partial resection following initial surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a cooperative group study of pre-radiation chemotherapy in 35 children with unresectable disease, 40 percent achieved a complete response, 17 percent had partial response, 29 percent had minor response or stable disease, and 14 percent demonstrated progressive tumor growth [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/55\">",
"     55",
"    </a>",
"    ]. The 5-year overall survival (OS) and event-free survival (EFS) of all patients was 71 and 57&thinsp;percent. The EFS in the pre-radiation group was comparable to that of patients with no residual tumor who received irradiation alone (55 versus 58 percent, P&thinsp;=&thinsp;0.45), although the benefit of chemotherapy was restricted to patients with greater than 90 percent tumor resection.",
"   </p>",
"   <p>",
"    This strongly suggests that limited pre-radiation chemotherapy can be used in patients with incompletely resectable disease, and may be combined with second-look surgery to improve the EFS and OS prior to focal radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chemotherapy in lieu of RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy may have a role in delaying or avoiding postoperative cranial irradiation in children less than three years old [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/34,35,49,56,57\">",
"     34,35,49,56,57",
"    </a>",
"    ]. There are no randomized trials comparing immediate RT following surgery with a strategy in which surgery is followed by chemotherapy, and RT is deferred.",
"   </p>",
"   <p>",
"    The potential role of this approach is illustrated by two cooperative group series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 80 children under five years of age who presented without metastatic disease, the initial treatment following maximal surgical resection consisted of seven cycles of chemotherapy. At a median follow-up of six years, the overall five-year survival was 63 percent, and the five-year event-free survival was 42 percent. Overall, 34 of 80 children (43 percent) required RT for recurrent disease.",
"     </li>",
"     <li>",
"      In another study, 89 children aged three years or less were treated with combination chemotherapy after maximal surgical resection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/57\">",
"       57",
"      </a>",
"      ]. Of the 80 patients without metastatic disease at presentation, 50 eventually relapsed. At a median follow-up of six years, the five-year event-free and overall survival rates were 63 and 42 percent, respectively, and the five-year incidence of avoiding RT was 42 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a pilot study, five children with anaplastic ependymoma, all under the age of three, were treated with high-dose chemotherapy and stem cell rescue [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/58\">",
"     58",
"    </a>",
"    ]. Four patients had bulk residual and three presented with metastatic disease. All patients made it to age three without radiation therapy, and only one progression has been noted at a median follow-up of 45 months.",
"   </p>",
"   <p>",
"    Additional study is needed to establish the role of chemotherapy as a component of primary treatment in young children with ependymoma, particularly with the emergence of conformal radiation techniques that have reduced concerns for developmental delay. At present, chemotherapy in place of RT should only be used within the context of a formal protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Adjuvant chemotherapy after surgery and RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adjuvant chemotherapy after surgery and postoperative RT is unclear.",
"   </p>",
"   <p>",
"    In one report, 19 children (aged 3 to 14 years) underwent postoperative chemotherapy and radiation after subtotal resection of an intracranial ependymoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/59\">",
"     59",
"    </a>",
"    ]. The five-year progression-free survival rate was 74 percent, a value that appears higher than published survival results for radiation alone. In contrast, two small randomized studies did not support the role of chemotherapy after surgical resection and RT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/34,60\">",
"     34,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the role of chemotherapy remains uncertain, it may be considered with RT in patients with residual tumor following resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis for patients with recurrent disease is poor, and while patients can be palliated for extend periods of time, most will eventually succumb within years of relapse. Recurrent disease may be due to local failure, distant disease, or a combination of both [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/61\">",
"     61",
"    </a>",
"    ]. While multiple treatment options are available, it is important that patients and caregivers understand the poor long-term prognosis of patients with recurrent or progressive ependymoma after radiation therapy. Careful selection of treatment options for these patients can provide excellent palliation and good quality of life; no single option is considered standard or proven effective.",
"   </p>",
"   <p>",
"    Outside of a formal clinical trial, each patient should be managed on a case-by-case basis, taking into account their age, location of the original and recurrent disease, presence of metastases, prior treatment and functional status.",
"   </p>",
"   <p>",
"    In addition to experimental therapy, multiple approaches have been tried in this population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive surgical resection may provide effective palliation in some patients. Chemotherapy with or without RT may have a role in reducing residual or recurrent tumor prior to attempted reresection , all aimed at prolonging the time to further disease progression and death [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/48,51,62\">",
"       48,51,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reirradiation of recurrent tumors may be beneficial and has yielded a salvage rate in carefully selected cases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/63-66\">",
"       63-66",
"      </a>",
"      ]. Available techniques include stereotactic radiosurgery (SRS), focal fractionated reirradiation, and craniospinal irradiation, depending upon the location and extent of recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/63\">",
"       63",
"      </a>",
"      ]. Patients treated with focal reirradiation remain at risk for the development of disseminated metastases, and recurrence at the primary site eventually occurs in most patients.",
"     </li>",
"     <li>",
"      High-dose chemotherapy with stem cell rescue has not demonstrated benefit in children with recurrent disease. In a series of 15 cases, five died of treatment-related toxicities within two months of marrow reinfusion, eight died from progressive disease a median of six months posttransplantation, one has died from unrelated causes, and one was alive at two years with further disease recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Conventional chemotherapy may provide symptom palliation. In a series of 28 adults with recurrent or progressive intracranial ependymoma, six had an objective response to chemotherapy; the response rate was higher with platinum-based regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/68\">",
"       68",
"      </a>",
"      ]. Responses are usually short-lived and tumor progression after chemotherapy alone usually occurs quickly.",
"     </li>",
"     <li>",
"      In a series of eight adults, six had a partial response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , with a median time to progression of six months [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/69\">",
"       69",
"      </a>",
"      ], although other retrospective series have not demonstrated significant efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/70\">",
"       70",
"      </a>",
"      ]. A clinical trial of bevacizumab and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      in 13 children with recurrent or progressive ependymoma also failed to show significant activity (no objective responses, median time to progression 2.2 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a growing interest in potential molecular targets for ependymoma, including the epidermal growth factor receptor (EGFR) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/72\">",
"       72",
"      </a>",
"      ] and c-Kit [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/73\">",
"       73",
"      </a>",
"      ]. Prospective trials have not yet been performed, and all of these approaches are currently considered investigational.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors affect the likelihood of disease-free survival after treatment of ependymomas arising in the brain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extent of resection  Approximately 90 percent of recurrences are local, underscoring the importance of a gross total resection to outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/36,37,74-76\">",
"       36,37,74-76",
"      </a>",
"      ]. Although the reported degree of benefit has varied, all studies have indicated that patients who can be treated with gross total resection have a better prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/36,37,74\">",
"       36,37,74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tumor location &mdash; Comparisons of survival based on tumor location have yielded conflicting results. While at least one study has suggested that supratentorial tumors have a better survival [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/77\">",
"       77",
"      </a>",
"      ], others have found that patients with infratentorial lesions do better [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/74\">",
"       74",
"      </a>",
"      ]. Involvement of the cervical spinal cord has been associated with decreased survival due to failures outside the primary site [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Histologic grade &mdash; Higher grade ependymomas are associated with poor outcome in most [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/78-82\">",
"       78-82",
"      </a>",
"      ] but not all studies [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/64,83\">",
"       64,83",
"      </a>",
"      ]. In one retrospective review of 80 patients with ependymoma, patients with low and high-grade tumors had a five-year survival rate of 87 and 27 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/81\">",
"       81",
"      </a>",
"      ]. Better results may reflect the inclusion of patients with subependymomas while poorer results may reflect including ependymoblastomas in the analyzed series.",
"     </li>",
"     <li>",
"      Other factors &mdash; In children, better performance status [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/84,85\">",
"       84,85",
"      </a>",
"      ] and older age are also associated with better prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/76\">",
"       76",
"      </a>",
"      ]. Compared to older children, infants may do less well partly because they have a higher incidence of infratentorial tumors, and partly because they tend not to receive timely adjuvant radiotherapy due to toxic effects on brain development.",
"     </li>",
"     <li>",
"      Chromosomal changes &mdash; Deletion of CDKN2A and gain of chromosome 1 are associated with shorter overall and progression-free survival. In contrast, loss of chromosome 6 or gains of chromosomes 9, 15, or 18 were associated with significantly better overall and progression-free survival [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adults &mdash; Two large European multi-institution series that included a total of 222 patients and 123 patients from a single US institution have analyzed the outcomes and prognostic factors for adults with intracranial ependymomas [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/86-88\">",
"       86-88",
"      </a>",
"      ]. In these series, the five-year survival rate ranged from 67 to 85 percent, and the ten-year survival varied from 50 to 77 percent. On multivariate analysis, factors associated with a poor prognosis included high histologic grade, incomplete surgical resection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/89\">",
"       89",
"      </a>",
"      ], location [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/88,90\">",
"       88,90",
"      </a>",
"      ], and a Karnofsky performance status &le;80 (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/87\">",
"       87",
"      </a>",
"      ]. The prognostic importance of incomplete resection has also been observed in a population-based study of both adults and children with ependymoma using the Surveillance Epidemiology and End Results (SEER) database [",
"      <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are long-term survivors after treatment for central nervous system tumors are at risk for a number of problems, including neurocognitive deficits, focal neurologic deficits, growth abnormalities, endocrine abnormalities, and second malignancies. These problems can be due to the damage originally done by the tumor or the treatment (surgery, RT,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/91-97\">",
"     91-97",
"    </a>",
"    ]. The nature and extent of these problems will be influenced by the location of the tumor and the specific treatment given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H15#H15\">",
"     \"Complications of cranial irradiation\", section on 'Late reactions'",
"    </a>",
"    .) Adult patients can experience significant long-term morbidity including fatigue, numbness, pain and altered sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the Children's Oncology Group, and are available at",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/51/15161/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ependymomas arising in the brain are uncommon glial tumors that typically develop within or adjacent to the ependymal lining of the ventricular system. These tumors are most commonly seen in young children.",
"   </p>",
"   <p>",
"    There are no published randomized clinical trials to guide the management of patients with ependymoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients with ependymoma arising in the brain, we recommend gross total resection, rather than biopsy or subtotal resection, when this can be accomplished without excessive morbidity (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Observational studies indicate that gross total resection is associated with an improved likelihood of prolonged survival compared to lesser resections. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an ependymoma who are older than age one to three years, we recommend adjuvant radiation therapy following complete resection, rather than observation and salvage therapy if a relapse occurs (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Observation following surgery may be an alternative for patients with a supratentorial non-anaplastic ependymoma who have undergone a gross total resection with a wide resection margin. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children less than one to three years of age who have had a complete resection of an ependymoma, we suggest adjuvant three-dimensional conformal radiation therapy following surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Chemotherapy may represent an alternative to RT following surgery to avoid the neurologic complications of radiation therapy, but this should be undertaken only in the context of a formal clinical trial. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with incompletely resected ependymoma arising in the brain, we suggest postoperative chemotherapy followed by second-look surgery in an attempt to achieve a gross total resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The management of ependymomas arising in the spinal cord is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link\">",
"       \"Spinal cord tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/1\">",
"      Shuangshoti S, Rushing EJ, Mena H, et al. Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients. Cancer 2005; 103:2598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/2\">",
"      Grill J, Pascal C, Chantal K. Childhood ependymoma: a systematic review of treatment options and strategies. Paediatr Drugs 2003; 5:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/3\">",
"      Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 1999; 155:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/4\">",
"      Pollack IF, Mulvihill JJ. Neurofibromatosis 1 and 2. Brain Pathol 1997; 7:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/5\">",
"      Rubio MP, Correa KM, Ramesh V, et al. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res 1994; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Classification of Tumours of the Nervous System, IARC Press, Lyon, France 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/7\">",
"      Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003; 163:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/8\">",
"      Ellison DW, Kocak M, Figarella-Branger D, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 2011; 10:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/9\">",
"      Milde T, Hielscher T, Witt H, et al. Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol 2012; 22:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/10\">",
"      Barton VN, Donson AM, Kleinschmidt-DeMasters BK, et al. Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol 2010; 20:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/11\">",
"      Rousseau A, Idbaih A, Ducray F, et al. Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade. J Neurooncol 2010; 97:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/12\">",
"      Reardon DA, Entrekin RE, Sublett J, et al. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer 1999; 24:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/13\">",
"      Mazewski C, Soukup S, Ballard E, et al. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet 1999; 113:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/14\">",
"      Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002; 86:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/15\">",
"      Yokota T, Tachizawa T, Fukino K, et al. A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor. J Hum Genet 2003; 48:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/16\">",
"      Hulsebos TJ, Oskam NT, Bijleveld EH, et al. Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. Br J Cancer 1999; 81:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/17\">",
"      Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol 2005; 7:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/18\">",
"      Huang B, Starostik P, Schraut H, et al. Human ependymomas reveal frequent deletions on chromosomes 6 and 9. Acta Neuropathol 2003; 106:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/19\">",
"      Korshunov A, Witt H, Hielscher T, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 2010; 28:3182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/20\">",
"      Wani K, Armstrong TS, Vera-Bolanos E, et al. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 2012; 123:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/21\">",
"      Yang I, Nagasawa DT, Kim W, et al. Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas. J Clin Neurosci 2012; 19:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/22\">",
"      Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 2010; 466:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/23\">",
"      Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011; 20:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/24\">",
"      Kilday JP, Mitra B, Domerg C, et al. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res 2012; 18:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/25\">",
"      Modena P, Buttarelli FR, Miceli R, et al. Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro Oncol 2012; 14:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/26\">",
"      Atkinson JM, Shelat AA, Carcaboso AM, et al. An integrated in&nbsp;vitro and in&nbsp;vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 2011; 20:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/27\">",
"      Prayson RA. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann Diagn Pathol 1999; 3:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/28\">",
"      Vanuytsel L, Brada M. The role of prophylactic spinal irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys 1991; 21:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/29\">",
"      Chen CJ, Tseng YC, Hsu HL, Jung SM. Imaging predictors of intracranial ependymomas. J Comput Assist Tomogr 2004; 28:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/30\">",
"      Maiuri F, Gangemi M, Iaconetta G, et al. Symptomatic subependymomas of the lateral ventricles. Report of eight cases. Clin Neurol Neurosurg 1997; 99:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/31\">",
"      Sun B, Wang C, Wang J, Liu A. MRI features of intramedullary spinal cord ependymomas. J Neuroimaging 2003; 13:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/32\">",
"      Moreno L, Pollack IF, Duffner PK, et al. Utility of cerebrospinal fluid cytology in newly diagnosed childhood ependymoma. J Pediatr Hematol Oncol 2010; 32:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/33\">",
"      Reni M. Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours. Forum (Genova) 2003; 13:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/34\">",
"      Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 1998; 88:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/35\">",
"      Duffner PK, Krischer JP, Sanford RA, et al. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg 1998; 28:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/36\">",
"      Healey EA, Barnes PD, Kupsky WJ, et al. The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery 1991; 28:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/37\">",
"      Timmermann B, Kortmann RD, K&uuml;hl J, et al. Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys 2000; 46:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/38\">",
"      Rodr&iacute;guez D, Cheung MC, Housri N, et al. Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res 2009; 156:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/39\">",
"      Amirian ES, Armstrong TS, Aldape KD, et al. Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. Neuroepidemiology 2012; 39:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/40\">",
"      Doxey D, Bruce D, Sklar F, et al. Posterior fossa syndrome: identifiable risk factors and irreversible complications. Pediatr Neurosurg 1999; 31:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/41\">",
"      Sanford RA, Kun LE, Heideman RL, Gajjar A. Cerebellar pontine angle ependymoma in infants. Pediatr Neurosurg 1997; 27:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/42\">",
"      Hukin J, Epstein F, Lefton D, Allen J. Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 1998; 29:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/43\">",
"      Palma L, Celli P, Mariottini A, et al. The importance of surgery in supratentorial ependymomas. Long-term survival in a series of 23 cases. Childs Nerv Syst 2000; 16:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/44\">",
"      Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg 2005; 102:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/45\">",
"      Merchant TE, Fouladi M. Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol 2005; 75:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/46\">",
"      Taylor RE. Review of radiotherapy dose and volume for intracranial ependymoma. Pediatr Blood Cancer 2004; 42:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/47\">",
"      Merchant TE, Li C, Xiong X, et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 2009; 10:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/48\">",
"      Siffert J, Allen JC. Chemotherapy in recurrent ependymoma. Pediatr Neurosurg 1998; 28:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/49\">",
"      Grill J, Le Deley MC, Gambarelli D, et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 2001; 19:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/50\">",
"      Chamberlain MC. Salvage chemotherapy for recurrent spinal cord ependymona. Cancer 2002; 95:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/51\">",
"      Gornet MK, Buckner JC, Marks RS, et al. Chemotherapy for advanced CNS ependymoma. J Neurooncol 1999; 45:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/52\">",
"      Bouffet E, Foreman N. Chemotherapy for intracranial ependymomas. Childs Nerv Syst 1999; 15:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/53\">",
"      Fouladi M, Gururangan S, Moghrabi A, et al. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer 2009; 115:3243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/54\">",
"      Van Poppel M, Klimo P Jr, Dewire M, et al. Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience. J Neurosurg Pediatr 2011; 8:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/55\">",
"      Garvin JH Jr, Selch MT, Holmes E, et al. Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/56\">",
"      van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, et al. Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg 2002; 97:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/57\">",
"      Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 2007; 8:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/58\">",
"      Sung KW, Lim do H, Lee SH, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation for anaplastic ependymoma in children younger than 3 years of age. J Neurooncol 2012; 107:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/59\">",
"      Needle MN, Goldwein JW, Grass J, et al. Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer 1997; 80:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/60\">",
"      Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, Finlay JL. Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study. Med Pediatr Oncol 1996; 27:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/61\">",
"      Zacharoulis S, Ashley S, Moreno L, et al. Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst 2010; 26:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/62\">",
"      Merchant TE. Current management of childhood ependymoma. Oncology (Williston Park) 2002; 16:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/63\">",
"      Merchant TE, Boop FA, Kun LE, Sanford RA. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 2008; 71:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/64\">",
"      Stafford SL, Pollock BE, Foote RL, et al. Stereotactic radiosurgery for recurrent ependymoma. Cancer 2000; 88:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/65\">",
"      Liu AK, Foreman NK, Gaspar LE, et al. Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children. Pediatr Blood Cancer 2009; 52:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/66\">",
"      Bouffet E, Hawkins CE, Ballourah W, et al. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys 2012; 83:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/67\">",
"      Mason WP, Goldman S, Yates AJ, et al. Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma--a report of the Children's Cancer Group. J Neurooncol 1998; 37:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/68\">",
"      Brandes AA, Cavallo G, Reni M, et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer 2005; 104:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/69\">",
"      Green RM, Cloughesy TF, Stupp R, et al. Bevacizumab for recurrent ependymoma. Neurology 2009; 73:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/70\">",
"      Couec ML, Andr&eacute; N, Thebaud E, et al. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr Blood Cancer 2012; 59:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/71\">",
"      Gururangan S, Fangusaro J, Young Poussaint T, et al. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro Oncol 2012; 14:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/72\">",
"      Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006; 12:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/73\">",
"      Zavalhia LS, Romitti M, Netto GC, et al. Evaluation of the expression of C-kit (CD117) in ependymomas and oligodendrogliomas. Dis Markers 2012; 33:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/74\">",
"      Mansur DB, Perry A, Rajaram V, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 2005; 61:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/75\">",
"      McLaughlin MP, Marcus RB Jr, Buatti JM, et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 1998; 40:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/76\">",
"      Bouffet E, Perilongo G, Canete A, Massimino M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998; 30:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/77\">",
"      Horn B, Heideman R, Geyer R, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol 1999; 21:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/78\">",
"      Shu HK, Sall WF, Maity A, et al. Childhood intracranial ependymoma: twenty-year experience from a single institution. Cancer 2007; 110:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/79\">",
"      Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 2004; 100:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/80\">",
"      Vanuytsel LJ, Bessell EM, Ashley SE, et al. Intracranial ependymoma: long-term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1992; 23:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/81\">",
"      Schwartz TH, Kim S, Glick RS, et al. Supratentorial ependymomas in adult patients. Neurosurgery 1999; 44:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/82\">",
"      Schild SE, Nisi K, Scheithauer BW, et al. The results of radiotherapy for ependymomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 1998; 42:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/83\">",
"      Ernestus RI, Schr&ouml;der R, St&uuml;tzer H, Klug N. The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg 1997; 11:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/84\">",
"      Ross GW, Rubinstein LJ. Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 1989; 70:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/85\">",
"      St&uuml;ben G, Stuschke M, Kroll M, et al. Postoperative radiotherapy of spinal and intracranial ependymomas: analysis of prognostic factors. Radiother Oncol 1997; 45:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/86\">",
"      Reni M, Brandes AA, Vavassori V, et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004; 100:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/87\">",
"      Metellus P, Barrie M, Figarella-Branger D, et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 2007; 130:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/88\">",
"      Armstrong TS, Vera-Bolanos E, Bekele BN, et al. Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol 2010; 12:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/89\">",
"      Vitanovics D, B&aacute;lint K, Hanz&eacute;ly Z, et al. Ependymoma in adults: surgery, reoperation and radiotherapy for survival. Pathol Oncol Res 2010; 16:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/90\">",
"      Amirian ES, Armstrong TS, Gilbert MR, Scheurer ME. Predictors of survival among older adults with ependymoma. J Neurooncol 2012; 107:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/91\">",
"      Broniscer A, Ke W, Fuller CE, et al. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer 2004; 100:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/92\">",
"      Spiegler BJ, Bouffet E, Greenberg ML, et al. Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol 2004; 22:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/93\">",
"      Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol 1998; 44:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/94\">",
"      Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 2000; 88:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/95\">",
"      Stavrou T, Bromley CM, Nicholson HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 2001; 23:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/96\">",
"      Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001; 93:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/97\">",
"      Devarahally SR, Severson RK, Chuba P, et al. Second malignant neoplasms after primary central nervous system malignancies of childhood and adolescence. Pediatr Hematol Oncol 2003; 20:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/98\">",
"      Armstrong TS, Vera-Bolanos E, Gilbert MR. Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. Cancer 2011; 117:5133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/51/15161/abstract/99\">",
"      Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5224 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15161=[""].join("\n");
var outline_f14_51_15161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age and anatomic location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1296274\">",
"      - Ependymoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1296289\">",
"      - Subependymoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1296296\">",
"      - Myxopapillary ependymoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1296303\">",
"      - Ependymoblastoma (ETANTR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ependymoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Subependymomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2530398\">",
"      - Chemotherapy after partial resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chemotherapy in lieu of RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Adjuvant chemotherapy after surgery and RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LONG-TERM OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5224\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5224|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/5/20561\" title=\"diagnostic image 1A\">",
"      Post fossa ependymoma MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/30/16879\" title=\"diagnostic image 1B\">",
"      Post fossa ependymoma MRI T2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/59/25535\" title=\"diagnostic image 1C\">",
"      Post fossa ependymoma MRIproton",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/56/15232\" title=\"diagnostic image 1D\">",
"      Post fossa ependymoma MRI Gad",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/50/5921\" title=\"diagnostic image 2\">",
"      Metastatic ependymoma MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5224|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/32/14861\" title=\"table 1\">",
"      WHO brain tumor classification by histology and grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=related_link\">",
"      Epidemiology, treatment, and prognosis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=related_link\">",
"      Risk factors for brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=related_link\">",
"      Spinal cord tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=related_link\">",
"      Uncommon brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_51_15162="Congenital myocardial infar";
var content_f14_51_15162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Congenital myocardial infarct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Papillary muscle with orangophillic discoloration in the center, classic for myocardial infarcts in the fetus which tend to be multifocal and non-coronary in distribution. Panel B) Wavy fibers, relatively recent myocardial infarction. Panel C) Calcified focus in papillary muscle which may be seen in Trisomy 21 or 13 or as evidence of a remote myocardial infarction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15162=[""].join("\n");
var outline_f14_51_15162=null;
var title_f14_51_15163="HIV medications affecting thyroid function";
var content_f14_51_15163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications used in the treatment of HIV or its complications that may affect thyroid function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intended clinical use",
"       </td>",
"       <td class=\"subtitle1\">",
"        Thyroid dysfunction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon-&alpha; (IFN-&alpha;)",
"       </td>",
"       <td>",
"        Treatment of co-infection with Hepatitis C",
"       </td>",
"       <td>",
"        Autoimmune thyroid disease; subacute or destructive thyroiditis",
"       </td>",
"       <td>",
"        Immune-mediated; direct thyrotoxic effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ritonavir",
"       </td>",
"       <td>",
"        Antiretroviral",
"       </td>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"       <td>",
"        Effects on hormone metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"       <td>",
"        Antibiotic and anti-mycobacterial agent (eg, tuberculosis)",
"       </td>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"       <td>",
"        Increases metabolic clearance of hormones",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15163=[""].join("\n");
var outline_f14_51_15163=null;
var title_f14_51_15164="Detection of pathologic minor papilla narrowing";
var content_f14_51_15164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Detection of pathologic minor papilla narrowing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-invasive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dorsal duct dilation or chronic pancreatitis changes confined to the dorsal pancreas as seen on CT scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged dilation of the dorsal duct diameter after intravenous secretin stimulation, as monitored by transcutaneous ultrasound (or CT or endoscopic ultrasound)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic ERCP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal dorsal ductography (dilation and/or chronic pancreatitus changes) in combination with a normal ventral ductogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic dilation of the terminal dorsal duct (santorinicele)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slow drainage of contrast from the dorsal duct (&ge;12 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain provocation during dorsal ductography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Special/therapeutic ERCP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Collection of pure pancreatic juice after deep dorsal duct cannulation and intravenous secretion stimulation (abnormal bicarbonate level &lt;105 mEq/L or volume &lt;3 mL/minute)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manometry of the minor papilla (abnormal ? &gt;40 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Observation of the degree of resistance to passage of .035 inch diameter guidewire and/or 3, 4, or 5 French dilation catheter over a guidewire passed into dorsal duct",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnostic/therapeutic trial of minor papilla dilation, stenting, and/or sphincterotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intraoperative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resistance to passage of a .75 mm diameter lacrimal probe into the minor papilla (after laparotomy and duodenostomy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Observation of parenchymal chronic pancreatitus changes limited to the dorsal pancreas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Histology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Observation of parenchymal chronic pancreatitis changes limited to the dorsal pancreas",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15164=[""].join("\n");
var outline_f14_51_15164=null;
var title_f14_51_15165="ACC AHA choice imaging CHD diagnosis unable to exercise";
var content_f14_51_15165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61603%7ECARD%2F77242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61603%7ECARD%2F77242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for cardiac stress imaging as the initial test for diagnosis of coronary heart disease (CHD) in patients with chronic stable angina who are unable to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography in patients with an intermediate pretest probability of CAD.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Adenosine or dipyridamole stress myocardial perfusion imaging or dobutamine echocardiography in patients with prior revascularization (either PTCA or CABG).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Adenosine or dipyridamole stress myocardial perfusion imaging or dobutamine echocardiography in patients with a low or high probability of CAD in the absence of electronically paced ventricular rhythm or left bundle-branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Adenosine or dipyridamole myocardial perfusion imaging in patients with a low or a high probability of CAD and one of the following baseline ECG abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       ACC/AHA classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class I:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Class II:",
"       </strong>",
"       Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIa:",
"       </strong>",
"       Weight of evidence/opinion is in favor of usefulness/efficacy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIb:",
"       </strong>",
"       Usefulness/efficacy less well established by evidence/opinion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class III:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data modified from: Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparative advantages of stress echocardiography and stress radionuclide perfusion imaging in diagnosis of coronary heart disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Advantages of stress echocardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Higher specificity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Versatility - more extensive evaluation of cardiac anatomy and function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Greater convenience, efficacy, availability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Lower cost",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Advantages of stress perfusion imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Higher technical success rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Higher sensitivity - especially for single vessel coronary disease involving the left circumflex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Better accuracy in evaluating possible ischemia when multiple resting left ventricular wall motion abnormalities are present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. More extensive published data base - especially in evaluation of prognosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149. Copyright &copy; 2003 American College of Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15165=[""].join("\n");
var outline_f14_51_15165=null;
var title_f14_51_15166="Change in FEV1 with aging";
var content_f14_51_15166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Change in FEV1 with aging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 258px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A general theoretical model of growth and decline of lung function with time. Curve A (red) shows normal change over time. Curve B (blue) indicates reduced lung growth and therefore a decrease in the peak level of lung function. Curve C (green) shows a premature decline in lung function, while Curve D (orange) depicts an accelerated decline in lung function. The horizontal gray line represents the development of COPD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Weiss, ST, Sparrow, D (Eds), Airways Responsiveness and Atopy in the Development of the Obstructive Airways Diseases, Raven Press, New York, 1989.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15166=[""].join("\n");
var outline_f14_51_15166=null;
var title_f14_51_15167="Fibroid embolization 2 PI";
var content_f14_51_15167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibroid embolization 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram showing embolic particles being released from the catheter and into the uterine arterial branches supplying the fibroid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_51_15167=[""].join("\n");
var outline_f14_51_15167=null;
